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ABSTRACT
Lentiviral vectors (LVs) are attractive tools for liver gene therapy, by virtue of their 
ability to stably integrate in the genome of target cells and the absence of pre-existing 
humoral and cellular immunity against vector components in most humans. We have 
previously reported long-term phenotypic correction of haemophilia B and transgene- 
specific immune tolerance induction after a single intravenous administration of LVs in 
mice, provided that transgene expression is stringently targeted to hepatocytes. This is 
achieved by a combination of transcriptional control, mediated by a synthetic 
hepatocyte-specific promoter and post-transcriptional control obtained by including in 
the transgene sequences complementary to the haematopoietic-specific microRNA 142, 
which binds and targets for degradation any residual transgene mRNA expressed in 
antigen presenting cells of liver and spleen.
We have now evaluated this gene therapy strategy in a large animal model. Our 
results show long-term canine Factor IX (FIX) expression up to 0.5-1% of normal levels 
and clinical improvement (almost complete prevention of spontaneous bleedings) in two 
haemophilia B dogs (>3.5 years cumulative follow up), with mild acute toxicity and 
without long-term adverse effects nor anti-transgene immune responses. The use of 
codon-optimised and hyper-functional FIX transgenes increased the potency of LVs (in 
the pharmacological meaning of efficacy per dose) >15-fold, allowing correction of the 
disease phenotype at low vector doses in mice, thus improving the therapeutic index of 
the gene therapy and prompting us to test this improvement in the next treated dog. We 
have investigated additional improvements in the potency of LVs for liver gene therapy, 
such as the use of the baculovirus envelope protein gp64, which improves hepatocyte 
targeting and LV particles resistance to complement-mediated inactivation. We 
performed a quantitative analysis of LV biodistribution within the liver cell populations 
and show that Kupffer cells uptake most vector genomes, despite being a small fraction 
of the total cells, and limit hepatocyte transduction at low administered LV doses. 
However, pre-treatment with a single dose of a clinically used proteasome inhibitor 
prior to LV administration reduces this trapping effect and increases hepatocyte 
transduction and therapeutic efficacy up to 3-fold in haemophilia B mice. We provide 
evidence that liver gene therapy can establish long-term FIX expression and immune
tolerance in mice even in the presence of pre-existing anti-FIX antibody immunity. 
Since insertional mutagenesis is a concern for integrating vectors, we set out to explore 
the potential advantages of integrase-defective LVs (IDLVs) to express transgenes in 
the adult liver, in which hepatocytes turnover is slow. We show that, while not optimal 
for stable gene replacement therapy in their current design, IDLVs may represent a 
valuable strategy to induce stable antigen-specific tolerance by transient gene transfer 
and offer a treatment for immune-mediated diseases. On the other hand, since LV 
integration is preferable for efficient stable liver gene transfer, we stringently assessed 
the risk of oncogenesis associated to LV integration in ad hoc mouse models that are 
sensitised to develop hepatocellular carcinoma and found no detectable increase in 
carcinogenesis upon liver gene therapy with LVs.
Overall our results position LVs as a promising platform for liver gene therapy that 
may well complement other available vectors to address the different challenges posed 
by the presentation of haemophilia and its complications in different patients and 
clinical conditions and may conceivably offer a therapeutic option for lysosomal and 
metabolic diseases.
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ACRONYMS AND ABBREVIATIONS
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APC antigen presenting cell
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
BDD B-domain deleted
BOEC blood-outgrowth endothelial cells
BU Bethesda units
cFIX canine Factor IX
co-cFIX codon-optimised cFIX
cPPT central polypurine tract
CTL cytotoxic T lymphocyte
CTS central termination sequence
DC dendritic cell
DIC disseminated intravascular coagulation
DMSO dimethyl sulfoxide
dsDNA double-stranded DNA
ELISA enzyme-linked immunosorbent assay
ELISPOT enzyme-linked immunospot
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FDA food and drug administration
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FVIII Factor VIII
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gDNA genomic DNA
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GMP good manufacturing practice
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HCV hepatitis C virus
HDAd helper-dependent Ad
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HIV human immunodeficiency virus
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IFA incomplete Freund adjuvant
IFN interferon
Ig Immunoglobulin
IHL intra-hepatic lymphocyte
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KC Kupffer cell
KO knockout
LAL limulus amebocyte lysate
LAM-PCR linear amplification-mediated PCR
LSEC liver sinusoidal endothelial cell
LTR long terminal repeat
LV lentiviral vector
MHC major histocompatibility complex
MHC-I MHC class-I
MHC-II MHC class-II
MOI multiplicity of infection
NHP non-human primate
nPC non-parenchymal cell
OT ornithine transcarbamylase
OVA ovalbumin
PAMP pathogen-associated molecular pattern
PBS phosphate buffered saline
PC parenchymal cell
PCR polymerase chain reaction
pDC plasmacytoid DC
PGK phosphoglycerate kinase
polyA polyadenilation signal
PT prothrombin time
qPCR quantitative PCR
RCL replication-competent lentivirus
RV gammaretroviral vector
SB sleeping beauty
scAAV self-complementary AAV
SCID severe combined immunodeficiency
SEM standard error of the mean
SIN self-inactivating
ssRNA single-stranded RNA
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TFPI tissue factor pathway inhibitor
TGF-|3 transforming growth factor-beta
TLR Toll-like receptor
TNF-a tumour necrosis factor-alpha
Tregs regulatory T cells
IT thrombin time
TU transducing unit
VCN vector copy number
vg vector genome
vp vector particle
VSV-G vesicular stomatitis virus glycoprotein G
VWF von Willebrand factor
WBCT whole-blood clotting time
wpre woodchuck hepatitis virus post-transcriptional regulatory element
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ZFN zinc-finger nuclease
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INTRODUCTION
1.1 Gene Therapy
Gene therapy is an innovative approach to molecular medicine, based on the idea that 
the transfer of a gene into a target cell can counteract a disease. This idea stems from 
the universality of the genetic code, which enables a cell to “understand” any foreign 
gene1.
Gene therapy was originally conceived to replace a defective function in a cell and 
treat genetic diseases. As molecular and cellular biology evolved and the 
pathophysiology of diseases were progressively elucidated, it was clear that many 
diseases have, at least in part, a genetic basis. Therefore it became apparent that gene 
therapy could be applied not only to monogenic diseases strictu sensu, but also to 
multigenic, multifactorial complex diseases, such as cardiovascular, neurodegenerative, 
infectious diseases and cancer. Scientists soon realised the enormous impact that gene 
therapy could have on medicine. The simple concept at the basis of gene therapy is the 
transfer of a classically defined gene or any regulatory nucleic acid in cells of human 
beings to cure or ameliorate a disease by instructing defective or new functions. 
However, this simple concept masks a stunning complexity, since mammalian cells and 
multicellular organisms have evolved physical, chemical and biological barriers to 
protect their own genetic information. To deliver the new gene (transgene) into a human 
tissue, a vehicle known as vector is needed in order to reach the target cells, pass the 
plasma membrane, enter the nucleus and appropriately direct expression of the gene, 
overcoming the immune defences outside and inside the cells (Figure I). Moreover, to 
make gene therapy acceptable for clinical administration, transgene delivery must be 
accomplished without causing adverse effects to patients. Since the first clinical trials in 
the 1990s, it took more than two decades to show convincing clinical benefits, a 
relatively short period, considering the significant hurdles and setbacks that had to be 
faced, undertaking such complex experimental therapies. Over 1,800 clinical trials have 
been conducted all over the world (www.wiley.com/legacy/wileychi/genmed/clinical), 
but only in recent years the therapeutic potential of gene therapy has become more 
widely appreciated throughout the scientific community2'5.
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Figure I: The major steps to gene transfer and potential barriers. (A) Uptake, 
transport and uncoating. Vectors bind to a cellular membrane and are internalised by 
various processes. Most uptake steps involve a ligand-receptor interaction. Once 
internalised, most vectors enter the endosome and undergo a complex set o f reactions 
that can result in their fu ll or partial degradation. Transport to the nucleus is also 
required for successful therapy. (B) Vector genome persistence. Once the vector 
reaches the nucleus, it can be further processed. Depending on the vector, the DNA can 
exist as an episomal molecule (and associate with the nuclear matrix) or it can be 
integrated (by covalent attachment) into the host chromosome. (C) Transcriptional 
activity and transgene persistence are dependent on many factors. (D) The immune 
response can limit the viability o f the genetically modified cells and/or neutralize the 
transgene product. Adapted from Kay et al., Nature Reviews Genetics, 2011.
1.1.1 A brief history of gene therapy
From the first demonstration in the 1940s that transferring genomic DNA between 
strains of bacteria transformed the recipient phenotype into that of the donor 
phenotype6, many years elapsed before mammalian cells were successfully transformed 
with foreign DNA, although with extreme inefficiency . As the techniques to transfer 
genetic material improved, gene transfer enabled the study of gene function as well as 
the production of recombinant proteins and it became clear that these tools might be 
used in humans to treat diseases.
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The first ideas to develop gene therapies date back to the 1970s8. However efficient 
methods for gene transfer were lacking, because knowledge of “transforming” viruses 
preceded the recombinant DNA era and it was not clear how to modify these viruses to 
incorporate and express foreign genes. Some of the first gene therapy experiments were 
designed to treat blood diseases, by introducing the correct gene into bone marrow 
hematopoietic cells and re-infusing them into recipient mice9. The basis for these 
attempts was that transplantation of bone marrow hematopoietic cells were already 
being performed in the clinics and thus would facilitate clinical translation. These were 
the first examples of those protocols today referred to as ex vivo gene therapy (see 
1.1.2). However, gene transfer technologies at that time could not allow the genetic 
modification of a significant number of cells. Because of this, attention focused to a 
specific type of haematopoietic disorders, the immune deficiencies, and in particular to 
the severe combined immune deficiency (SCID) due to the defective adenosine 
deaminase enzyme (ADA-SCID), whose gene was cloned in the 1980s. The rationale 
for choosing SCIDs as target diseases was based on the assumption that only a small 
fraction of corrected cells (potentially gaining selective growth advantage) could allow 
improvement of the immune-deficient phenotype, as compared to the high number of 
functional progenitors necessary for correcting other blood defects, such as anaemias10.
The first approved gene therapy trial started in 1990 and involved the transfer of the 
ADA gene in T cells from two young patients11. In the same years, the pioneering work 
by Claudio Bordignon and his team led to the first human gene therapy clinical trial 
involving genetically modified bone marrow hematopoietic cells and T cells in patients 
affected by ADA-SCID12. While the gene therapy resulted to be safe, enzyme activity 
was transient or subtherapeutic, mainly because of inefficient gene transfer and limited 
engraftment of the gene-modified cells. The 1990s were characterised by important 
technological developments and most of the virus-derived vectors that today are still in 
use in pre-clinical and clinical gene therapy were designed and generated. Since viruses 
had already evolved strategies to overcome the barriers to gene transfer into cells 
mentioned above (1.1), virus-derived vectors were conceived as the trojan horses that 
would carry the therapeutic genes into human cells (the most widely used viral vectors 
are discussed in more details in 1.3.4). After some of the technologies of genetic
11
manipulation were refined, a second set of clinical trials started in the late 1990s, for 
ADA-SCID and the X-linked SCID.
While the first encouraging results were emerging, a series of serious adverse events 
tuned down the enthusiasm and fuelled scepticism over gene therapy. Two of these 
major adverse events were due to host immune responses to a vector (upon systemic 
vector injection) and insertional mutagenesis caused by other vectors (in an ex vivo gene 
therapy trial). In 1999 Jesse Geslinger, a young boy with a relatively mild form of the 
nitrogen metabolism disorder ornithine transcarbamylase (OT) deficiency died on a 
gene therapy trial, after infusion to the liver of a viral vector carrying the OT transgene, 
causing a fatal inflammatory response13. This event was most probably caused by 
several interactions between the innate immune system and the vector delivered 
systemically. These interactions were insufficiently monitored in preclinical animal 
models. In the same years the first cases of leukaemias in gene therapy-treated SCID 
children were reported14. The young patients received infusion of their own 
hematopoietic stem and progenitor cells (HSPCs) genetically corrected with the 
functional gene of the interleukin-2 receptor y chain, whose deficiency causes failure of 
lymphocytes to differentiate. The viral vector used to shuttle the gene inserted its 
genome close to a proto-oncogene and promoted its over-expression and subsequent 
aberrant T cells proliferation. This phenomenon, referred to as insertional mutagenesis, 
was observed with unexpectedly high frequency even in subsequent clinical trials for 
other immune deficiencies (see also 1.1.6)15'17. Both the host immune response and 
insertional mutagenesis still remain two major hurdles for gene therapy.
These adverse events soon hid the scientific and therapeutic progress in the press and 
gene therapy became perceived as a dangerous technology that did not live up the 
expectations that had raised18. Over-optimism in the initial years gave the way to 
disappointing results of lack of efficacy and unacceptable toxicities, such as in the 
above described trials. Regulatory authorities put gene therapies under intense scrutiny 
and threw the field into recession. However, this disillusionment forced gene therapists 
to better investigate the interactions between the vectors and both the immune system 
and genome of the host, to develop improved vectors and gene transfer protocols and to 
adopt more sensitive animal models. Overall, this turn of events taught not to 
underestimate the challenges faced by any novel therapy at the initial stage18. Only in
12
recent years the results of some successful clinical trials has renewed the promise of 
gene therapy.
Today some of the most successful examples of clinical gene therapy have been 
obtained in monogenic diseases. Several studies have now reported remarkable clinical 
improvements after gene therapy in patients with Leber’s congenital amaurosis, a form 
of retinal blindness19"21. Affected patients received injections of the vector carrying the 
retinal pigment epithelium-specific 65 kDa protein gene necessary to reconstitute 
photoreceptor function directly into the eye, an immune-privileged site. In 2009 Aiuti et 
al. reported a 10-year follow up of ADA-SCID patients who received transplantation of 
autologous HSPCs modified with a vector carrying the functional ADA transgene, 
showing long-term ADA expression and therapeutic efficacy without adverse events22. 
The development of newer, more efficient and potentially safer vectors has allowed the 
genetic modification of a higher number of HSPCs leading to the initiation of a clinical 
trial for p-thalassaemia and a clinical trial for the lysosomal storage disorder 
adrenoleukodystrophy24. The latter trial was based on the rationale of over-expressing 
the functional lysosomal enzyme in HSPC-derived tissue macrophages and microglia. 
In both trials some clinical benefits have been observed: in the first trial one adult 
patient had a stable improvement in haemoglobin levels, in the second trial progression 
of the disease was halted in treated children. Successful results have also been reported 
for haemophilia B in a recent clinical trial (see 1.3.4.3)25. Other successful results have 
been recently reported also for Duchenne muscular dystrophy, Parkinson disease and 
for cancer immunotherapy (through the genetic modifications of T cells)5.
As we have now reached a more balanced view of the risks and benefits of gene 
therapy, the unavoidability of adverse effects has been gradually accepted as the price 
we pay for otherwise effective therapies. Retrospectively it was unrealistic to ask of 
gene therapy what no other therapy has ever provided in medicine, efficacy without side 
effects. Gene therapy for SCID continues to show promise, with more than 90 patients 
treated, with the vast majority experiencing clinical benefit and the overall 5% mortality 
being much lower than the 25% mortality risk in allogenic bone marrow transplantation, 
which is the current standard of care . Pharmaceutical companies are now filing the 
first applications to the institutional drug agencies for marketing gene therapies.
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Whereas the therapeutic potential of gene therapy is becoming more established, the 
risk-benefit ratio needs to be carefully evaluated in each condition. The recurrence of 
insertional mutagenesis and other immune-mediated side effects calls for continued 
vector improvements, careful pre-clinical risk assessment and molecular and 
immunological follow up of treated patients. The “bench to bedside and back” cycle 
between clinical and laboratory animal investigations is crucial to drive these complex 
biological therapies forward. The continuous improvements and sophistication of 
genetic engineering tools can be coupled with the growing capacity of isolation and 
manipulation of stem cells, including reprogramming and differentiation and promise 
that more safe and effective therapies for currently untreatable diseases are to come in 
the near future. Thus a productive marriage is envisioned between stem cells and gene 
therapy27.
Even if the scientific and clinical maturity may be reached, nowadays the large-scale 
production of these complex biological therapies to Good Manufacturing Practice 
(GMP)-grade remains a biotechnological challenge and constitute one of the most 
complex organizational and regulatory areas currently approached by preclinical 
research5. The ultimate success of gene therapy strictly depends on a virtuous cycle 
between a rich open-minded society, academic scientists, physicians, small 
biotechnological companies and the large pharmaceutical industry27.
1.1.2 Gene therapy strategies
Gene therapy strategies can be classified in gene replacement, gene addition, gene 
subtraction and gene correction1. Gene replacement involves the delivery of the wild 
type (wt) gene encoding for the protein that is missing or dysfunctional in target cells, 
owing to genetic mutations and it represents the prototypical protocol devised to treat 
monogenic diseases. Gene addition consists of the delivery of a gene conferring novel 
functions normally not present or present at lower levels in target cells. For instance, 
this can be useful to induce drug resistance or to alter immune responses to counteract 
infectious diseases or cancer. Gene subtraction can be achieved by down-regulating the 
expression of endogenous genes, exploiting the RNA interference (RNAi) pathways, or 
by disrupting the coding sequence of the endogenous gene, exploiting genome editing 
technologies, such as sequence-specific engineered endonucleases. Gene subtraction
14
strategies are intended to counteract the effect of gain-of-function mutations or fight 
infectious diseases, e.g. by targeting directly the genome of a virus or one of its cellular 
receptors. Gene correction means repairing genetic mutations at their own site or 
introducing a functional cDNA downstream of the endogenous promoter and can be 
obtained by exploiting the mechanism of homologous recombination (see 1.1.7). Also, 
introduction into target cells of a functional cDNA coupled with a strong splice acceptor 
may favour the splicing of the endogenous mutated transcript with the functional 
mRNA, thus generating chimeric mRNAs encoding for a wt protein. This procedure is 
referred to as trans-splicing and can be considered a gene correction approach, although 
this is not performed at the genome level. Although challenging, gene correction is 
considered the ultimate goal of gene therapy as it would restore the endogenous control 
of gene expression with minimal impact on the genome. As the technologies to perform 
genome editing evolve, clinical application are envisaged for the near future27. More 
recently, the development of antisense oligonucleotides able to interfere with the 
endogenous splicing machinery has opened the possibility to force endogenous 
transcripts to avoid the inclusion of the mutated exon (usually containing a premature 
stop codon) and can generate incomplete but still functional proteins. This procedure is 
referred to as exon skipping28.
Regardless of the approach, any gene therapy protocol comprises (i) the therapeutic 
gene (transgene) or the regulatory nucleic acid, (ii) the target cells and (iii) the delivery 
method (vector). All gene therapy approaches can target only somatic cells, since the 
genetic modification of germline stem cells and its eventual transmission to the progeny 
is not allowed for ethical reasons and must be carefully avoided29.
The desired gene therapy strategy can be accomplished by an in vivo or ex vivo 
approach. In vivo approaches involve the administration of the vector directly to 
patients, either by localized means (tissue injection) or by systemic means (intravenous 
injection). Ex vivo approaches involve the isolation of stem, progenitor or differentiated 
cells from patients, their in vitro genetic modification and reinfusion into patients27.
1.1.3 Gene transfer vectors
The delivery vectors need to fulfil a series of requirements. They need to be 
produced in sufficient quantity and purity and formulated in a relatively small volume
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that can be administered. In the case of virus-derived vectors, the absence of a 
replication-competent virus contaminating the vector preparation must be guaranteed. 
Vectors need to be able to reach the target cells, enter the nucleus, persist and sustain 
expression of the transgene for the time needed to meet the therapeutic purpose (Figure 
I). Vectors can mediate integration of their genetic cargo in host cells’ chromatin 
(integrating vectors) or remain in the nucleus as an extrachromosomal element 
(episome), which is lost as cells cycle, unless able to replicate1. Recently artificial 
chromosomes are being developed; they contain the minimal functional elements 
(centromere, telomeres) and are transmitted at mitosis30. In some cases, such as in gene 
replacement therapy, lifelong vector persistence and transgene expression is desirable, 
thus integrating vectors are needed when targeting dividing cells or stable episomes can 
be used in tissues with relatively slow turnover such as muscle, liver and brain. In other 
cases, when the aim is to induce a specific temporary response, transient gene transfer 
or expression is preferable1,31,32.
In most cases, vectors cannot incorporate the entire gene, thus the cDNA is used. The 
absence of maturation of the primary transcripts may result in mRNA instability and 
inefficient nuclear export, thus splicing sites may need to be re-introduced when 
possible or compensatory elements have to be included. In addition to the transgene, 
gene therapy vectors have to carry the elements necessary to express it, such as 
transcriptional regulatory sequences and a polyadenylation signal (polyA). Together the 
transgene plus its expression regulatory elements are referred to as expression 
cassette29.
1.1.4 Transgene expression control
Expression of the transgene can be directed by promoter/enhancer sequences of viral 
or eukaryotic -  including human -  origin, complete or partially reconstituted, chimeric 
or synthetic. Promoter/enhancers can be exogenously regulated, relatively strong or 
weak, ubiquitously expressed or tissue/cell type-specific. The most appropriate choice is 
dependent on the diverse therapeutic need. In gene replacement strategies, sustained 
life-long expression is desirable. Some applications require cell type-specific transgene 
expression, in other cases robust ubiquitous expression is preferable. In some cases 
switching transgene expression on and off may be necessary. Depending on whether the
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transgene is integrated or not and according to the integration sites, its expression may 
vary. Transgene expression can also be epigenetically silenced during chromatin 
remodelling, such as in cell differentiation processes, or by genome surveillance 
mechanisms33. In most cases size constraints in vectors ability to incorporate nucleic 
acids (cloning capacity) limit the number and length of regulatory elements that can be 
included and often results in imprecise transcriptional control and undesired expression. 
A recently proposed approach to improve the stringency of transgene expression 
regulation is to exploit the differential expression of microRNAs between cell lineages 
or differentiation states (see also 1.4.1)34,35. By incorporating the target sequence for a 
microRNA in the 3’ untranslated region (UTR) of a transgene, its expression is 
suppressed specifically in the cells that express that microRNA and expression can be 
de-targeted from unwanted cell types. Since this control is post-transcriptional, it can 
be combined with transcriptional control to obtain sophisticated transgene expression 
patterns36.
1.1.5 Immune response
One of the most significant obstacles against successful gene therapy is the host 
immune system (reviewed in37). An immune response can be raised against the vector, 
the transgene or both (Figure I). Most patients (and animal models) affected by a 
genetic disease are immunologically nai've to the wt gene product and therefore are 
prone to initiate an immune response against therapeutic transgenes. Gene therapy 
vectors, especially virus-derived vectors, can be highly immunogenic, which is also true 
for non-viral vectors (see also 1.3.2). Immune responses can be divided into innate and 
adaptive, the latter ones comprising both humoral and cell-mediated. Innate responses 
to vectors can cause local or systemic toxicities immediately following administration 
and enhance adaptive anti-transgene immunity. Pre-existing humoral responses to 
vectors can block vectors’ ability to enter cells. Most virus-derived vectors induce 
primary humoral immune responses that would probably limit any strategy that require 
re-administration of the same vector. Primary humoral and cell-mediated immunity to 
transgenes can neutralize their protein product or eliminate transgene-containing cells, 
or both. The development of such immune responses represents a serious risk, since it 
may result in a failure of the therapeutic strategy and may also expose the patient to the
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risk of developing autoimmunity and becoming refractory to other types of replacement 
therapy. A number of different factors dictate whether an anti-transgene immune 
response is initiated or not, including the transgene itself, the type and dose of vector, 
the route of administration, the host genetic background and underlying disease 
mutation. The accumulated experience indicates that transgene expression in antigen 
presenting cells (APCs) is one of the major determinants of anti-transgene immunity. 
Therefore, restricting transgene expression to target cells via tissue/cell type-specific 
promoters can reduce the probability of such an event (see also 1.4.1)34,38~42. Over the 
years, extensive investigations have been performed in order to avoid detrimental 
immune responses in many gene therapy approaches. Immune responses are instead 
desired when developing genetic vaccines to fight infectious diseases or cancer gene 
therapy, as anti-vector immunity may in some cases be helpful in amplifying anti­
cancer immunity.
1.1.6 Insertional mutagenesis
When integrating vectors are used, a crucial issue to be faced is insertional 
mutagenesis. Integration of exogenous DNA into the host genome can provide an 
initiating mutation that causes expansion of a clonal population which, upon selective 
pressure and accumulation of secondary mutations, may progress to neoplastic 
transformation43. Depending on the insertion site and the type of vector, the integrated 
vector can cause the generation of over-expressed, chimeric (with parts of the vector), 
truncated or inactive transcripts that can in turn promote cellular transformation.
The main mechanisms of insertional mutagenesis comprise promoter/enhancer 
insertion and splice sites/poly A insertion. Transcriptional enhancement is probably the 
most frequent mechanism of gene activation by insertional mutagenesis: integrated 
vectors could initiate chimeric, spliced transcripts from their own enhancer/promoters 
and/ore provide an enhancer effect on host transcription, thus determining an up- 
regulation of the genes neighbouring the insertion site, with transcription starting from 
their physiological transcription start site. Vector-derived enhancers may also affect the 
expression activity of genes located at a distance because of chromatin loops. 
Integration in intragenic regions could also happen. In this case, cis-acting sequences 
located in the vector (such as deliberately introduced or cryptic polyA and splice sites)
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could affect the result of transcription, leading to the synthesis of aberrant mRNAs. In 
most cases this would result in loss-of-fimction mutants and the other allele would still 
exert its normal function, however truncated or aberrant proteins may possess dominant 
negative properties or display enhanced or reduced activity and induce tumourigenesis. 
Enhancer activation could act in concert with these vector-induced premature- 
termination/aberrant-splicing events, thus generating high levels of a mutant protein44. 
Over the years insertional mutagenesis has represented a significant burden in gene 
therapy and a flurry of studies have investigated the causes of these events, devised 
ways to decrease them and developed tools and models to predict their occurrence and it 
is still an active area of investigation27.
1.1.7 Site-specific integration
Site-specific integration is considered the holy grail of gene replacement therapy 
since it would ensure predictable and stable transgene expression with minimal 
consequences to cellular genomic regulation. Site-specific integration of template DNA 
can be exploited for gene correction strategies, for example, repairing genetic mutations 
at their own site or introducing a functional cDNA downstream the endogenous 
promoter45. Alternatively site-specific integration can target the insertion of an 
autonomous expression cassette into a specific genomic locus that is permissive and 
tolerant to integration and transgene expression, so called “safe harbour”46.
Site-specific integration can be achieved by providing target cells with a template 
DNA carrying sequences homologous to the desired site and exploiting the cellular 
machinery of homologous recombination to insert the exogenous DNA in that specific 
site47. This process has been exploited to perform gene targeting, typically in mouse 
embryonic stem cells, to obtain the knock out (KO) of endogenous genes, or knock-in 
of DNA elements or specific mutations and generate genetically modified animals. In 
order to direct homologous recombination at specific sites and improve the efficiency of 
the process, engineered sequence-specific endonucleases have been developed, such as 
zinc finger nucleases (ZFNs)48. The availability of these designer sequence-specific 
nucleases has brought the possibility to perform targeted genome modification within 
the reach of gene therapy. Upon such nucleases generate a site-specific double-strand 
break in the genome, target cells can repair it by the error-prone mechanism non-
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homologous end joining, which can be exploited to perform gene disruption. 
Alternatively, the break can be repaired by homologous recombination of homologous 
template DNA co-delivered with the nucleases to target cells, giving rise to the desired 
modification.
Because efficient site-specific targeting may require expansion and characterization 
of targeted-cell clones, it is mostly limited to ex vivo gene therapy strategies. Recently 
proof-of-principle of targeted integration has been achieved in the mouse liver by an in 
vivo gene therapy approach (see 1.3.4.3)49.
1.1.8 Liver gene therapy
Although ex vivo gene replacement strategies using HSPCs are in a more advanced 
stage of clinical development, the liver remains a highly desired target organ for gene 
therapy50.
The liver is a biochemical factory and hepatocytes carry out most catabolic and 
anabolic pathways involving biological molecules. Therefore, numerous diseases such 
as metabolic disorders, lysosomal storage disorders and plasma protein deficiencies 
have their origin in this organ. Liver-directed gene therapy holds promise not only for 
the treatment of genetic diseases directly affecting the liver, but also for all other 
diseases that cause extra-hepatic manifestations, owing to alterations of specific 
hepatocyte functions. Indeed, expression of the therapeutic protein in hepatocytes and 
its secretion into the bloodstream could provide benefit to these conditions. Thanks to 
its high synthesis and secretory activity, the liver can be exploited as a protein factory 
for other gene replacement or gene addition purposes. Acquired liver diseases such as 
viral hepatitis, liver cancer and liver failure can also benefit from gene therapy 
approaches. Liver gene transfer can be performed by in vivo or ex vivo strategies. In 
vivo strategies are relatively easy as hepatocytes are readily accessible via the blood 
stream. Ex vivo strategies are currently limited by the difficulties of in vitro 
manipulation of hepatocytes and their inefficient repopulation of the recipient liver, 
particularly in the absence of a selective advantage51'53.
The liver offers unique features for gene therapy. It is the largest organ in the body 
and is highly vascularised, by a dual vascular supply. The endothelium of hepatic 
capillaries (sinusoids) has fenestrations that allow macromolecules and viral particles to
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reach hepatocytes. Hepatic blood flow accounts for one-fifth of the cardiac output. 
Hepatocytes have a very slow turnover (<1% under normal conditions) but retain the 
capacity to proliferate and regenerate the entire liver following some types of injuries53. 
Another peculiar advantage offered by gene transfer to hepatocytes over other cell types 
is the likelihood of inducing immunological tolerance rather than immunity to the 
transgene product. This outcome allows for long-term expression of the therapeutic 
protein and ensures that the host will be protected in the case of future immunisation 
with the therapeutic protein. Moreover, since hepatic gene transfer can favour the 
induction of tolerance it may also be considered for prevention or treatment of 
autoimmune diseases54.
1.1.8.1 Immune tolerance induction upon liver gene transfer
Considerable evidence supporting the tolerogenic properties of the liver has been 
observed. Among the first experiments was the successful transplantation of a major 
histocompatibility complex (MHC)-mismatched liver in a pig55 and the induction of 
immune tolerance towards portal vein-delivered antigens56. The liver is susceptible to 
hepatotropic pathogens (such as hepatitis B and C viruses) that can succeed in 
establishing chronic infection, avoiding eradication by the host immune system. 
Physiologically, the liver receives blood draining from the intestine and spleen through 
the portal vein. Thus harmless food antigens, microbial antigens from the gut flora and 
products of hepatocyte metabolism reach the liver. However, potentially harmful 
pathogens invading the circulation may also gain access to the liver. While it is 
advantageous for the organism to maintain tolerance towards harmless antigens, a lack 
of response against pathogens would be detrimental. As such, the liver needs to 
maintain a state of hyporesponsiveness to inflammatory stimuli under normal 
circumstances. Nevertheless the hepatic environment must also be able to mount an 
appropriate immune response when necessary.
The exact mechanisms by which the liver can skew the immune system towards 
tolerance and switch between immune tolerance and immune response to antigens 
remain incompletely understood. Several studies investigating these aspects suggest that 
the liver follows peculiar immunological rules and that most of its cells are in a broad 
sense APCs. These APCs generally present antigen in a tolerogenic way (reviewed
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in57). Conventional and plasmacytoid dendritic cells (DCs), Kupffer cells (KCs), a 
specialised population of tissue macrophages, as well as liver sinusoidal endothelial 
cells (LSECs) can present circulating as well as hepatocyte-derived antigens and have 
tolerogenic properties under steady-state conditions. Nonetheless, these cells express 
various pattern recognition receptors, such as Toll-like receptors (TLRs) that can sense 
pathogen-associated molecular patterns (PAMPs) and allow them to initiate innate 
immune responses. Although these sentinel cells can be stimulated by PAMPs to release 
pro-inflammatory mediators, the concomitant expression of regulatory mediators (such 
as interleukin 10, IL-10, or transforming growth factor-|3, TGF-(3) leads to a state of 
hypo- or non-reactivity to subsequent stimuli. This hyporesponsive state is achieved 
through negative regulators of TLR signalling (cell-intrinsic mechanism) or by high 
local concentrations of immune regulatory molecules. Liver APCs are less prone to 
induce adaptive immunity upon PAMPs stimulation, whereas similar stimuli would 
promote strong immunity in other organs.
Liver DCs express low levels of MHC class II (MHC-II) and co-stimulatory 
molecules and they are poor stimulators of naive T cells, while promoting the induction 
of regulatory T cells (Tregs), a well known class of T lymphocytes capable of 
suppressing effector responses58. Unstimulated plasmacytoid DCs (pDCs) have been 
shown to induce T cell tolerance59. KCs are the major producers of IL-10 and TGF-(3 
under steady-state conditions. They can inhibit DC-induced T cell activation and 
stimulate the suppressive activity of Tregs. These KCs functions can be overridden by 
strong TLRs activators 60'62. LSECs can scavenge and sample circulating and 
hepatocyte-derived antigens for processing and presentation in MHC class I (MHC-I) 
and MHC-II molecules. LSECs have also been implicated in promoting tolerance, as T 
cells priming by these cells fails to induce effector functions, due to low expression of 
MHC-II, co-stimulatory molecules and pro-inflammatory cytokines63. Tolerogenic 
programming of T cells by LSECs can be subverted by increasing co-stimulatory 
signalling. Also hepatocytes have been shown to possess antigen presenting capacity. 
Lymphocytes circulating in hepatic sinusoids can extend cytoplasmic protrusions 
entering through sinusoidal fenestrations into the space of Disse where they can contact 
with hepatocytes64. In contrast to other parenchymal cells in non-lymphoid organs in the 
body, hepatocytes can directly prime T cells65'67. Hepatocyte-primed T cells undergo
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initial clonal expansion but are eventually eliminated because of the lack of sufficient 
co-stimulation and the subsequent activation of pro-apoptotic programs.
While antigen presentation in the tolerogenic liver environment favours the induction 
of tolerance, the initiation of immune responses can occur after APCs activation and 
migration to lymphnodes where antigen presentation occur in a canonical context. Thus 
the outcome of the immune response against an antigen could be the result of the 
balance between intra-hepatic and intra-nodal antigen presentation. The site of primary 
T cell activation may thus determine the balance between immunity and tolerance. T 
cell activation with subsequent tolerance may prevail when intra-hepatic antigen 
presentation is greater or begins earlier than intra-nodal antigen presentation68.
Potentially, the inherent tolerogenicity of the liver could be exploited to prevent or 
suppress unwanted immune responses. Targeted expression of foreign or auto-antigens 
in hepatocytes through gene transfer has been shown to induce antigen-specific Tregs 
and tolerance towards a number of model or therapeutic antigens and using a variety of 
delivery vectors69'76. Specific tolerance to transgene products can thus be achieved upon 
hepatic gene transfer, when transgene expression is specifically targeted to hepatocytes 
and minimised in APCs and the gene transfer vectors cause little innate immunity 
stimulation and tissue damage. It is unclear whether this outcome can be observed for 
all types of transgenes or conditions. It is likely that certain transgenes are more 
immunogenic than others and the host genetic background or the underlying disease 
may render the host more prone to develop an immune response. In these cases, other 
immune modulatory approaches can be coupled to liver gene transfer to favour 
tolerance induction54. The growing knowledge of the liver immunoregulatory circuits 
and of ways to manipulate them may allow the development of powerful approaches for 
immune-mediated diseases.
1.2 Haemophilia
Haemophilia is an inherited coagulation disorder caused by the deficiency or 
dysfunction of coagulation Factor VIII (FVIII) or coagulation Factor IX (FIX), the 
former being referred to as haemophilia A or classic haemophilia, the latter as 
haemophilia B or Christmas disease (named after the family in which the factor was 
described). Factor XI deficiency (originally called haemophilia C) is less common and
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in most cases mild coagulation disorder. Haemophilia has an X-linked recessive 
inheritance and is due to mutations in FVTII-encoding (F8) or FIX-encoding (F9) gene. 
Haemophilia has a prevalence of 1 in 10,000 males worldwide (1 in 5,000 for 
haemophilia A, 1 in 30,000 for haemophilia B). Male individuals are clinically affected, 
while women are carriers and are generally asymptomatic77.
Haemophilia is notorious from a historical perspective since Queen Victoria of 
England was a carrier and the trait was passed along the royal families of Prussia, Spain 
and Russia during the XIX and XX centuries. Recent molecular analysis of original 
specimens from the Romanovs revealed mutations in the F9 gene, thus the royal disease 
turned out to be the less common haemophilia B78.
The F8 and F9 genes were cloned in the 1980s and are both located on the long arm 
of chromosome X. F8 gene is very large (186 kb, with approximately 9 kb of exons), 
while F9 gene measures 33 kb, with approximately 2 kb of exons. Some thousands of 
different mutations are recorded in databases, with approximately one third of them 
arising de novo19. Several types of alterations can affect F8 gene, including gene 
rearrangements, missense and nonsense mutations, abnormal splicing, deletions or 
insertions of genetic elements. One of the most common mutations (affecting about 
45% of individuals with haemophilia A) is intron 22 inversion, a unique combined gene 
inversion that disrupts the gene. During meiosis, crossing over occurs between 
homologous sequences located nested in the intron and extragenic. This mutation arises 
almost exclusively in the male germline80. Mutations in the F9 gene have been 
described in all regions, the majority being point mutations, while short additions or 
deletion, gross deletions or complex rearrangements are less frequent79. Mutations in 
the promoter have been described leading to the haemophilia B Leiden phenotype, in 
which FIX levels gradually rise following puberty81.
FVIII is a 2351-amino acids long glycoprotein that consists of two chains. It can be 
synthesised and released into the bloodstream by hepatocytes, although the primary site 
of production in humans is debated and extra-hepatic FVIII production has been 
reported in several tissues (spleen, lymph nodes, pancreas, kidney, muscle)82. Clinical 
evidence from haemophilia A donor liver transplantation and studies conducted in 
animal models suggest that FVIII can also be synthesised by other cells, such as 
endothelial cells and bone marrow-derived monocytes and tissue macrophages and
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mesenchymal stromal cells83'85. The protein contains a large B domain that is not 
essential for coagulant activity. In the blood, FVIII mainly circulates in a stable non- 
covalent complex with von Willebrand factor (VWF), an endothelial-cell derived 
plasma glycoprotein that protects it from proteolysis. FVIII has a half-life of about 12 
hours and is found at 100 ng/ml in normal plasma86.
FIX is a 415-amino acids serine protease produced by hepatocytes. Because it is less 
complex than FVIII, FIX has been studied in greater detail. The protein consists of a 
signal peptide that targets the protein for secretion to the circulation. The propeptide is 
necessary for posttranslational modification of glutamic acid residues by an intracellular 
vitamin K-dependent carboxylase. The y-carboxyglutamic acid residues are necessary 
for calcium-dependent lipid binding and are crucial to biological activity. Besides y- 
carboxylation, the protein undergoes other post-translational modifications, such as 
disulfide bond formation, beta-hydroxylation and glycosylation. The propeptide is 
cleaved from the mature protein on transit from the Golgi apparatus before it enters the 
circulation. During clotting, the activation peptide is cleaved from the zymogen form, 
resulting in the two-chain active enzyme. FIX has a half-life of about 24 hours and its 
concentration in normal plasma is 5 pg/ml77.
1.2.1 Pathogenesis
The hallmark of haemophilia is uncontrollable bleeding, either spontaneous or post- 
traumatic. Bleeding occurs due to failure of secondary haemostasis. During primary 
haemostasis, formation of the platelet plug is not impaired, but stabilisation of the plug 
by fibrin is defective, because insufficient amounts of thrombin are generated.
The current model of the coagulation system involves a series of reactions that 
culminate in the production of thrombin, the key effector enzyme. Each of the reactions 
relies on the formation of a surface-bound complex and the conversion of inactive 
precursor enzymes (zymogens) into active proteases. Inactive factors are indicated by 
roman numerals and the active form by the addition of a lowercase “a”. Under normal 
conditions, natural anticoagulants mechanisms prevail over the procoagulant activity. 
The coagulation cascade is triggered in response to damage of the endothelium, 
exposure of extravascular tissues and platelet activation. Blood coagulation is achieved 
when a stable fibrin clot forms and subsequent vessel repair and wound healing can
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occur (as well as rapid fibrinolysis). Fibrinogen is converted into insoluble fibrin by 
thrombin (and by the concurrently activated Factor XIII). Thrombin is in turn activated 
from its pro-enzyme prothrombin. The latter reaction is catalyzed by activated Factor X 
(FXa), in combination with calcium, phospholipids and activated Factor V (FVa), the 
central reaction of coagulation, referred to as common pathway (Figure II). Activation 
of FX occurs either by activated Factor VII (FVIIa) and tissue factor (extrinsic 
pathway) or by activated FIX (FIXa) in a complex with calcium, phospholipids and 
activated FVIII (FVIIIa), an essential cofactor. FVIIIa and FIXa associate on the surface 
of activated platelets, forming the FX-activating complex (“tenase” or “Xase”). FIX 
activation is catalyzed by activated Factor XI, which is in turn activated by activated 
Factor XII (intrinsic pathway). Although the classic view of coagulation proposes two 
separate pathways, FVIII and FIX are known to be central to the process. Activation of 
FIX indeed occurs as well by the tissue factor-Vila complex. Once coagulation is 
initiated, the tissue factor pathway inhibitors (TFPI) block the extrinsic pathway and 
elements of the intrinsic pathway, particularly FVIII and FIX become the dominant 
regulators of thrombin generation (Figure II). Haemophilia results from reduced tenase
87activity, owing to decreased amounts of and/or functionally abnormal FVIII or FIX .
The laboratory tests employed to assay blood coagulation defects include: activated 
partial thromboplastin time (aPTT), the prothrombin time (PT) and the thrombin time 
(TT). These tests measure the time of plasma to clot upon addition of calcium and a 
phospholipidic activator. The aPTT assesses the function of the intrinsic pathway, while 
the PT assesses the function of the extrinsic pathway, as an excess of tissue factor is 
added. The TT assesses fibrin formation as thrombin is added in the test (Figure II). The 
bleeding time instead can detect platelet dysfunction and defects in primary 
haemostasis. In haemophilia the aPTT is prolonged, while PT and TT are generally in 
the normal range.
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Figure II: Coagulation cascade and laboratory tests to assess coagulation disorders.
Schematic o f the reactions involved in blood coagulation in vivo and negative 
regulators. PL: phospholipids. TFPI: tissue factor pathway inhibitors. aPTT: activated 
partial thromboplastin time. PT: prothrombin time. TT: thrombin time.
1.2.2 Clinical manifestations
Haemophilia A and B are clinically indistinguishable. The disease is characterized by 
excessive bleeding into various organs. Soft tissue haematomas and haemarthroses are 
highly characteristic. Haemophilia has been broadly classified in severe, moderate and 
mild, based on the severity of clinical manifestations. In severely affected patients (<1% 
of normal activity) recurrent haemarthroses resulting in chronic haemophilic 
arthropathy occur by young adulthood and are highly debilitating without treatment. 
Serious haemorrhages can compromise vital organs, however, episodes are intermittent 
and, except for intracranial bleeding, death because of haemorrhage is rare. Moderately 
affected patients (1-5% of normal activity) have occasional spontaneous haemarthroses 
and usually, but not always, following trauma. Mildly affected patients (6-30%) have
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rare spontaneous haemorrhages. The disease may go undiagnosed and discovered only
oo
following routine pre-surgery testing .
Bleeding into joints accounts for approximately 75% of bleeding in severely affected 
patients. The joint usually swells, becomes warm and exhibits limited mobility. 
Repeated bleedings into the joints eventually cause destruction of articular cartilage, 
synovial thickening and other reactive changes in the adjacent bone and tissues. The 
major complication is joint rigidity complicated by muscle atrophy and soft tissue 
contractures. The tendency for repeated bleeding episodes results in the clinically 
recognized “target joint”. Haemorrhage into subcutaneous connective tissue or into 
muscles may occur with or without trauma. As a result, large haematomas may form 
and progressively enlarge in severely affected patients. Retroperitoneal haematomas can 
expand through the diaphragm into the chest and neck and compromise the airways. 
Oropharyngeal haematomas, sometimes as a complication of simple colds may enlarge 
and lead to airways obstruction. Mucous membrane bleeding is common, often resulting 
from allergic reactions or trauma and can be associated with local lesions involving the 
respiratory tract. Intracranial haemorrhage is the most dangerous event and can put life 
at serious risk. Bleeding into the central nervous system may be spontaneous but usually 
follows trauma. Haemorrhage into the spinal cord is uncommon but can result in 
paraplegia77.
1.2.3 Treatment
There is currently no cure for haemophilia. The treatment aims at raising missing 
factor to sufficient plasma levels in order to restrain spontaneous bleedings or arrest 
haemorrhages following trauma or surgery. Bleeding events can be managed by 
exogenously replacing the missing factor (replacement therapy).
Whole blood transfusion was shown to treat haemophilia-associated bleedings in the 
1800s. The modem treatment started during the 1940s with plasma transfusion.
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However, plasma-transfused clotting factors were not enough to stop severe bleeding . 
Subsequent advances in blood fractionation and the discovery of the plasma fraction 
enriched for clotting factors in the 1960s led to the availability of the first factor 
concentrates, capable of delivering large amounts of clotting factors in a relatively small 
volume90. The expectancy and quality of life of severe haemophiliacs dramatically
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improved thanks to such concentrates and home infusion therapy was introduced in the 
1970s. After the advent of factor concentrates, the morbidity and mortality in 
haemophilia were significantly reduced and the life span of haemophilic patients began 
to approach that of normal individuals. Unfortunately, this advance was overshadowed 
by contamination of the factor concentrates with hepatitis B virus, hepatitis C virus 
(HCV) and, later on, human immunodeficiency virus (HIV). Complication of HIV and 
HCV is the leading cause of death in the haemophilia population treated before 1985, 
when viral inactivation steps were introduced in the preparation of plasma-derived 
products91. However, this procedure does not guarantee the absence of blood-borne 
infectious agents, as non-enveloped viruses cannot be completely eliminated and 
transmission of prion disease has been a concern, though never proved. Cloning of the 
genes for FVIII and FIX has allowed the production of purified recombinant proteins by 
genetic engineering technologies. These recombinant clotting factors, both licensed in 
the 1990s, are generally safe in terms of viral disease transmission91.
Replacement therapy can be administered either in response to bleeding (on demand) 
or as a prophylaxis, which aims to maintain the missing clotting factor levels at about 
1% or higher in order to prevent spontaneous bleedings, especially into joints. 
Prophylaxis has gradually become the preferred choice, especially in young patients. 
Regular intravenous (i.v.) infusions of FVIII (3 times/week) or FIX (2 times/week) 
prevent joint abnormalities in most patients receiving prophylaxis early in life. Factor 
levels at 30-50% are sufficient to treat mild bleedings, such as uncomplicated 
haemarthroses or superficial haematomas, while bleeding into deep muscles or large 
haematomas require factor levels of 50% or higher. The control of serious bleeding 
affecting pharyngeal or retroperitoneal spaces or the central nervous system necessitates 
sustained factor levels of 50-100% for 7-10 days. Prophylactic replacement for surgery 
is intended to achieve normal factor levels (100%) for a period of 7-10 days. 
Prophylactic replacement therapy with recombinant factors is considered effective and 
safe and currently patients undergoing this type of treatment from the young age have a 
nearly normal life expectancy (about 65 years)91.
Liver transplantation has been performed in some cases in older haemophilic patients 
co-affected by chronic hepatitis and resulted in a cure of the disease. However it cannot 
been proposed as a standard therapy92.
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1.2.4 Inhibitors development and management
The major complication of factor replacement therapy is the formation of allo- 
antibodies against the supplied factor that can neutralize its activity. Neutralizing anti­
factor antibodies are frequently referred to as inhibitors. Inhibitors develop in 20-30% 
of patients with severe haemophilia A and 3-5% of patients with haemophilia B 
following replacement therapy93. Rarely, inhibitors can arise as auto-antibodies against 
clotting factors leading to acquired haemophilia94. Mutations with substantial loss of 
coding regions, such as large deletions or inversions, predispose patients to inhibitor 
development and represent the main predictor of this complication, as central immune 
tolerance may not develop towards the missing clotting factor. Family history and 
genetic background, such as African descent, some HLA haplotypes or the genetic 
profile of immune regulatory genes are other risk factors. Usually inhibitors appear 
early after the initiation of replacement therapy. However, the risk of inhibitor 
formation is increased during intensive replacement therapy, such as for trauma, major 
bleeding or surgery, as the latter ones can represent “danger signals” for the immune 
system to attack the supplied factor. On the contrary, the degree of purity of the 
replaced factor does not seem to affect the probability of inhibitor formation95.
The clinical management of inhibitor-positive haemophilic patients is challenging. 
Inhibitors are diagnosed in an aPTT assay in which normal plasma does not correct the 
aPTT in a 1:1 mix with test plasma. The Bethesda titre is defined as the inverse of the 
dilution of test plasma that inhibits 50% of normal plasma (1 Bethesda Unit, BU =1:1 
dilution). Based on the inhibitor titre, patients are arbitrarily classified in low responders 
(<10 BU) and high responders (>10 BU). Treatment in inhibitor patients aims at 
controlling bleeding episodes and eradicating the inhibitors. In low responders, 
bleedings can be managed by administering high doses of recombinant factor which can 
overcome inhibition, or recombinant factor from other species such as porcine FVIII, if 
inhibitors do not cross-react. High-responder patients usually do not respond to FVIII or 
FIX concentrates and the control of bleeding events can be achieved using bypassing 
agents, such as prothrombin complex concentrates (containing variable amounts of 
activated factors such as FVIIa, FIXa, FXa) or recombinant activated FVII. How these 
agents bypass the inhibitors is not known, but it is postulated that they enhance the
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extrinsic coagulation pathway. Although it is believed that they act at the site of vessel 
injury, where activated platelets are localized, there is the risk that these agents are 
thrombogenic96,91.
The most effective approach for eradicating inhibitors is immune tolerance induction 
(ITI). ITI is based on the daily administration of high doses of recombinant factor until 
the inhibitors disappear, which typically requires more than one year. Recently low- 
dose regimen have been shown to be as effective as high-dose regimen and thus are 
being preferred in the clinical practice. ITI can be combined with immune suppression 
or immune adsorption protocols. ITI has a success rate in the range of 60%, but is very 
expensive and demanding. Complications due to central venous access may occur. 
Because of the lower frequency of inhibitor development, there is less experience in the 
management of inhibitor patients with haemophilia B. ITI can be attempted in these 
patients, but the risk of anaphylaxis or nephrotic syndrome is higher98, " .  The 
mechanism by which ITI acts is not completely understood. It has been hypothesized 
that chronic exposure to the antigen in “non-dangerous” conditions (without activation 
of innate immunity) induces immune tolerance. Induction of Tregs and 
anergy/inactivation of memory B and T cells have been reported100. The management of 
patients with inhibitors resistant to eradication is very challenging: classic immune 
suppression or administration of monoclonal anti-CD20 antibodies are generally 
ineffective. Inhibitors increase both morbidity and mortality in haemophilia and in 
general the management of inhibitor-positive haemophilic patients is still an unmet 
medical need.
1.2.5 Bioengineered clotting factors
Recently a number of novel approaches have been conceived to bypass or improve 
current factor replacement therapy regimens. In particular, increasing the circulation 
half-life of clotting factors is desirable, as it would reduce the frequency of infusions 
needed to maintain a mean trough of 1% above baseline, reducing patient inconvenience 
and non-compliance to therapy. Towards this goal, several bioengineered versions of 
the clotting factors have been developed101. Early attempts to improve the stability of 
recombinant clotting factors by conjugation with high molecular weight molecules such 
as polyethylene glycole (PEGylation) have been mostly unsuccessful101. Another
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approach consists in the fusion of recombinant FVIII or FIX to the fragment 
crystallisable (Fc) domain of human immunoglobulin (Ig). The Fc domain permits 
binding to recycling receptors that rescue antibodies and Fc-fusion proteins from 
lysosomal degradation upon phagocytosis. Both FVIII-Fc and FIX-Fc have been 
developed and resulted in improved pharmacokinetic profile in clinical trials, with 1.5- 
to 3-fold increased half-life102,103. Interestingly the more modest increase observed for 
FVIII-Fc suggest a predominant role for VWF in determining FVIII half-life. 
Alternatively FIX has been fused with albumin, showing promising result in a clinical 
trial104. Other approaches to enhance thrombin formation bypassing the intrinsic 
pathway have been tried. These include inhibition of key negative regulatory pathways 
such as TFPI or activated protein C inhibition, or the use of factor muteins such as 
FVIH-independent FIX or FVIII/FIX-independent FX101, 105. Although promising, the 
efficacy and safety (in terms of immunogenicity or thrombogenicity) of these 
approaches need to be determined with more extensive investigations.
1.3 Haemophilia gene therapy
Prophylactic replacement therapy with recombinant products, which are devoid of 
contaminating viral pathogens, is the current standard of care for haemophilia in high- 
income countries (see 1.2.3). This form of treatment is considered effective and safe and 
has substantially improved the quality and expectancy of life of severe haemophilic 
patients. Nevertheless this treatment has several drawbacks. First of all, the high cost of 
recombinant clotting factors results in a considerable expense for the health care system 
(estimated about 100,000 $ per year per patient). Second, the short half-life of 
recombinant clotting factors imposes frequent (2-3 times per week) i.v. injections to 
minimise the risk of spontaneous bleeds, with resulting discomfort and inconvenience 
for patients and in some cases non-compliance (central venous access devices may be 
necessary with the related risks of infections or thrombosis). Third, factor replacement 
therapy entails the serious risk of inhibitors formation, which challenges further 
treatments (see 1.2.4). It should be underlined that today about 80% of haemophiliacs 
live with any or unsatisfactory treatment world-wide, mainly in developing countries106. 
For these reasons the development of alternative forms of treatment is encouraged.
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In contrast to replacement therapy, gene therapy offers a greater prospect of a 
definitive cure for haemophilia, through restoration of endogenous, life-long production 
of the missing clotting factor at therapeutic levels. Haemophilia is an ideal target 
disease for gene therapy for a number of important reasons. The disease-causing genes 
are known and have been cloned. The therapeutic goal is relatively modest, as clinical 
experience indicates that stably rising FVIII or FIX levels to just as 1% of normal levels 
can significantly ameliorate the bleeding diathesis. These levels do not require tight 
regulation, since up to 150% of normal are considered safe107. Although the liver is the 
natural site of production of most plasma protein, FVIII and FIX can be expressed in a 
variety of cell types, as soon as biologically active molecules can reach the circulation. 
The outcome measures are quite straightforward as factor levels and clotting activity 
can be assessed relatively easily with a blood withdrawal and these levels correlate well 
with the clinical phenotype. Finally excellent animal models that closely recapitulate the 
human disease are available for pre-clinical testing of gene therapy strategies. Both KO 
mice for F8 and F9 genes have been generated and dogs affected by haemophilia A and 
B due to spontaneous mutations are being maintained108. While haemophilia can benefit 
from gene therapy, the vice versa is also true. The development of gene therapy 
strategies for haemophilia, where the therapeutic goal is relatively easy to accomplish, 
has served as trailblazer for applications in more demanding monogenic and complex 
diseases. The aforementioned features of haemophilia and the significant limitations of 
its current treatment modality justify more than 20 years of intense research in 
haemophilia gene therapy. A variety of gene delivery systems adopting in vivo or ex 
vivo approaches and targeting different tissues (most often liver and muscle) have been 
reported with varying degree of success in preclinical small and large animal models 
and clinical trials107' 109413.
1.3.1 Ex vivo gene transfer
Ex vivo gene therapy strategies for haemophilia are attractive because of the hurdles 
of direct in vivo gene delivery. The very first attempts in haemophilia gene therapy were 
represented by ex vivo strategies, but were mostly unsuccessful due to low levels of 
circulating clotting factors and limited survival of genetically modified cells after return 
into the host114. Ex vivo genetic modification of fibroblast with FVIII-expressing vectors
33
and implantation into immune deficient mice resulted in persistence of viable 
fibroblasts for 2 months, capable of FVIII secretion in tissue culture. However plasma 
FVIII expression could not be detected in mice115. The first clinical trial was carried out 
by ex vivo modification of fibroblasts obtained from 2 patients affected by severe 
haemophilia B with a FIX-expressing vector and re-implanted back into patients. 
Expression of active FIX in the plasma was observed at 2% of normal levels, however 
the cumbersome nature of the procedure was prohibitive and prevented the initiation of 
further trials116. A subsequent trial was held in which fibroblasts from patients affected 
by severe haemophilia A were transfected ex vivo with DNA plasmids encoding hFVIII. 
However, upon re-implantation of the cells, FVIII expression was transient and no
117significant clinical benefit was detected .
Ex vivo strategies are gradually regaining interest along with the advances in the 
technology of in vitro manipulation and genetic modification of human cells. The main 
difficulty lies in establishing the appropriate environment and blood supply for 
implanted cells to survive and release the desired clotting factor into the bloodstream. 
One interesting approach is to target FVIII expression in endothelial cells, which 
naturally express the protein and its carrier VWF. Transplantation of wt LSECs in 
haemophilia A mice following damage to recipient LSECs to facilitate engraftment 
restored normal haemostasis84. In a recent study by Kren et al. efficient targeting of the 
FVIII transgene has been demonstrated to LSECs118. However engraftment of these 
LSECs still poses a significant hurdle for the success of these approaches. Alternatively 
circulating blood outgrowth endothelial cells (BOECs) can be isolated from peripheral 
blood and expanded in vitro. Sustained therapeutic hFVIII expression levels could be 
achieved in immune deficient mice after i.v. administration of transfected BOECs or 
after subcutaneous administration in scaffolds119,120. A similar strategy resulted in FIX 
expression in myoblasts implanted in bioartificial scaffolds engineered to express 
vascular endothelial growth factor121. None of these strategies has been tested beyond 
small animal models and their efficacy and safety assessment requires more extensive 
investigation.
Due to the large experience with ex vivo genetic modification and transplantation of 
HSPCs, this approach has been considered a valid alternative to in vivo gene delivery 
for treatment of haemophilia122'124. As expected by the resetting of the immune system
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after pre-conditioning and HSPC transplantation, tolerance was achieved to both FVIII 
and FIX. However, potential toxicities due to ectopic unregulated clotting factor 
expression in HSPCs and blood lineages remain to be clarified. Recently, novel 
approaches involving ex vivo HSPCs gene therapy have been reported. In one study, 
HSPCs were gene-engineered with a vector encoding a FVIII cDNA under the control 
of a megakaryocyte-specific promoter. After bone marrow transplantation, FVIII 
expression was selectively targeted in platelets and this was sufficient to correct the 
bleeding diathesis in haemophilia A mice. Interestingly, this happened even in mice 
with inhibitors against FVIII, likely due to the fact that platelets release FVIII within the 
forming clot where it may be hardly accessible to neutralizing antibodies125'127. 
Similarly, FIX could be expressed and stored in platelets granules, normalizing 
haemostasis in haemophilia B mice128. Another approach involves red blood cell- 
targeted FIX production. Erythroid-derived FIX was shown to be biologically active 
and to correct the bleeding disorder, following transduction of HSPCs with a vector 
carrying the human FIX transgene under the control of human (3-globin promoter, 
enhancer and locus control region . A concern for these approaches is whether the 
production of clotting factors that are normally plasmatic in red blood cells or platelets 
alters the normal coagulation profile in treated subjects130. Moreover, a significant 
limitation of all approaches involving HSPC gene therapy is the substantial toxicity 
associated with the transplantation procedure in myeloablative conditions, whereas non- 
myeloablative conditions may not allow sufficient engraftment or transgene tolerance 
induction and their clinical relevance requires careful risk/benefit assessment in each 
specific condition131.
1.3.2 Non-viral vectors
Non-viral vectors such as simple naked DNA represent the most obvious carrier of a 
transgene. However it is unlikely that such DNA would survive the journey from the 
extracellular space to the nucleus of target cells. To facilitate this task, chemical and 
physical methods have been studied132. Plasmid DNA can be delivered in a complex 
with cationic polymers, liposomes or nanoparticles which improve stability, cell uptake 
and intracellular trafficking.
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The advantages of non-viral vectors are their relative ease and low cost of 
production, the absence of virus-derived products, the virtually unlimited size of DNA 
that can be delivered and the potential for repeated administrations. Although it was 
initially believed that non-viral vectors cause little inflammation and toxicity, bacterial 
DNA, in particular unmethylated CpG motifs can activate innate immune responses1. 
However, the general low efficiency of gene transfer and the transient expression levels 
are considerable disadvantages of naked DNA vectors for haemophilia gene therapy.
While non-viral vectors can result in good efficiencies of gene transfer in cell 
cultures, their efficiency for in vivo gene delivery is low. One way to achieve relatively 
efficient hepatocyte transfection (up to 40%) in mice is by hydrodynamic injection133. 
This technique is based on high-pressure infusion obtained by rapid i.v. injection (3-5 
seconds) of DNA in a large volume (10% of body weight). The simplicity of this 
technique has allowed a wide range of use for in vivo studies in mice. However this 
technique can cause transient liver damage and is not readily suitable for clinical 
translation, although efforts to render it more feasible and safer have been made in 
larger animals132.
Even with hydrodynamic infusion into the liver, gene delivery can be short lived, 
unless chromosomal integration or episome stabilization is achieved. Moreover, 
transgene expression usually decreases rapidly over several weeks, not necessarily 
because of the loss of vector DNA, but due to the loss of transgene mRNA, for reasons 
that are not still well understood1. It has been shown that minicircle DNA vectors can 
solve this issue. Minicircle DNA vectors are devoid of bacterial plasmid backbone 
sequences and essentially deliver only the transgene expression cassette. They have 
been shown to drive transgene expression at levels 2-3 orders of magnitude greater than 
routine plasmids134.
FVIII and FIX transfer has been reported in normal and haemophilic mice using 
hydrodynamic liver delivery of a DNA plasmid containing hepatocyte-specific 
expression cassettes optimized for robust expression and stability, by incorporation of 
locus control regions and matrix attachment regions135. Human FIX (hFIX) expression
1 36was maintained at therapeutic levels for more than 1 year in haemophilia B mice . 
While long-term expression of a human B-domain deleted FVIII (hBDD-FVIII; see 
1.3.4.2) was obtained in immune deficient mice137, a strong humoral anti-transgene
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immune response was elicited in haemophilia A mice independently of whether human, 
canine or murine BDD-FVIII was delivered138. Subsequent studies have shown that 
transient immune suppression or immune modulation with T cell-depleting antibodies, 
co-stimulatory blockade or Tregs boosters (complex biological molecules known to 
increase Tregs/T effectors ratio) can promote long-term expression and tolerance to 
plasmid-mediated FVIII delivery in haemophilia A mice139'141. These strategies, 
however, have never been tested in large animal models of the disease and may be 
difficult to translate in the clinical setting because of the current requirement for 
hydrodynamic delivery.
1.3.3 Non-viral integration and gene correction strategies
Several methods to mediate transgene integration into the genome of target cells 
have been developed and may compare favourably with respect to viral vector-mediated 
integration. Among these, DNA transposons, bacteriophage recombinases and site- 
specific engineered nucleases have been adopted as alternative strategies for 
haemophilia gene therapy (see also 1.1.7). These strategies rely on the (desirably 
transient) co-delivery of the integrase or nuclease proteins together with an appropriate 
substrate DNA to be integrated1. Sleeping Beauty (SB) is one of the mostly used 
transponsases in gene therapy and can direct non-homologous integration of a transgene 
flanked by the recognized transposition sites into TA dinucleotides in the genome. SB- 
mediated integration of a transposon carrying a FIX expression cassette has been 
achieved in haemophilia B mice through co-delivery via hydrodynamic liver 
transfection of two plasmids expressing SB and carrying the FIX-expressing 
transposon142. The same strategy also resulted in BDD-FVIII expression in haemophilia 
A mice, although these mice required pre-tolerization to FVIII to avoid inhibitor 
formation143. Recently, a hyperactive SB transposase (SB100X) was derived from the 
original protein by selection from engineered mutant libraries144. SB100X could 
transpose 100-fold more efficiently a FIX-expressing transposon in the liver of normal 
mice by hydrodynamic DNA delivery, and in haemophilia B dogs through co-delivery 
of two adenoviral vectors (see 1.3.4.2): one carrying a cFIX expression cassette and the 
other encoding for SB and a recombinase to circularize the transposon DNA145. 
Bacteriophage recombinases, such as cpC31, can mediate integration of a DNA sequence
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flanked by specific recognition sites into pseudo-sites in the genome that resemble the 
endogenous prokaryotic consensus sites. Co-delivery of the recombinase and a FIX- 
expressing DNA by hydrodynamic injection in normal mice resulted in hFIX 
expression146. RNA trans-splicing has also been obtained in vivo in the liver of 
haemophilia A mice administered with naked DNA containing the trans-splicing 
construct. This resulted in partial short-term correction of the defective haemostasis147. 
Recently, in an elegant study, it was reported proof-of-principle of in vivo genome 
editing in hepatocytes. This study was performed in ad hoc generated normal and 
haemophilia B mice transgenic for a truncated form of human F9 gene under the 
transcriptional control of a hepatocyte-specific promoter. Neonatal mice were co­
administered with two adeno-associated viral vectors (see 1.3.4.3), one expressing 
ZFNs designed against the first intron of the F9 gene and the other carrying a donor 
DNA bearing a promoterless FIX cDNA spanning exons 2-8. This procedure resulted in 
targeting of the corrective cDNA to the homologous transgenic sites and expression of 
FIX at 5% of normal levels49. It is unclear whether this approach is feasible in adults, as 
ZFNs expression would predictably be long-lasting in genetically modified hepatocytes. 
While powerful and fascinating from the molecular and technological point of view, all 
these approaches require efficient in vivo delivery of the nucleases/template DNA 
combination and their main limitations fall into the same category as the limitations of 
the delivery vectors. These approaches may be better suited for ex vivo strategies. 
Moreover, the safety of such nucleases in gene therapy applications has yet to be 
thoroughly assessed.
1.3.4 Viral vectors
The development of viruses-derived vectors stems from the necessity to find an 
efficient vehicle to shuttle the foreign genetic materials into the nucleus of mammalian 
cells1,148. Recombinant viral vectors are designed to harness the native viral infection 
pathway to perform this task. Most viral vectors are constructed ad hoc to lead to a non- 
replicative life cycle, which ends with the insertion of the recombinant viral genome 
into target cells (referred to as transduction). The principle for recombinant viral vector 
construction is the physical separation of the cis- and trans-acting genetic elements. 
This is performed in order to generate a replication-defective viral vector and to
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minimize the risk of formation of replication-competent particles. On one side, the 
trans-acting sequences of the original viral genome that encodes for proteins involved 
in virion assembly and transfer of genetic material are maintained and expressed in 
trans in the producer cells (by packaging constructs). Instead, all the viral genes coding 
for toxic or pathogenic proteins should be eliminated. On the other side, the engineered 
vector genome contains the therapeutic transgene expression cassette together with the 
only c/s-acting elements from the original virus necessary for gene transfer purposes. 
This is the only nucleic acid sequence containing the packaging signal, encapsidated 
into viral vector particles and transferred to target cells. The packaging constructs and 
recombinant vector genome can be provided by transient plasmid transfection or stably 
expressed in the producer cells, if available.
Viral vectors can be broadly categorised in integrating and non-integrating, 
depending on their ability to mediate integration of the vector genome into recipient 
cells’ nuclear DNA. Efficient integration is a property of gammaretroviral and lentiviral 
vectors, while adenoviral and adeno-associated viral vectors are classified as non­
integrating vectors. These are the most widely used viral vectors in gene replacement 
therapy.
1.3.4.1 Gammaretroviral vectors
Gammaretroviral vectors (RVs) derive from gammaretroviruses, belonging to the 
family of Retroviridae. This family comprises several animal viruses that are now being 
exploited as gene transfer vehicles: alpharetro viruses, gammaretro viruses, lentiviruses 
and spumaviruses. Retroviruses are enveloped viruses of about 100 nm with a 7-10 kb 
positive single-stranded RNA (ssRNA) genome present in two copies inside the 
particle. For productive infection, the viral genome must be converted into double­
stranded DNA (dsDNA) by the viral reverse transcriptase, packaged inside virions. 
Once the reverse transcribed genome is transferred to the cell nucleus by means of 
passive or active mechanisms, all retroviruses are able to integrate their genome into the 
host cell chromatin. Gammaretroviruses harbour a simple genome bearing the essential 
genes gag (encoding for capsid proteins), pol (encoding for reverse transcriptase, 
integrase and protease) and env (encoding for the envelop protein). Lentiviruses and 
spumaviruses have a more complex genome harbouring the essential genes together
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with additional regulatory and accessory genes responsible for regulation of viral gene
• 9 0expression, life-cycle and pathogenicity .
Gammaretroviruses were among the first viruses to be exploited to develop viral 
vectors for gene therapy, because of the extensive knowledge about these viruses, the 
absence of natural infections in humans and the possibility to produce them with a non­
native envelope (pseudotyping). RVs allow the stable transfer of up to 7 kb of genetic 
material because they integrate into the host cell genome, thus leading to transgene 
transmission to the cell progeny upon cell division. Over the years, stable packaging 
cell lines have been developed, thus facilitating the scaling-up of vector production for 
clinical translation149. RVs were the first viral vectors to enter clinical trials and have 
brought important advances in gene therapy with ex vivo transduction of HSPCs (see 
1.1.1).
A significant drawback of RVs is that they rely on cell mitosis and disassembly of 
the nuclear envelope to integrate their genome into the target cell chromatin, therefore 
they can only transduce actively proliferating cells. For this reason they are better suited 
for ex vivo transduction, rather than direct in vivo administration. Liver gene transfer by 
RVs requires stimulation of hepatocyte replication or neonatal delivery in order to 
achieve efficient transduction. To encourage hepatocyte replication different methods 
were introduced including partial hepatectomy and growth factor-induced hepatocyte 
proliferation. The pioneering work by Kay et al. in the early 1990s resulted in the first 
long-term somatic gene therapy in a large animal model. Haemophilia B dogs were 
treated by portal vein infusion of canine FIX (cFIX)-expressing RVs upon partial 
hepatectomy. The procedure resulted in stable low-level FIX expression (0.1% of 
normal)150. Subsequent work focused on neonatal or hepatocyte growth factor (HGF)- 
potentiated administration of FVIII or FIX in haemophilic mice and dogs. Functional 
hFVIII expression was first obtained upon neonatal RV delivery in haemophilia A mice, 
yet in some mice inhibitors developed151. Neonatal delivery of cFIX-expressing RVs 
also resulted in therapeutic transgene levels in haemophilia B dogs152. Interestingly 
neonatal liver gene transfer resulted in immune tolerance to FIX, probably due to the 
immaturity of the immune system of a neonate, while the same RV administered to 
adult HGF-treated haemophilia B mice induced anti-cFIX antibodies. RV-mediated 
neonatal liver gene therapy in haemophilia A dogs resulted in therapeutically relevant
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FVIII levels which were maintained for nearly 3 years153. A phase I/II clinical trial was 
performed in adult patients with severe haemophilia A involving multiple peripheral i.v. 
administrations of RVs expressing hFVIII. Adverse events were not observed but very 
low and transient amounts of FVIII were detected154.
The genotoxicity of RVs observed in clinical trials for inherited immune 
deficiencies15'17 raises important concerns over further use of these vectors in the 
clinical setting. Although improved RVs have been generated which are less prone to 
induce insertional mutagenesis, the genotoxic potential of RVs remains an issue1, 21. 
This, coupled to the inefficient transduction of quiescent hepatocytes currently restricts 
their adoption as a possible form of therapy for haemophilia.
1.3.4.2 Adenoviral vectors
Adenoviruses are medium-sized (80-100 nm) non enveloped viruses composed of a 
nucleocapsid and a linear dsDNA genome. Several different serotypes have been 
isolated, many causing upper respiratory tract and gastro-intestinal infections in 
humans. Adenoviruses were also among the first viruses exploited as recombinant viral 
vectors for gene therapy. Recombinant adenoviral vectors (Ads) present a number of 
attractive features for gene therapy. Ads are relatively easy to produce at high titres, 
efficiently transduce a variety of cell types including non-dividing cells, can 
accommodate large amounts of DNA and efficiently express transgenes episomally 
without integration into the host cell genome. Ads trigger massive innate and adaptive 
immune responses which represent a major obstacle for their clinical use in gene 
replacement therapy155.
To obtain recombinant replication-defective vectors, first generation of Ads was 
constructed by deleting from the viral genome of origin the early region (E) 1 and E3 
genes, responsible for the expression of early viral genes and replication. First- 
generation Ads were shown to mediate FIX and FVIII expression in mice and dogs 
upon i.v. administration. The first evidence of FIX expression with Ads was achieved in 
normal mice156. The study was then extended to haemophilia B dogs, in which portal 
vein administration of first-generation Ads resulted in cFIX expression at supra- 
physiological levels which declined over a period of 100 days. This decline was 
consistent with gradual loss of vector DNA from transduced hepatocytes. At that time it
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was not clear whether this loss was due to dilution/instability of Ad episome, a 
cytotoxic immune response or both. Mild hepatocyte necrosis was detected at necropsy 
and a mild episode of disseminated intravascular coagulation (DIC) was suspected157. 
The inherent features of FVIII, such as mRNA instability, inefficient protein processing 
and secretion and the protein instability in the absence o f VWF, initially delayed efforts 
to incorporate it from vectors158. The first evidence of FVIII expression in vivo was 
obtained upon i.v. administration of Ads in normal mice158. A short form of the FVIII 
transgene was used, in which the B-domain was deleted. Removal of the B-domain was 
shown to have no effect on protein function or immunogenicity159 and was subsequently 
largely adopted in haemophilia A gene therapy studies. High-levels of hBDD-FVIII 
(300% of normal) were achieved in the first week and slowly decreased to background 
in few weeks158. Administration of lower vector doses resulted in longer-lasting FVIII 
expression in adult normal mice (5 months after vector injection) and a dose-dependent 
hepatotoxicity was apparent160. Subsequently a study was performed which showed, for 
the first time, proof-of-concept haemophilia A gene therapy in dogs. Peripheral vein 
administration of Ads resulted in circulating hBDD-FVIII levels well above the 
therapeutic threshold, which lasted for 2 weeks, when high-titre inhibitors developed161. 
This event highlighted the need to use specie-specific transgene to more appropriately 
evaluate the immune consequences of gene therapy. A more in-depth analysis of Ads- 
triggered toxicity was carried out in haemophilia A dogs treated with peripheral vein 
administration of Ads expressing canine BDD-FVIII (cBDD-FVIII). In these dogs a 
biphasic liver toxicity was detected. The first phase occurred within a few days after 
vector injection and was a dose-dependent response to the Ads particles. The second 
dose-independent phase arose at 7-10 days after vector injection and was consistent 
with an adaptive immune response that caused cytotoxic T lymphocyte (CTL)-mediated 
killing of transduced hepatocytes expressing both Ad backbone viral antigens and the 
transgene product. This immune response also led to the development of inhibitors. 
Although a hepatocyte-specific promoter was used, this immune response probably 
occurred following a strong innate immune activation induced by the Ads162. Despite 
the E1/E3 deletion, first-generation Ads, though being replication-defective, could still 
express viral proteins in transduced cells and this was thought to substantially contribute 
to the observed hepatotoxicity and immune responses.
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A significant advance in Ad technology was the development of progressively 
attenuated Ads with further deletions of the original viral genome until the latest 
generation of Ads, termed gutless, high-capacity or helper-dependent Ads (HD Ads) was 
introduced. HDAds are devoid of all viral genes, which are provided in trans during 
vector production by a helper virus and can carry up to 35 kb of DNA between the viral 
inverted terminal repeats (ITRs)163. HDAds were shown to provide sustained FIX or 
FVIII expression in mice, dogs and nonhuman primates (NHPs). I.v. administration of 
HDAds carrying the full-length hFVIII cDNA under the control of a 12-kb albumin 
promoter allowed high-level expression slowly decreasing over a period of 1 year in 
those haemophilia A mice that did not developed antibodies164. Ehrhardt et al. 
developed a HDAd bearing a previously optimized hepatocyte-specific cassette135 for 
hFIX or cFIX expression and containing matrix attachment regions and human 
centromeric repeats as “stuffer” DNA. This HDAd was able to provide therapeutically 
relevant FIX expression in haemophilia B mice and dogs at non-toxic doses, lasting for 
only few months in one dog165, 166. More prolonged therapeutic cFIX expression was 
obtained in older haemophilia B dogs receiving higher doses of HDAds, but transient 
hepatotoxicity and thrombocytopenia were observed167. Therapeutic FVIII levels were 
obtained in haemophilia A mice and dogs treated with i.v. infusion of HDAds 
expressing human or canine BDD-FVIII under the control of hepatocyte-specific 
promoters. In immune competent haemophilia A mice anti-transgene cellular and 
humoral immune responses were elicited and transgene expression was maintained for 
only 2 weeks in one dog, even if inhibitors did not develop168. Longer-lasting 
expression of cBDD-FVIII without anti-transgene immune response was achieved in 
haemophilia A dogs receiving higher doses of HDAds containing a more potent 
hepatocyte-specific expression cassette, but transient hepatotoxicity and 
thrombocytopenia were observed169. Low-level expression of cBDD-FVIII and partial 
correction of the clotting defects were reported to persist for more than 1 year in 
haemophilia A dogs, but transient acute toxicity was also observed170. Overall HDAds 
showed an improved toxicity profile and reduced immunogenicity due to the absence of 
viral gene expression and attained prolonged clotting factors expression in haemophilic 
animals. However it became clear that acute toxicity was mostly mediated by the Ad 
capsid and genome per se and was rather independent of whether a first-generation or
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HD Ad was used171. Brunetti-Pierri et al. reported dose-dependent acute toxicity after
19 13systemic injection of HD Ads into NHPs. Doses of 5x10 or 1x10 vector particles per 
kilogram of body weight (vp/kg) resulted in 50% or 100% hepatocyte transduction 
respectively, but were accompanied by a strong acute inflammatory response which was 
lethal at the higher dose. This response was characterized by a rise in serum liver 
enzymes and other markers of liver damage, increase in white blood cell counts, 
elevation of serum interleukin (IL) -6 and markers of DIC172.
Further efforts were devoted to understanding the dangerous relationships 
maintained by HDAds and the immune system and to decrease their toxicity and/or 
increase their efficacy in order to find a clinically applicable therapeutic window in 
which a vector dose is effective and not toxic. The interactions between Ads and the 
immune system are multifaceted (reviewed in155). Systemic administration of Ads leads 
to their contact with blood cells and blood-borne proteins, all of which play a role in 
acute toxicity. Migration of infiltrating leukocytes, platelet aggregation and production 
of proinflammatory cytokines and chemokines occur as a result of activation of the 
complement system by Ads. Both neutralizing and naturally occurring non-specific 
cross-reacting antibodies opsonise viral particles and in turn activate macrophages. Ads 
can stimulate platelet-activating factor, a shock inducer lipid signalling molecule. Ads 
activate TLRs both through capsid proteins and vector genome, which is also 
recognized by a TLR-independent nucleic acid-sensing mechanism known as the 
inflammasome173. It is challenging to find simple ways to dampen the innate immune 
response because of the many factors that contribute to Ad acute toxicity.
A phase I clinical study was initiated using systemic delivery of a HD Ad carrying the 
full length hFVIII cDNA, but the trial was put on hold, after the transient 
thrombocytopenia and signs of hepatotoxicity in the first patient treated. These results 
were never reported in a peer-reviewed format155.
Recently a minimally invasive method was introduced which improved hepatocyte 
transduction of HDAds in NHPs. A balloon occlusion catheter is percutaneously placed 
in the inferior vena cava to occlude blood outflow from the hepatic vein and vector is 
infused to the occluded liver via catheterized hepatic artery174,175. This procedure (based 
on a similar principle as hydrodynamic injection) resulted in therapeutically relevant 
hFIX expression levels at clinically relevant doses (lxlO11 vp/kg) in NHPs, that
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persisted for up to 3 years after injection. However, after the Jesse Geslinger death in 
the OT trial, who received 6xlOn vp/kg of a second-generation El/E4-deleted Ad (see 
1.1.1) and the results of the abovementioned trial, there is reluctance in further clinical 
testing of Ads for gene replacement therapy applications. Moreover, naturally occurring 
infections with adenoviruses can lead to the development of antibodies able to 
neutralize transduction by related Ads after systemic administration. On the other hand, 
the strong immune stimulatory properties of Ads make them attractive vehicles for 
vaccination and cancer gene therapy37.
1.3.4.3 Adeno-associated viral vectors
In the last decade, adeno-associated virus (AAV) vectors have arguably become the 
vectors of choice for in vivo gene therapy and currently the most compelling pre-clinical 
and clinical results in gene therapy for haemophilia have been achieved using these 
vehicles. AAVs are small, non-enveloped viruses of the family of Parvoviridae with a 
single-stranded DNA genome of 4.7 kb. The genome comprises ITRs at both ends of 
the DNA strand, and two genes, rep and cap required for the life cycle and the 
construction of the viral capsid. After entry, trafficking to the nucleus and uncoating, 
the genome of the wt viruses must be converted into dsDNA by viral proteins and the 
cellular machinery and can be retained in circular episomal forms or integrated into the 
AAVS1 site. For productive replication, these viruses require accessory proteins, 
derived from co-infection with adenovirus or herpes virus.
There are several advantages for using AAV vectors in gene therapy. AAV vectors 
derive from non-pathogenic viruses, are weakly immunogenic, do not express viral 
proteins and can efficiently transduce both dividing and quiescent cells. Various viral 
serotypes have been isolated from different species, which show different tissue-tropism 
and transduction properties. Efficient methods for the production of high-titre vector 
stocks have been developed and capsid stability allows for purification and
1 'JZ
concentration during vector preparation . Most (>99%) of proviral AAV genomes 
remain episomal in the nucleus of transduced cells, often in the form of concatameric 
DNA molecules. However integration can occur, preferentially into chromosomal 
breaks, perhaps explaining the bias for actively transcribed genes177. One important 
limitation of AAV vectors is the small size of the genome of the original virus that
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imposes a maximum size of 4-5 kb for the encapsidated DNA. Another challenge is the 
spread of natural AAV infections in the general population, leading to anti-capsid 
immune responses which can reduce the efficacy of gene therapy with AAV vectors, if 
administered in the circulation178.
Preclinical evaluation of this delivery system has primarily been assessed with the 
FIX transgene because of the limited cloning capacity of AAV vectors. The prototypical 
AAV vector is derived from adeno-associated virus type 2 serotype (AAV2). The use of 
AAV vectors for haemophilia gene therapy has been explored either by intramuscular 
(i.m.) or liver-directed vector administration. The muscle offer advantages as a target 
organ since it is directly accessible without systemic vector administration and may be 
better suited for those haemophiliac patients with concurrent liver disease. However, 
muscle-directed expression may not efficiently release clotting factors into the 
bloodstream and disfavours the onset of tolerance induction towards transgene antigens, 
rather it increases the likelihood of triggering an anti-transgene immune response. On 
the other hand liver-targeted transgene expression allows potentially higher levels of 
protein expression and secretion and is more tolerogenic (see 1.1.8.1). Stable hFIX 
expression at therapeutic levels was demonstrated in normal mice upon liver gene 
transfer with AAV vectors and in immune deficient mice upon i.m. injections of AAV
1 7 0vectors. In normal mice the i.m. procedure resulted in an anti-FIX antibody response ’ 
18°. These studies were then extended to haemophilia B dogs, showing stable cFIX at 1- 
2% of normal levels for 8-17 months (longest time reported) and partial correction of 
the clotting defects without toxicity or anti-transgene immune responses using either the 
muscle- or liver-directed approaches181, 182. Stable expression of hFIX to therapeutic 
levels (1-25% of normal) was also achieved for up to 1 year in NHPs183. Further studies 
evaluated improved AAV vectors containing a hepatocyte-specific expression cassette 
and reported therapeutic levels of cFIX (5-12% of normal) and nearly complete 
phenotypic correction. These levels were stable for over 17 months and could be 
achieved even in dogs carrying a null mutation in the F9 gene and thus more prone to 
develop anti-FIX immune responses39,184. Of note, a recent report showed stable cFIX 
expression in these dogs after 8 years, with no evidence of anti-transgene immunity or 
long-term toxicity185. Numerous studies suggest that hepatic gene transfer by these 
AAV vectors can induce transgene-specific Tregs and tolerance, which protect the host
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from subsequent immunological challenges (see also 1.1.8.1)69, 72,186. On the contrary, 
FIX inhibitors developed following intramuscular AAV vector treatment in inhibitor- 
prone dogs while sustained expression and partial correction of the haemostatic defect 
was achieved in one dog only when transient immune suppression was given at the time 
of vector administration187. The risk of inhibitor development, even in dogs carrying 
point mutations, increased with increasing vector doses and correlated most strongly 
with increased dose per site188.
These encouraging preclinical studies led to two phase I/II dose-escalating clinical 
trials employing AAV2 vectors for the treatment of individuals with severe haemophilia 
B. In one trial, patients (exclusively with missense mutations) were injected i.m. with 
2x10*1 to 2xl012 vector genomes (vg)/kg of an AAV vector expressing FIX. The 
procedure was safe, but plasma levels of FIX did not rise above 1% and limited clinical 
benefit was observed189. In another trial, AAV2 vectors containing a hepatocyte-specific 
expression cassette was targeted to the liver of severe haemophilia B patients via 
hepatic artery delivery. AAV vector infusion was not associated with acute or chronic 
toxicities. In the high-dose cohort (2xl012 vg/kg), plasma FIX levels of up to 12% of 
normal titres were detected. However, this increase was followed by a transient rise in 
serum transaminases levels, beginning at 4 weeks after vector injection and a 
concomitant loss of FIX expression was observed. Since anti-hFIX humoral or cellular 
responses were not detected in treated subjects, this clinical picture and further studies 
suggest that elimination of transduced hepatocytes was due to an AAV capsid-specific
/irriT  190CTL response .
This event was unanticipated considering results from preclinical animal models 
where transgene expression is observed to be long-lived. Instead humans are natural 
hosts for AAVs infection and previous encounters with the virus can give rise to clones 
of memory CD8+ T cells that can be stimulated following secondary encounter with the 
specific AAV antigens. In the clinical trial, although patients were selected for the 
absence of neutralizing anti-AAV antibodies, memory T cells specific for AAV capsid 
antigens were detected and it is believed that they may cause the clearance of FIX- 
expressing hepatocytes. Moreover epitope mapping revealed that these anti-AAV2 
capsid T cells recognize capisd epitopes conserved among different serotypes191. It was 
shown that primary human hepatocytes in vitro transduced with AAV vectors slowly
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degrade capsid remnants, that can be presented by MHC-I molecules for long time after 
transduction, thus leading to CTL recognition and killing of transduced cells192.
Based on this experience, the clinical protocol has been modified to include a 
transient immune suppression, in order to avoid the T cell response until capsid antigens 
are completely degraded by transduced hepatocytes113. The appropriate immune 
modulation regimen was chosen after validation in NHPs that it did not cause acute 
toxicity or interfere with AAV vector transduction or tolerance induction to the 
therapeutic transgene193. Results of this trial have not been reported yet.
Several studies in pre-clinical models have attempted to investigate the mechanisms 
of the unexpected anti-AAV capsid immune response observed in the AAV2 liver- 
directed clinical trial and to devise ways to restrain them. However, it was hard to 
replicate clearance of AAV vector-transduced cells by capsid-specific CTL in mice, 
even upon CTL adoptive transfer or vaccination by AAV capsid-expressing Ads194'196. 
CTL-mediated lysis of AAV vector-transduced hepatocytes could be inhibited in vitro 
by soluble T cell receptors, however this strategy would need to be personalised for 
each patient192. In addition, proteasome inhibition has been shown both to increase 
transduction and decrease capsid antigen presentation by limiting proteasome-mediated 
cytosolic capsid degradation and loading in MHC-I molecules, a process already known
■I QH 1 QO
to negatively impact on AAV-mediated transduction efficiency ’ . Along the same
line, site-directed mutagenesis of surface-exposed tyrosine residues allows the capsids 
to escape proteasome-mediated degradation and antigenic presentation, lacking 
phosphorylation and subsequent ubiquitination199. The use of alternative AAV serotypes 
has been proposed as a means to limit anti-AAV2 immune responses. In particular AAV 
vectors based on the NHP serotype 8 (which has less frequent pre-existing immunity in 
humans than AAV2) have been shown to allow 10- to 100-fold higher transduction of 
liver in mice than observed with other serotypes200. Moreover AAV8 does not bind 
heparan sulfate proteoglycan receptor, resulting in decreased uptake by APCs and
O fi1  TAOimproved tolerance induction ’ . Libraries of randomly shuffled capsid from native
serotypes can be generated and placed under selective pressure for the desired 
properties203. However, evasion from anti-AAV capsid immunity is not guaranteed, as 
capsid-specific T cells were activated in a recent clinical trial involving intramuscular 
administration of alternate serotype AAV1 vectors204. One key advance in AAV vector
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technology has been represented by the development of self-complementary AAV 
(scAAV) vectors. The self-complementary design removes the need for host cell- 
mediated second strand synthesis, the rate-limiting step for AAV transduction, and 
results in more efficient transduction and transgene expression205.
The combination of some of the highlighted improvements to circumvent the anti- 
AAV capsid immune response resulted in the generation of novel AAV vectors, which 
recently reached the stage of clinical testing. These AAV vectors are based on a self- 
complementary configuration and the more hepato-tropic serotype 8. They carry a novel 
expression cassette with a minimal hepatocyte-specific promoter and a codon-optimised 
hFIX transgene. These scAAV8 allowed safe and efficient transduction of the liver in 
mice and NHP and resulted in stable hFIX expression at therapeutic levels, even after
0CY1peripheral vein administration ’ . These results paved the way for a new phase I/II
clinical trial for haemophilia B, in which patients suffering from severe haemophilia B 
have been treated with a single peripheral vein administration of the described scAAV8. 
Based on the evidence that the anti-AAV capsid immune response was dose-dependent, 
the rationale behind this new clinical trial was that the use of more efficient vectors 
would allow therapeutic transgene expression levels at doses that may not re-activate 
the memory T cells. The three main modifications with respect to the previous trial by 
Manno et al. (self-complementary design, alternate serotype 8, codon-optimised 
transgene) were indeed designed to achieve this goal. The results of this clinical trial 
showed long-term therapeutic hFIX expression in the range of 1-3% of normal levels in 
4 patients treated at the first two dose cohorts. At the highest dose (2xl012 vg/Kg), 2 
more patients initially demonstrated higher hFIX levels in the circulation, but a rise in 
serum liver enzymes was apparent 8-9 weeks after vector injection and a drop in hFIX 
levels was detected. Based on the experience of the previous liver-directed trial, the two 
subjects were immediately started on a course (4-8-weeks) of glucocorticoid therapy 
and stabilised at about 3-7% of normal hFIX levels for over 1 year. In both subjects 
AAV8 capsid-specific T cells were detected. Four of the six treated subjects were able 
to discontinue prophylactic FIX replacement therapy and in the other two the frequency 
of injections was decreased25. These results showed, for the first time, that gene therapy 
can provide stable therapeutic hFIX expression levels in humans after a single vector 
administration. Extension of this study to a larger number of patients will be essential to
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better understand the frequency of the anti-capsid immune response occurrence and 
whether immune suppression by transient glucocorticoid administration will reliably 
control this response.
Besides the success of the liver-directed approaches, the interest in i.m. AAV vector 
administration has not subsided. The AAV2 muscle-directed trial clearly demonstrated 
that stable gene transfer in muscle fibres is feasible, provided that the vector dose per 
site is limited and only patients with a missense mutation are enrolled. It has been 
shown persistent transduction in muscle biopsies from treated patients for 10 years208. 
However, hFIX expression levels were subtherapeutic at the dose tested. Higher dosing 
appeared impractical owing to the high number of required injections, in addition, 
studies in the dogs suggested that higher doses might induce inhibitor formation188. To 
overcome this limitation, the use of alternative serotype AAV1 vectors have been 
evaluated and demonstrated 50-fold higher levels of expression but with increased 
inhibitor formation in mice and dogs209. Regional vascular techniques for the delivery 
o f AAV vectors to more extensive areas of skeletal muscle have also been developed, 
leading to cFIX expression levels up to 10-fold higher than those obtained with classical 
i.m. administration in haemophilia B dogs210,21 \  These results have not been translated 
clinically yet and the need to perform transient immune suppression remains a concern.
The length and complexity of the FVIII transgene has hindered the development of 
haemophilia A gene therapy strategies employing AAV vectors. It is not clear whether 
muscle-directed gene therapy can be applied to FVIII delivery as well, given its large 
size, association with VWF and susceptibility to proteases in the extracellular space. 
Thus efforts have focused on liver gene transfer. The packaging limitations of AAV 
vectors can be overcome by splitting the FVIII light and heavy chains in two different 
vectors to be co-administered in the host (“dual vector” approach) or by exploiting the 
propensity of AAV vectors to form concatamers212,213. Alternatively, a minimal cassette 
containing the BDD form of FVIII can be adopted214. Both these approaches have 
resulted in therapeutically relevant levels of cFVIII (2-5% of normal) in haemophilia A 
dogs for up to 4 years214'216. However, the dose required to achieve therapeutic FVIII 
activity is higher than those clinically tested and it seems that alternative serotype 
AAV8 vectors did not reproduce in dogs the same improvements observed in mouse 
studies215, 216. New FVIII transgene engineered for high expression and secretion are
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being developed and may facilitate clinical translation of AAV-mediated haemophilia A
717gene therapy .
Although most AAV vectors remain episomal in transduced cells and these forms 
contribute to long-term expression, sequencing of vector-genome junctions from target 
organs in animals has shown that integration can occur177. The extent of the long-term 
risk associated with AAV insertional mutagenesis is still debated. A single report 
showed that neonatal AAV vectors delivery was associated with a higher incidence of 
late-onset hepatocellular carcinoma (HCC) in a mouse model of a lysosomal storage 
disorder218. AAV integration analysis showed that 4 HCCs harboured integrations in a 
complex regulatory region that has been implicated in HCC219. In another study, high- 
dose liver-directed AAV administration in adult mice was followed for 18 months after 
vector injection. There was no change in the rate of HCC compared to control 
animals220. More extensive investigations are warranted to further clarify this aspect.
An alternative treatment strategy for haemophilia is based on the delivery of an 
engineered FVII transgene that can be directly secreted as activated FVII, as a result of 
intracellular processing. Although FVII deficiency is very rare, recombinant FVIIa has 
been introduced as a bypassing agent for inhibitor-bearing haemophilic patients (see 
1.2.4). Stable endogenous production of this bioengineered FVIIa may also be devised 
as “bypassing” strategy for naive haemophiliac patients. AAV-mediated liver gene 
transfer of the FVIIa transgene allowed complete and partial correction of haemophilia
771 777A and B in mice and dogs, respectively ’ . This strategy offers the advantage of non
immunogenicity of the FVII protein and the risk of thrombotic complications appear 
low below certain doses223.
As a direct result of their good efficiency, remarkably low toxicity and 
immunogenicity profile, AAVs have rapidly gained acceptance as vehicles for in vivo 
gene therapy. In the previously mentioned landmark study, long-term therapeutic FIX 
expression has been achieved for the first time in haemophilia B patients upon liver 
gene therapy with AAV vectors25. This study also restored optimism in the field of 
haemophilia gene therapy. Nevertheless, pre-existing immunity against AAV capsid is 
still a concern and will deserve further attention. Moreover it is reasonable to predict 
that only people resulting negative to neutralizing anti-AAV capsid antibodies may 
benefit from AAV vectors-mediated gene therapy in the near future (when the vector is
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administered in the circulation)224. The incorporation of large transgenes such as FVIII 
remains challenging.
1.4 Lentiviral vectors
Lentivirus is a genus of the Retroviridae family (see 1.3.4.1). Lentiviruses comprise 
several animal immunodeficiency viruses, including HIV 1 and 2. Many of these 
viruses have been exploited to generate gene transfer vectors and the most well studied 
and advanced in clinical development are HIV-1-derived lentiviral vectors (LVs). LVs 
are hybrid particles, comprising HIV-1 enzymatic and structural capsid proteins and the 
envelope proteins derived from a heterologous virus (pseudotype). By changing the 
pseudotype, it is possible to redirect transduction, either widening or restricting the 
spectrum of target tissue tropism. Most LVs are pseudotyped with the vesicular 
stomatitis virus glycoprotein G (VSV-G), which makes the vector pantropic. The VSV- 
G envelope confers stability to the vector particles, allowing long-term conservation and
99S 9 9 £ \concentration by ultracentrifugation ’
Cis-acting sequences regulate packaging, reverse transcription, nuclear translocation, 
pro virus integration into recipient cell’s genome and are maintained in the recombinant 
vector genome where the expression cassette is included. 7><ms'-acting sequences are 
present in the packaging construct and complement the vector genome construct in the 
producer cells, encoding virion structural and enzymatic proteins. For LV construction, 
at least three different constructs are necessary: an envelope protein-encoding construct, 
a packaging construct encoding HIV-derived proteins, and the vector genome construct, 
bearing the transgene expression cassette together with the cis-acting sequences227.
Given the highly pathogenic nature of the parental virus, the risk of emergence of a 
replication-competent lentivirus (RCL) contaminating vector preparation needs to be 
carefully addressed. RCL might form upon recombination between the genetic 
sequences used to construct the vector. Advanced-generation LVs are produced by a 
combination of at least four different plasmids with minimal sequence homology. All 
the accessory genes have been removed from the packaging constructs, as well as the 
tat gene, implicated in viral pathogenesis, while the rev gene, which allows nuclear 
export of unspliced viral RNAs, has been placed into a third construct, and 
autonomously expressed under a heterologous promoter. In this way the expression of
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all the necessary packaging proteins is complementation-dependent and possible only in 
producer cells228. This split design and the minimal packaging constructs alleviate 
concerns for the generation of a RCL. The fourth construct encodes for the envelope 
protein of an unrelated virus, which makes generation of a wt virus impossible and 
recombination among constructs very unlikely because of lack of homology. Moreover, 
the use of a minimal set of viral genes to package the vector ensures that even the 
unlikely RCL could not have the pathogenic features of the parental virus (Figure III).
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Figure III: Four-plasmid system fo r  the production o f  third-generation LVs. (A)
Transfer vector. The HIV U3 region at the 5 ’ LTR has been replaced by the 
cytomegalovirus promoter/enhancer (CMV) that allows the synthesis o f  the full-length 
RNA fo r packaging without the need for HIV Tat. A deletion o f  the HIV  
enhancer/promoter in the U3 region at the 3 ’ LTR has been introduced. This modified 
U3 region is copied at the 5 ’ LTR upon reverse transcription in transduced cells, thus 
obtaining a SIN LV. SD: splicing donor site. SA: splicing acceptor site. ly: packaging 
signal, including 5 ’ portion o f GAG gene (GA). RRE: Rev responsive element. cPPT- 
CTS: central polypurine tract to central termination sequence, wpre: woodchuck 
hepatitis virus post-regulatory element. (B) Packaging constructs expressing the HIV  
structural proteins and enzymes and the Rev protein. GAG: gene encoding fo r  HIV
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capsid, matrix, nucleocapsid proteins. PRO: HIV protease-encoding gene. POL: HIV  
reverse transcriptase and integrase-encoding gene. polyA: simian virus 40 
polyadenilation signal. REV: regulatory viral protein-encoding gene. (C) Envelope 
construct expressing the envelope glycoprotein(s) from an unrelated virus (pseudotype).
In order to improve the safety of LVs, careful deletions have been made in the viral 
long terminal repeats (LTRs) to create self-inactivating (SIN) LV229. This modification 
abrogates the function of the native viral promoter/enhancer and diminishes the 
possibility of vector mobilization, as well as LTR influence on genes neighbouring the 
site of insertion. It also permits the addition of internal promoters, including tissue- 
specific and regulatable elements, for controlling transgene expression.
Further improvement of the LV vector platform has brought about the reintroduction 
of the original viral sequence from the central polypurine tract (cPPT) to the central 
termination site (CTS) at the 5’ region of the vector genome in order to increase nuclear 
import inside transduced cells230. Vector genome constructs also include sequences like 
the woodchuck hepatitis B virus post-transcriptional regulatory element (wpre) that, 
when inserted at the transgene 3’ end, stabilizes the transcripts, promoting nuclear 
export and improved polyadenylation efficiency of both the transgene in transduced 
cells and the vector genome in producer cells231. The wpre contains a transcriptionally 
active promoter and the first few amino acids of the woodchuck hepatitis B virus X 
protein, which has oncogenic potential by still unknown mechanisms232. Although 
expression of this small fragment of the X protein has never been demonstrated, 
precautions have been taken by generating a mutated wpre (wpre*) that lacks the X 
protein open reading frame and containing mutations in the region putatively crucial for 
promoter activity233. This mutated version (wpre*) has been shown to maintain RNA 
stabilization capacity and thus has been incorporated into LV constructs which may 
undertake clinical translation (Figure III).
Importantly, this vector platform has now entered clinical testing in HSPC-mediated 
ex vivo gene therapy, with a reassuring safety profile, both for the absence of detectable 
RCL and obvious sings of genotoxicity24.
LVs offer several advantages for gene therapy applications. Unlike RVs, they can 
transduce a variety of cell types, including dividing and non-dividing cells, such as 
quiescent stem cells, hepatocytes and neurons because LVs exploit active cellular 
mechanisms for the nuclear import of the viral genome. Integration of the LV into the
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host cell chromatin allows stable gene transfer to the target cell and its progeny. LVs 
can package up to 9 kb of genetic material and transgene expression is unlikely to 
undergo transcriptional silencing. Importantly, since most of the human population is 
seronegative, LVs can be injected systemically without the risk of pre-existing 
immunity against vector components. However, LV technology has limitations as well. 
For one, vector production still relies on plasmid transient transfection because of the 
lack of stable packaging cell lines and this represents a hurdle for the industrial scaling- 
up of vector manufacturing and the production of large quantities of purified LVs. 
Moreover, considering the integrating nature of LVs, there are safety concerns 
associated with the risk of germ-line transmission and insertional mutagenesis " .
1.4.1 Liver gene therapy with LVs
LVs are attractive tools for liver-directed gene therapy because of their ability to 
accommodate relatively large transgenes, stably integrate in non-dividing cells, and lack 
of pre-existing immunity in most of the human population. Initial studies, using reporter 
or therapeutic genes, have characterized the biodistribution of LV following intravenous 
or intraportal delivery to mice. They have shown transduction primarily of the liver, to a
777lesser extent the spleen and less frequently of bone marrow stroma and lungs ’ 
Early attempts of delivering FVIII and FIX upon systemic administration of LVs 
resulted in only small percentages of transduced hepatocytes. For this reason it was 
initially thought that hepatocyte proliferation triggered by partial hepatectomy was 
needed to obtain efficient transduction by LVs239, 240. The introduction of cPPT and 
CTS in LV genome increased the transduction efficiency of hepatocytes both in vitro 
and in vivo upon intravenous delivery even without partial hepatectomy237. Systemic 
injection of mice with LVs expressing hFIX under the transcriptional control of an 
ubiquitously expressed promoter resulted in up to 4% of normal circulating FIX levels 
in immune deficient mice237, 238. As expected, it was not possible to obtain the same 
results in immune competent mice, because a cellular immune response developed 
against transduced cells and a humoral response developed against the FIX antigen41.
Further studies were designed to elucidate both innate and adaptive immune 
responses induced by LV systemic administration. LVs trigger an early and rapidly 
decreasing inflammatory response which enhances adaptive immunity and limits
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hepatocyte transduction. LVs activate pDCs with ssRNA, which is sensed by 
endosomal TLR7. Upon TLR7 stimulation, pDCs secrete interferon a  (IFN-a), which 
poses hepatocytes in an anti-viral state, reducing their permissiveness to transduction. 
Type-I IFNs in turn induce the activation of other APCs and transient production of IL- 
1 and tumour necrosis factor-a (TNF-a)241. Moreover, upon intravenous administration, 
VSV-G-pseudotyped LVs readily transduce and express the transgene in APCs such as 
liver KCs and spleen APCs, leading to productive antigen presentation to T cells and 
initiation of an immune response against transduced cells and the transgene products237, 
242. Other groups’ and our own studies have shown that the introduction of hepatocyte- 
specific promoters in vectors reduced transgene expression in APCs and subsequent 
antigen presentation, limiting undesired anti-transgene immune responses. Indeed, liver 
gene transfer with LVs expressing green fluorescent protein (GFP) or hFIX under the 
control of hepatocyte-specific promoters circumvented the anti-transgene immune 
response and resulted in long-term transgene expression in normal mice41.
However, evaluation of LVs expressing human FIX from hepatocyte-specific 
promoters failed to achieve sustained FIX expression in haemophilia B mice due to the 
induction of an anti-FIX cellular immune response73. This occurs because human FIX is 
a stronger immunogen in haemophilia B mice, which do not express the mouse 
homolog. Additional analysis suggested that anti-transgene immunity may be a result of 
off-target transgene expression in hematopoietic-lineage cells of the liver and spleen, 
because of leaky hepatocyte-specific promoter activity in non-hepatocyte cells and 
promoter/enhancer trapping events. In order to overcome this problem, the LVs were 
modified to contain target sequences for the hematopoietic-specific microRNA 142 
(miR-142) in the transgene 3’ UTR, making it subject to post-transcriptional regulation 
(see also 1.1.4)34. This novel strategy eliminated off-target expression in hematopoietic- 
lineage cells, evading the immune response and enabling sustained gene transfer in 
haemophilia B mice for more than 1 year (longest time assayed) after a single LV 
administration. Treated mice had around 10% of normal hFIX activity, no detectable 
anti-FIX antibodies and were tolerant to hFIX, since they were unresponsive to protein 
immunisation. Importantly, the mice survived tail-clip challenge, thus demonstrating 
phenotypic correction of their bleeding diathesis73. We have since performed specific 
immunological studies aimed at shedding light on the mechanism by which this
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approach can induce transgene-specific tolerance. We have shown that in vivo 
administration of a miR-142-regulated transgene induces an initial expansion of 
antigen-specific CD8+ T cells which rapidly contract concomitantly with a significant 
increase of CD4+CD25+FoxP3+ Tregs. These Tregs mediate a robust state of antigen- 
specific immunological tolerance, which cannot be broken by vaccination and can be 
transferred in vivo to naive hosts which become unresponsive to antigen-loaded target 
cells after intravenous administration76.
These advanced-design miR-142-regulated LVs which stringently target transgene 
expression to hepatocytes, by coupling transcriptional and post-transcriptional 
regulation, hold significant potential for liver-directed gene therapy applications. Their 
efficacy has been demonstrated in mouse models of haemophilia A and B and in a rat 
model of hyperbilirubinemia73,243,244. Evaluation of these LVs in large animal models is 
thus crucial towards a potential clinical translation.
1.4.2 Integrase-defective LVs
Integrase-defective LVs (IDLVs) can be generated by packaging the vector with 
catalytically inactive HIV integrase227, 245. The class I D64V mutation in the integrase 
catalytic site substantially reduces integration (100- to 1000-fold) without 
compromising other steps in the transduction pathway246'250. Upon transduction, IDLVs 
can support transgene expression from the non-integrated proviral forms, which 
accumulate in the nucleus of transduced cells. Because this episomal DNA is 
progressively lost in actively dividing cells, transgene expression is only transient45,246, 
248. In contrast, IDLVs have been reported to support sustained transgene expression in 
quiescent mouse tissues, such as the retina and the brain, likely because the episomal 
vector DNA is retained within the post-mitotic nucleus249'251.
The ability of IDLVs to achieve therapeutically relevant transgene expression 
following hepatic gene delivery and to induce immune tolerance have never been 
studied. We have shown the feasibility of gene replacement therapy and immune 
tolerance induction using LV-mediated liver gene therapy73, 76. However, concerns 
remain about the potential long-term adverse effects of vector integration due to 
insertional mutagenesis. Moreover it is not known whether the tolerogenic outcome of 
microRNA-regulated LV delivery depends on sustained high levels of transgene
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expression within hepatocytes, which requires substantial levels of LV integration and 
would limit application of this finding outside of gene replacement strategies for the 
correction of monogenic diseases. These important gaps deserve further studies.
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2.AIMS OF THE WORK
The overall objective of this thesis was to gain a more comprehensive understanding 
of the feasibility, efficacy, safety of liver gene therapy with LVs and its relevance 
compared to existing technologies, in order to pursue its clinical translation.
The specifics aims of this work were:
1) To evaluate LV-mediated liver-directed gene therapy in a canine model of 
haemophilia B.
Haemophilic dogs are spontaneous large animal models of the disease and represent 
a valuable setting to assess the feasibility, efficacy and safety of new strategies aimed at 
treating haemophilia in patients. Issues such as scale-up of manufacturing, acute 
toxicity, immunogenicity, efficacy in achieving therapeutic end-points and potentially 
long-term toxicity can be more stringently and appropriately addressed in dog rather 
than mouse disease models.
2) To increase the potency (in its pharmacological meaning of efficacy per  dose) of 
LVs for liver gene therapy by evaluating improvements in vector and transgene design 
and in the transduction protocols.
Increasing the potency of gene transfer vectors is crucial in gene therapy 
applications. It would allow using lower doses to obtain therapeutic benefit, thus 
reducing potential acute and long-term toxicities and immune activation associated with 
vector administration, as well as easing manufacturing needs. Towards this goal, we set 
out to evaluate an alternative envelope, codon-optimised and hyper-functional 
transgenes and the administration of a proteasome inhibitor before LV, first exploiting 
the haemophilia B mouse model and then to evaluate the most promising approach(es) 
in the haemophilia B dog.
3) To evaluate LV-mediated liver-directed gene therapy in haemophilia B mice with 
pre-existing anti-FIX immunity.
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We have already shown that LV-mediated liver gene therapy can induce specific 
immune tolerance to different transgenes, provided that transgene expression is 
stringently targeted to hepatocytes. However, the tolerogenic outcome was achieved in 
mice naive to the specific antigens. We set out to challenge this outcome by treating 
mice with induced pre-existing anti-transgene immunity, in order to test the potential of 
immune tolerance to revert an established immune response. If successful, liver gene 
therapy may thus become a preferred therapeutic option also for inhibitors-positive 
haemophilic patients.
4) To evaluate IDLVs for liver gene therapy.
Since insertional mutagenesis is a concern for integrating vectors, we set out to 
explore the potential advantages of IDLVs to express transgenes in the adult liver, in 
which hepatocytes turnover is slow. To this aim we assessed the efficiency and stability 
of IDLV-mediated liver gene transfer as well as the ability to induce immune tolerance, 
as compared to those achieved with canonical integrating LV.
60
3.MATERIALS AND METHODS
3.1 Plasmid construction
Plasmid construction was carried out using standard cloning techniques. The 
plasmids pCCLsin.cPPT.PGK.GFP.wpre, pCCLsin.cPPT.PGK.GFP.wpre. 142T, 
pCCLsin.cPPT.ET.GFP.wpre, pCCLsin.cPPT.ET.GFP.wpre.142T and
pCCLsin.cPPT.hFIX.wpre.142T were previously described34, 73. The plasmid 
pCCLsin.cPPT.ET.OVA.wpre.142T was obtained by exchanging the Nhel-GFP-Sall 
transgene with the PCR-amplified Nhel-OVA-Sall transgene from pBluescript-OVA (a 
kind gift from Dr. G. Casorati, San Raffaele Scientific Institute). The plasmid 
pCCLsin.cPPT.ET.cFIX.wpre*.142T was obtained by first exchanging the Agel-GFP- 
Sall from pCCLsin.cPPT.ET.GFP.wpre. 142T with the PCR-amplified Agel-cFIX-Sall 
from pCEP4-cFIX (a kind gift from Dr. T. Nichols, University of North Carolina) and 
subsequently exchanging Sall-wpre-SacII with SalI-wpre*-SacII from 
pCCLsin.cPPT.PGK.GFP.wpre*. The plasmid pCCLsin.cPPT.co-cFIX.wpre*.142T was 
obtained by exchanging the wt cFIX transgene (Nhel-digested and blunt-ended at the 5’ 
-  Sail-digested at the 3’) from pCCLsin.cPPT.ET.cFIX.wpre*.142T with the codon- 
optimised cFIX Smal-co-cFIX-Sall fragment from pBC-co-cFIX (a kind gift from Dr. 
T. VandenDriessche, Free University of Brussels). The R338L mutation was introduced 
using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies), 
according to manufacturer’s instructions. The identity of plasmids was verified by 
sequencing of the interested pieces.
3.2 Plasmid DNA preparation
Large-scale preparation of plasmid DNA was carried out using the Macherey-Nagel 
endotoxin-free high purity plasmid maxi prep system, according to manufacturer’s 
instructions. After a modified alkaline/SDS procedure to lyse the cells and precipitate 
the genomic DNA, the cleared lysate is passed over an ion-exchange column, at the 
appropriate salt concentration and pH. The plasmid DNA is eluted under high-salt 
conditions. It is then desalted and concentrated by alcohol precipitation. Plasmid DNA 
is finally resuspended in TE (10 mM TrisHcl pH 8.0, 1 mM EDTA).
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Large-scale preparation of plasmid DNA for large-scale LV production and quality 
controls were outsourced to Nature Technology Corporation.
3.3 Lab-scale LV production and titration
Third-generation LVs were produced by calcium phosphate transient transfection of 
293T cells of the selected transfer vector, the packaging plasmid pMDLg/p.RRE (for 
integrase-competent LVs) or pMDLg/p.RRED64Vint (for IDLVs,), pCMV.REV, the 
VSV-G envelope plasmid pMD2.G or the gp64 envelope plasmid pBAcNPVgp64 and 
the pAdVAntage plasmid (Promega), as previously described226.
3.3.1 Calcium phosphate-mediated transfection
Nine millions 293T cells are seeded 24 hours before transfection in 15-cm dishes. 
Two hours before transfection culture medium is replaced with fresh medium. For each 
dish, a solution containing a mix of the selected transfer plasmid, the packaging 
plasmids pMDLg/pRRE (or pMDLg/p.RRED64Vint for IDLVs) and pCMV.REV, 
pMD2.G (or pBAcNPVgp64 for gp64-pseudotyped LVs) and the pAdVAntage plasmid 
is prepared using 35, 12.5, 6.25, 9 and 15 pg of plasmid DNA, respectively. A 0.1X TE 
solution (10 mM Tris-HCl, 1 mM EDTA pH 8.0 in dH20) and water (1:2) is added to 
the DNA mix to 1250 pi of final volume. The solution is left on a spinning wheel for 
20-30 minutes, then 125 pi of 2.5 M CaCL are added. Right before transfection, a 
precipitate is formed by adding 1250 pi of 2X HBS (281 mM NaCl, 100 mM HEPES, 
1.5 mM Na2HPC>4, pH 7.12) while the solution is kept in agitation on a vortex. The 
precipitate is immediately added to the culture medium and left on cells for 14-16 hours 
and after that the culture medium is changed. Supernatant is collected 30 hours after 
medium change and passed through a 0.22 pm filter (Millipore). Filtered supernatant is 
transferred into sterile 25 x 89 mm poliallomer tubes (Beckman) and centrifuged at 
20,000g for 120 min at 20°C (Beckman Optima XL-100K Ultracentrifuge). Vector 
pellet is dissolved in the appropriate volume of PBS to allow a 500X concentration.
3.3.2 LV titration
For integrase-competent LVs, 105 293T cells were transduced with serial vector 
dilutions in the presence of polybrene (16 pg/ml). Genomic DNA (gDNA) was
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extracted 14 days after transduction. gDNA is extracted by using Maxwell 16 Cell DNA 
Purification Kit (Promega) according to manufacturer’s instructions. Vector copies per 
diploid genome (vector copy number, VCN) were quantified by quantitative PCR 
(qPCR) starting from 100 ng of template gDNA using primers (HIV sense: 5’- 
TACTGACGCTCTCGCACC-3 ’; HIV antisense: 5’-TCTCGACGCAGGACTCG-3’) 
and a probe (FAM 5’-ATCTCTCTCCTTCTAGCCTC-3’) against the primer binding 
site region of LVs. Endogenous DNA amount was quantified by a primers/probe set 
against the human telomerase gene (Telo sense: 5’-GGCACACGTGGCTTTTCG-3’; 
Telo antisense: 5’-GGTGAACCTCGTAAGTTTATGCAA-3’; Telo probe: VIC 5’- 
TCAGGACGTCGAGTGGACACGGTG-3’ TAMRA). Copies per genome were 
calculated by the formula = [ng LV/ng endogenous DNA] x [n° of LV integrations in 
the standard curve]. The standard curve was generated by using a CEM cell line stably 
carrying 4 vector integrants, which were previously determined by Southern blot and 
FISH analysis. All reactions were carried out in duplicate or triplicate in an ABI Prism 
7900HT Realtime PCR thermal cycler (Applied Biosystems). Each qPCR run carries an 
internal control generated by using a CEM cell line stably carrying 1 vector integrant, 
which were previously determined by Southern blot and FISH analysis. Titre is 
expressed as transducing unitS293T (TU)/ml and calculated using the formula TU/ml = 
[VCNxl05xl/dilution factor]. Vector particles were measured by HIV-1 Gag p24 
antigen immunocapture assay (Perkin Elmer) according to manufacturer’s instructions. 
Vector infectivity is calculated as the ratio between titre and particles.
For IDLVs, titre in reverse transcribed units (TU)/ml was determined on 293T cells 3 
days after transduction, using an ad hoc qPCR, which selectively amplifies the reverse 
transcribed vector genome (both integrated and non-integrated) discriminating it from 
plasmid carried over from the transient transfection (RT-LV; AU3 sense: 5’- 
TCACTCCCAACGAAGACAAGATC-3’, gag antisense: 5’
GAGTCCTGCGTCGAGAGAG-3’). The amount of human DNA loaded in the reaction 
was quantified with a qPCR designed to amplify the human telomerase gene as 
described above.
3.4 Large-scale LV production and quality controls
Large-scale LV production for dog studies were outsourced to MolMed or Genethon.
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The vector lots were produced by using a large-scale validated process252. The vectors 
were produced following pre-GMP guidelines. Briefly, the LV is produced by transient 
4 plasmid transfection of 293T cells. 293T cells are derived from HEK 293 cells with 
stable transfection of the temperature-sensitive SV40 T-antigen; a subclone of the 293T 
selected for its high yield performance in production of LVs by transient transfection 
was used for master cell bank establishment; 293T cells from the master cell bank are 
expanded in 10-tray cell factories and transiently transfected by calcium phosphate 
precipitation with 4 plasmids as described in 3.3.1. Twenty four hours after removal of 
the transfection medium, the cell supernatant is harvested and stored at 4°C. The culture 
medium is replaced and after further 24 hours a second harvest is performed. The 
medium collected from the two harvests is pooled and filtered through 5/0.45 pm filters 
to discard cell debris. The downstream purification process includes a benzonase 
treatment overnight at 4°C, followed by a DiEthylAmino Anion Exchange (DEAE) 
chromatography step, concentration and gel filtration in PBS or PBS 5% dimethyl 
sulfoxide (DMSO). The benzonase treatment is aimed at degrading plasmid DNA and 
producer-cell derived DNA present in the clarified cell supernatant, thus facilitating 
their removal through subsequent purification steps. Anion exchange chromatography 
involves the absorption of negatively charged LV particles to positively charged 
chromatographic support; viral particles are eluted by increasing ionic strength. This 
step is aimed at the removal of contaminants such as producer-cell proteins and serum- 
derived proteins such as bovine serum albumin. Gel filtration, also defined as size 
exclusion chromatography, relies on the inability of the large LV particles to be retained 
by matrix pores. This step is aimed at the removal of salts and small size contaminants 
such as DNA fragments, as well as at medium exchange. The resulting LV preparation, 
undergoes one sterilizing 0.2 pm filtration and aseptic filling. The purified vector 
preparation is stored at -80°C.
3.4.1 Transgene activity assay
Huh7 cells (HCC cell line) were transduced with 2 vector dilutions. Three days after 
transduction, 105 transduced cells are seeded and conditioned medium is collected 48 
hours later and concentrated by Amicon Ultra 50 kD gel filtration columns (Millipore). 
The retentate is tested for FIX activity by aPTT.
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3.4.2 Total DNA contamination assay
The assay is based on the use of a commercial kit (Topac). This assay is an 
ultrasensitive fluorescent nucleic acid stain to detect and quantify small quantity of 
dsDNA. The assay detects small fragments of DNA. A standard curve of Lambda DNA 
is analyzed in each test and the range of quantification is between 25 ng/ml and 1.56 
ng/ml. Standard curve, samples and controls are excited at 485 nrn and fluorescence 
emission intensity is measured at 535 nm by spectrofluorometer. Fluorescence emission 
intensity is plotted versus DNA concentration.
3.4.3 Producer-cell protein contamination assay
The assay is based on the use of a commercial enzyme-linked immunosorbent assay 
(ELISA) kit for the measurement of 293 cell proteins (Cygnus Technologies). Briefly, 
samples, which may contain proteins derived from 293 or 293T cells, are reacted in 
microtiter strips coated with an affinity-purified capture antibody. A standard curve is 
seeded for each test run. A second horseradish peroxydase (HRP) enzyme-labelled anti- 
293 antibody is reacted simultaneously, resulting in the formation of a sandwich 
complex of solid-phase antibody 293 proteins enzyme labeled antibody. The microtiter 
strips are washed to remove any unbound reactants, then the substrate tetramethyl 
benzidine (TMB) is added to each well and the reaction is stopped by the addition of kit 
stop solution. The amount of hydrolysed substrate is read on a microtiter plate reader at 
450nm and is directly proportional to the concentration of 293 proteins present.
3.4.4 Endotoxin contamination assay
The assay is based on a kinetic chromogenic method (Charles River) for detection 
and quantification of bacterial endotoxin. In the test, co-lyophilised limulus amebocyte 
lysate (LAL) and substrate reagent are mixed with test sample in a microplate and 
incubate in a reader at 37° C. Absorbance measurements are collected with time after 
addition of chromo LAL. The time (onset time) taken for a sample to reach a specified 
absorbance (onset OD) is calculated; and a standard curve, showing the linear 
correlation between the log onset time and the log concentration of standard endotoxin, 
is generated.
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3.4.5 Sterility assay
This assay is carried out using an automated system (BacT/ALERT instrument). Test 
samples are inoculated in two bottles containing media for aerobic and anaerobic 
microorganisms. The sample is automatically monitored for the presence of CO2 
eventually produced by microorganisms by a photodetector, which records a shift of the 
media colour from blue/green to yellow.
3.4.6 RCL assay
The assay is performed according to a published method253,254. RCL assay has been 
validated for sensitivity and specificity. The permissive cells C8166-45 are cultivated in 
presence of the LV sample for 28 days to allow amplification of a potential RCL. The 
cultures are inoculated at high cell density to maximise the chances for an RCL to 
infect. To ensure sensitivity and cell viability for 7 days the culture is minimally diluted 
by addition of medium but no portion of the cells is discarded. After 7 days the cell 
suspension is splitted 1:4 every 3 or 4 days for a total of seven passages. The RCL 
detection is done by ELISA determination of the HIV p24 protein concentration in 
culture supernatant. Moreover, C8166-45 gDNA is extracted to verify the absence of 
VSV-G DNA by qPCR. For each lot, at least 5% of total vector production is tested, 
according to what is recommended by United States Food and Drug Administration 
(FDA) for testing of retroviral vector-based gene therapy products for replication- 
competent retrovirus (FDA-CBER Guidance for Industry, 2006). As test positive 
control, pseudotyped virus R8.7 is used: this is an engineered virus derived from HIV, 
attenuated by inactivation of the four accessory genes vif, vpr, vpu and nef and 
pseudotyped with VSV-G, as described254.
3.5 Cell cultures
Cell lines (293T, Huh7 and DH82) were maintained in Iscove's modified Dulbecco’s 
medium (IMDM, Sigma) supplemented with 10% foetal bovine serum (FBS, Gibco), 
1% glutamine, penicillin 100 IU/ml and streptomycin 100 jig/ml. Primary hepatocytes 
were purchased from Biopredic (France) according to a protocol approved by the San 
Raffaele Ethical Committee (TIGET-HPCT) and maintained in proprietary media
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following manufacturer’s instructions. All cells were maintained in a 5% CO2 
humidified atmosphere at 37° C. Cells were cultured using cell culture-treated plastic 
devices (Falcon). Sub-confluent adherent cell lines were washed with sterile PBS 
(Sigma) and detached with 0.05% tripsin, 4 mM EDTA in PBS.
3.6 Complement sensitivity assay
Serum samples were obtained from healthy human donors, a pool of canine serum or 
individual dogs (provided by Dr. T. Nichols, University of North Carolina) to be 
screened before LV administration. Sera were thawed and half of each serum sample 
was heated at 56° C for 1 h to inactivate the complement. PGK.GFP LV particles were 
diluted in IMDM 10% FBS. A measure of 30 pi of the vector was diluted 1:5 into 
normal or heat-inactivated serum (or IMDM 10% FBS as the no-serum control) and the 
mixture was incubated at 37° C for 1 h. Following the incubation, medium was added to 
the reaction and then serially diluted and used to transduce 293T cells for end-point titre 
determination (see 3.3.2). The titre value was divided by the titre determined for the 
vector mixed with medium (the no-serum control) and reported as the percentage of 
recovery of titre compared to this control.
3.7 In vitro experiments
DH82 cells were transduced at the indicated multiplicity of infection (MOI) and GFP 
expression was analysed by flow cytometry (BD Canto System) 1 week after 
transduction. Huh7 cells were transduced with ICLVs or IDLVs at MOI 0.5, 5 or 50 and 
3 days and 2 weeks after transduction GFP expression was analyzed by flow cytometry 
(BD Canto System) and total DNA was extracted using DNeasy Blood & Tissue Kit 
(Qiagen), according to manufacturer’s instructions. Human and canine primary 
hepatocytes were transduced at the indicated MOL After 1 week of culture, nuclei were 
stained with Hoecsht 33258 (Sigma) and analyzed by live fluorescence microscopy; 
total DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen), according to 
manufacturer’s instructions. VCN was determined using an ad hoc qPCR, which 
selectively amplifies the reverse transcribed vector genome (both integrated and non­
integrated) discriminating it from plasmid carried over from the transient transfection 
(RT-LV; AU3 sense: 5’-TCACTCCCAACGAAGACAAGATC-3’, gag antisense: 5’
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GAGTCCTGCGTCGAGAGAG-3’). The amount of human DNA loaded in the reaction 
was quantified with a qPCR designed to amplify the human telomerase gene as 
described in 3.3.2.
3.8 MicroRNA analysis
Small RNAs were isolated from DH82 cells by mirVana™ miRNA Isolation Kit 
according to manufacturer’s instructions (Ambion). For analysis of miRNA expression, 
the Applied Biosystems Taqman® microRNA Assay system was used, as described35. 
For each miRNA analyzed, 5 ng of small RNA was subjected to RT-PCR according to 
manufacturer’s instructions. To determine absolute copy number, a standard curve was 
generated using an SDS-PAGE purified RNA oligonucleotide corresponding to let-7a 
(Primm). Five ng of total yeast RNA were spiked with concentrations of 
oligonucleotide ranging from 102 to 108 copies, and analyzed by the Taqman® 
microRNA Assay. Reactions were carried out in duplicate in an ABI Prism 7900.
3.9 Mice experiments
Founder C57BL/6 F9 KO mice were obtained from the laboratory of Dr. Inder 
Verma at the Salk Institute255. Mice defective for type-I IFN receptor 129/SVEV 
(IfnaRl~A) mice were obtained from B&K Universal Limited. Wt C57BL/6 and Balb/c 
mice were purchased by Charles River. All the mice were maintained in specific- 
pathogen free conditions. Vector administration was carried out in adult (7-10 weeks 
old) mice by tail-vein injections. Mice were bled from the retro-orbital plexus using 
capillary tubes and blood was collected into 0.38% sodium citrate buffer, pH 7.4. Mice 
were anesthetised with tribromoethanol (Avertin) and euthanized by CO2 inhalation at 
the expected time points. All animal procedures were performed according to protocols 
approved by the Institutional Animal Care and Use Committee.
3.10 Dog experiments
Haemophilia B dogs (carrying a E379G single amino-acid substitution in the FIX 
protein) were maintained at the Francis Owen blood research laboratory, that has both 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
and United States Department of Agriculture (USDA) approval as an animal research
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facility. The facility provides for breeding, whelping, housing, treating, and performing 
the experiments in the dogs on site. Complete blood counts and platelet counts were 
performed on EDTA-anti coagulated blood with a cell counter (Heska) calibrated for 
canine cells. Serum liver enzymes were obtained from a commercial veterinarian 
source.
3.10.1 Portal vein administration
Prior to making an incision, cFIX levels are raised to at least 10 to 20% by infusing 
an appropriate amount of normal canine plasma. A skin incision is made from the 
xyphoid down to the lower abdomen (-10 cm) and then the abdominal cavity is opened 
via its muscle layers. A baseline liver biopsy is taken for control tissue to determine 
VCN or gene expression. A small wedge of liver tissue is encircled with suture material 
and the tissue is processed for molecular and histological studies. The spleen is 
carefully exteriorized and a 4 or 5 French balloon tipped catheter is prepared by 
inflating the balloon for leaks (-0.5 to 1.0 ml). An appropriately sized branch of the 
splenic vein is isolated, circumferential sutures are positioned proximally and distally 
over about 2 cm, this branch of the splenic vein is punctured, the balloon tipped catheter 
is inserted and advanced into the portal vein, usually between 10 and 20 cm. The 
position of the catheter in the portal vein is confirmed visually or by palpation. The 
distal port of the balloon tipped catheter is aspirated to confirm blood can be withdrawn 
even when the balloon is securely inflate and occluding the portal vein. When the 
catheter position is optimised, a small amount (-1 ml) of vector is infused while the 
balloon is inflated. Infusion rates are adjusted as the blood pressure tolerates. After the 
vector is infused, the catheter is removed and the branch of the splenic vein is ligated 
proximally and distally and the spleen is returned to the abdomen. The surgical incision 
is closed in layers using suture material.
3.11 Protein immunisation and antigen re-challenge
Protein immunisation in naive haemophilia B mice was carried out by subcutaneous 
administration of 50 pg of recombinant hFIX protein (Pfizer) in incomplete Freund 
adjuvant (IFA, Sigma). Antigen re-challenge was carried by subcutaneous 
administration of 5 pg of cFIX protein (Innovative Research) in IFA or by i.m. DNA
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vaccination of a GFP-expressing plasmid, as described76. Briefly, 0.5 nmol cardiotoxin- 
1 (Sigma) is injected in triadic leg muscles. Five days later mice are injected again in 
the same position with 50 pg/leg of pCCLsin.cPPT.CMV.GFP.wpre plasmid.
3.12 FIX, anti-FIX antibodies and canine cytokines ELISA
The concentration of hFIX or cFIX was determined in mouse or dog plasma by 
ELISA specific for hFIX or cFIX antigen respectively (Asserachrome, Affinity 
Biologicals, respectively) according to manufacturer’s instructions. Absorbance of each 
sample is determined spectrophotometrically, using Elx800 automated microplate reader 
(BIO TEK Instruments) and normalised to antigen standard curves. The lower limit of 
quantification of the cFIX ELISA is 1 ng/ml or 0.02% of normal FIX levels, defined as 
the mean of 4 independent blank samples plus 3 standard deviations.
Mouse plasma samples were tested for the presence of anti-hFIX or anti-cFIX 
antibodies by ELISA as described41. Briefly, microtitre plates are coated with 
recombinant hFIX (Pfizer) or cFIX (Innovative Reseacrh) at 0.2 pg/well in 0.1 M 
carbonate buffer, pH 9.6. Two dilutions (1:100 and 1:1000) of mouse plasma are added 
and antibodies are detected with HRP-conjugated rabbit anti-mouse Ig (Dako). Plates 
are reacted with H2O2 and ortho-phenylenediamine and read at 492 nm. Plasma 
collected from haemophilia B mice previously immunised by subcutaneous 
administration of 50 pg of hFIX or cFIX antigen in IFA was used as a positive control 
for antibodies.
Canine cytokines concentration were determined in serum from treated and untreated 
dogs by a multiplex ELISA (Milliplex canine cytokine assay, Millipore), according to 
manufacturer’s instructions.
3.13 Coagulation assays
Whole blood clotting times (WBCT) were performed on blood collected from treated 
dogs by a two-tube procedure at 28° C256. One ml of whole blood collected with a 1-ml 
syringe is distributed equally between two siliconised tubes (Vacutainer, Becton- 
Dickinson). The first tube is tilted every 30 sec. After a clot forms, the second tube is 
tilted and observed every 30 sec. The endpoint is the clotting time of the second tube. 
Canine FIX activity was determined in dog samples by aPTT, as described256. The
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variability of the assay has been reported256.
Canine FIX activity was determined in mouse samples by a modified aPTT assay 
using canine FIX-deficient plasma (kindly provided by Dr. T. Nichols, University of 
North Carolina) and a semiautomated coagulometer (BioMerieux). Calibration curves 
were constructed with serial dilutions of pooled normal canine plasma (kindly provided 
by Dr. T. Nichols, University of North Carolina) and arbitrarily assigned a value of 
100% FIX antigen or activity. Alternatively, cFIX activity was determined using a 
chromogenic assay, according to manufacturer’s instructions (Hyphen Biomed), using 
serially diluted cFIX standards for calibration.
FIX inhibitor was determined by the Nijmegen modification of Bethesda assay257. 
The basic procedure is a 2-hour incubation of the test sample with Imidazole buffered 
(pH 7.4) normal canine pooled plasma with FIX activity of 100%. A reference mixture 
of test-specific normal canine pooled plasma with cFIX-deficient plasma is also 
prepared. After incubation the residual FIX activity (the relative percentage of FIX 
activity in the test sample mixture compared to the reference mixture) is converted into 
inhibitor Units/ml, where one inhibitor Unit is defined as the amount of inhibitor that 
yields 50% residual FIX activity. Inhibitor activity of test sample is read from a semi- 
logarithmic plot representing the correlation between residual FIX activity (logarithmic) 
and inhibitor activity (linear). The regression line is fully defined by 100% residual FIX 
activity with no inhibitor and 50% residual FIX activity with 1U inhibitor/ml.
3.14 Tail-clipping assay
Tail-clipping assay was performed as described223. Mice were anesthetised and tail 
was placed in pre-warmed 37° C normal saline solution for 2 minutes and subsequently 
cut at 2.5-3 mm diameter. Tail was then immediately placed in 37° C normal saline 
solution and monitored for bleeding or clotting for 10 minutes. Blood-containing saline 
was centrifuged at 520 g for 10 min at 4° C to collect erythrocytes and resuspended in 6 
ml of lysis buffer (10 mM KHCO3, 150 mM NH4CI, 0.1 mM EDTA). Lysis proceeded 
for 10 minutes at room temperature and samples were centrifuged as above. OD at 575 
nm of supernatants was measured.
3.15 Fractionation and sorting of liver cell populations
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Mice were anesthetised with tribromoethanol (Avertin) and the abdomen and thorax 
were exposed. The liver was perfused (2.5 ml/min) via the inferior vena cava with 12.5 
ml of the following solutions: 1) PBS EDTA (0.5 mM), 2) HBSS (Hank’s balanced salt 
solution, Gibco-Life Technologies) and HEPES (10 mM), 3) HBSS-HEPES 0.03% 
Collagenase IV (Sigma). The dissociated liver tissue was harvested and smashed, 
passed through a 100 pm cell strainer (BD-Falcon) and processed into a single-cell 
suspension. This suspension was subsequently centrifuged three times at 35, 30 and 25 
g to obtain hepatocyte-containing pellets. The non-parenchymal cells (nPC)-containing 
supernatant was loaded into a 30-60% Percoll (Sigma) gradient, centrifuged at 500 g 
and the nPC interface was collected. The nPC suspension was subsequently incubated 
with the following monoclonal antibodies: Fluorescein Isothiocyanate (FITC)- 
conjugated anti-CD45, Allophicocyanin (APC)-conjugated anti-F4/80, phycoerythrin 
(PE)-conjugated anti-CD31, APC-Cy7-conjugated anti-B220 (all from BD 
Biosciences). nPC subpopulations were sorted by fluorescence-activated cell sorting 
(FACS; MOFLO-DAKO-Beckman Coulter) according to the following markers: LSEC: 
CD45' CD31+; KC CD45+ F4/80+ B220low.
3.16 T- and B-cell assays and adoptive transfer
Mice were euthanized at the expected time point, spleens, livers and lymph nodes 
were collected and processed into single-cell suspension. Splenic CD8+ T cells were 
magnetically isolated from splenocytes by negative selection kit (Miltenyi Biotec). 
Intra-hepatic leukocytes (IHLs), which include T cell infiltrates, were isolated from the 
liver by smashing the tissue and running the sample on a Percoll (Sigma) gradient, as 
previously described76. IFN-y-secreting cells were enumerated by enzyme-linked 
immunospot (ELISPOT) assay in response to GFP-expressing cells as described . 
Splenocytes and IHLs were incubated with the following monoclonal antibodies: 
Allophicocyanin (APC)-conjugated Foxp3 staining kit (e-Bioscience); R-phycoerythrin 
(PE)-conjugated anti-CD25, Peridinin Chlorophyll (PerCP)-conjugated anti-CD8a; 
Pacific Blue-conjugated anti-CD4 (all from BD Biosciences). Detection of GFP-specific 
CD8+ T cells was performed by APC-labelled Pro5 MHC pentamer H-2Kd 
HYLSTQSAL (GFP200-208) according to manufacturer’s instructions (Proimmune).
Anti-FIX antibody secreting B cells were enumerated by ELISPOT culturing lymph
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node, spleen and bone marrow cells for 24 hours. Lymph node cells were incubated 
with the following monoclonal antibodies: FITC-conjugated anti-CD 19, PerCp- 
conjugated anti-B220, PB-conjugated anti-IgD, PE-Cy7-conjugated anti-IgM (all from 
BD Biosciences), Alexa647-conjugated recombinant hFIX (Pfizer). The conjugation 
reaction was performed by Alexa647 carboxilic acid, succinimidyil ester (Molecular 
Probe), according to manufacturer’s instructions. Stained cells were analyzed with a 
FACSCanto flow cytometer equipped with Diva software (BD Biosciences). FIX- 
specific memory B cells were identified as CD19+ B220+ IgD' IgM' FIX-Alexa647+ 
cells.
C57B1/6 OT-II TCR transgenic Ly5.2 mice were crossed with C57B1/6 FOXP3-GFP 
knock-in Ly5.2 mice. FACS-sorted Ly5.2 OT-II CD4+ F0XP3'GFP‘ were administered into 
C57B1/6 Ly5.1 recipient mice by tail vein injection (2.5xl06 cells/mouse), one day 
before OVA-encoding IDLV or IDLV.142T administration. Reconstitution of Rag27 y- 
chain7" mice was performed by intraperitoneal injection of pooled splenocytes and liver 
lymphocytes (6xl07 cells/mouse) isolated from nai've, IDLV-treated or IDLV-142T- 
treated as described above.
3.17 Tissue analysis
The liver was fixed in 4% paraformaldehyde, embedded in optimal cutting 
temperature (OCT) and frozen in iso-penthane pre-cooled in liquid nitrogen. Cryostat 
sections (10 pm thick) were blocked with 5% FBS (Gibco), 1% bovine serum albumine, 
0.1% Triton X-100 in PBS, and either directly analyzed under a 3-laser confocal 
microscope (Radiance 2100, Bio-Rad), or previously incubated with rabbit anti-GFP 
(Molecular Probe) washed and incubated with (FITC)-conjugated goat anti-rabbit Ig. 
Sections form untreated mice were used as negative controls. Nuclei were stained with 
TOPRO-3 (Molecular Probe).
3.18 Histopathology analysis
Histopathological evaluation was performed on liver, spleen, kidneys, heart, lungs 
and brain of mice treated with LVs expressing R338L or wt cFIX and on liver from one 
treated dog. Mice were euthanized at 1 year of age and approximately 10 months after 
LV administration, and organs were harvested, fixed in formalin and embedded in
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paraffin. Canine liver was obtained through a surgical biopsy carried out 16 months 
after LV administration. One randomly collected 3 mm section for each mouse organ 
and 10 sections from canine liver were stained with haematoxylin and eosin and scored 
for any pathological sign.
3.19 VCN determination
Vector DNA was quantified as follows: gDNA was extracted from liver samples or 
fractionated/sorted liver cells by using Maxwell 16 Tissue DNA Purification Kit 
(Promega), or DNeasy Blood & Tissue Kit (Qiagen), respectively, according to 
manufacturer’s instructions. VCN was quantified by qPCR using primers (HIV sense: 
5 ’-TACTGACGCTCTCGCACC-3 ’; HIV antisense: 5’-TCTCGACGCAGGACTCG- 
3’) and a probe (FAM 5’-ATCTCTCTCCTTCTAGCCTC-3’) against the primer 
binding site region of LVs.. Endogenous DNA amount was quantified by a 
primer/probe set against the murine B-actin gene (B-Act sense: 5’-
AGAGGGAAATCGTGCGTGAC-3 ’; B-Act antisense: 5’-
CAATAGTGATGACCTGGCCGT-3 ’; B-Act probe: VIC 5’-
CACTGCCGCATCCTCTTCCTCCC-3’). Copies per genome were calculated as 
described (3.3.2) The standard curve was generated by using samples with previously 
determined copies by Southern blot analysis.
3.20 Integration site analysis
To analyze ICLV and IDLV integrations we used standard and non-restrictive 5’- 
and 3’-LTR mediated linear-amplification mediated (LAM)-PCR258,259. Briefly, lOOng 
(for standard) or 500ng (for non-restrictive) DNA samples were pre-amplified by linear 
PCR using biotinylated primers hybridizing to LTR sequences: 5‘-
TTAGCCAGAGAGCTCCCAGG-3 ‘ for 5’-LTR LAM-PCR and 5‘- 
AGCTTGCCTTGAGTGCTTCA-3 ‘ for 3’-LTR LAM-PCR. In combination with the 
previously reported linker cassette primers, two additional exponential amplifications 
were achieved using the following LTR primers, respectively: 5‘-
GATCTGGTCTAACCAGAGAG-3 ‘ and 5 ‘-CCCAGTACAAGCAAAAAGCAG-3 ‘ for 
5’-LTR LAM-PCR; 5‘-AGTAGTGTGTGCCCGTCTGT-3’ and 5‘-
GATCCCTCAGACCCTTTTAGTC-3‘ for 3’-LTR LAM-PCR. LAM-PCR amplicons
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were purified, tagged for downstream 454 pyrosequencing and bioinformatical analyses 
as previously described24. Because of possible deletions in the LTR of the IDLV an 
amplicon sequence was considered as valid vector-host genome junction if the 
megaprimer sequence and at least 5 or 18 nucleotides of the LTR were present. The 
remaining sequences were automatically aligned to the mouse genome (assembly 
NCBI37/mm9) using BLAT260. Alignments with at least 95% sequence identity were 
reported as integration sites.
3.21 Statistical analysis
Standard statistical analyses were performed using Student t-test and ANOVA in 
experiment comparing variables at each time-point at a=0.05 level of confidence.
In order to test differences in transgene expression or clotting activity over time, 
instead we applied a statistical methodology within a nonparametric permutation 
setting.
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4.RESULTS
4.1 Evaluating LV-mediated liver gene therapy in the haemophilia B 
canine model
Haemophilic dogs are valuable models for stringently evaluating the efficacy, acute 
and long-term toxicity and immunogenicity of new therapeutic strategies. They also 
provide a more realistic and predictive model to assess dose-response as compared to 
mice. The haemophilia B dogs of the Chapel Hill colony (North Carolina, USA) have a 
spontaneous missense mutation that causes a single amino-acid substitution in the FIX 
protein (E379G), leading to impaired protein folding and secretion into the 
bloodstream261. These dogs are thus completely devoid of FIX activity in the circulation 
and closely recapitulate the human disease phenotype. They undergo spontaneous 
bleedings 5.5 times a year on average and are cared by on-demand plasma transfusions 
from normal dogs. We set out to translate and evaluate in this model our LV-mediated 
liver gene therapy approach that proved effective in haemophilia B mice73.
4.1.1 LVs efficiently transduce canine hepatocvtes. the activity of ET promoter and 
miR-142 is preserved in canine cells and canine serum minimally inactivate LV 
particles
We first aimed to address issues that may negatively affect the feasibility of 
translation of our LV-mediated liver gene therapy strategy to dogs. We first generated a 
LV expressing the specie-specific cFIX transgene under the control of the synthetic 
hepatocyte-specific promoter designated as ET (Enhanced Transthyretin)262 and 
carrying target sequences for miR-142 (ET.cFIX.142T, Figure 1). In order to verify in 
vivo transgene activity, we intravenously injected 5xl08 transducing units (TU, 
determined by end-point titration on a permissive cell line), corresponding to 
approximately 10 p,g of HIV Gag p24 equivalents (p24) of ET.cFIX.142T in 
haemophilia B mice (n=2). In both mice we measured approximately 5% of normal 
cFIX activity over time in the plasma of treated mice, thus confirming transgene 
functionality (Figure 2A).
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Figure 1
LV (ICLV/IDLV).
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Figure 1: Schematic o f  LVs used in this work. Schematic representation o f the third- 
generation self-inactivating LVs (provirus) used in this work and how they are referred 
to as in text. SD: splicing donor site. SA: splicing acceptor site, y/: packaging signal, 
including 5 ’ portion o f GAG gene (GA). RRE: Rev responsive element. cPPT-CTS: 
central polypurine tract to central termination sequence, wpre/wpre*: woodchuck 
hepatitis virus post-regulatory element/mutated wpre (see 1.4). 142T: miR-142 target 
sequence made o f 4 tandem copies o f  a sequence perfectly complementary to miR-142. 
Promoters used: ubiquitously expressed phosphoglycerokinase (PGK) promoter, 
hepatocyte-specific enhanced transthyretin (ET) promoter composed o f  synthetic 
hepatocyte-specific enhancers and transthyretin promoter. Transgenes used: green 
fluorescent protein (GFP), chicken ovalbumin (OVA), wt human or canine coagulation 
Factor IX  (hFIX, cFIX), codon-optimised cFIX (co-cFIX), hyper-active cFIX  
(cFIXR338L), codon-optimised hyper-active cFIX (co-cFIXR338L). Vectors were 
produced with integrase-competent (ICLV) or integrase-defective (IDLV) packaging 
constructs (see 1.4.2). Unless othei'wise indicated LVs were produced with canonical 
integi'ase-competent packaging consti'ucts. Unless otherwise indicated LVs were 
pseudotypeded with the VSV-G envelope.
It has been shown that mouse serum has little effect on the stability of LV particles in 
the circulation, whereas human and NHP serum may inactivate vector particles through 
the complement system263, 264. To determine the extent of complement-mediated 
inactivation, LV titres were measured after exposure to canine serum and the results 
reported as percentage of recovery of titre compared to control samples not exposed to 
serum (Figure 2B). LV displayed some sensitivity to canine serum with 2- to 5-fold 
reduction in titre and some. inter-individual variability. Pre-incubation of LV with the 
serum obtained from 2 healthy human donors resulted in 10-fold titre reduction. These 
data show that there is no major inactivation of LV in canine serum. However, we
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decided to pre-screen serum from 3 candidate dogs and select for infusion the dog 
whose serum displayed the lowest neutralizing potential against LV.
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Figure 2: Feasibility o f  translation o f  LV-mediated liver gene therapy to dogs. (A)
cFIX activity measured by aPTT in plasma collected at the indicated times after LV  
administration in haemophilia B mice. Results are presented for individual mice. (B) 
Percentage o f titre remaining after LV incubation with normal (dark grey bars) or heat- 
inactivated (light grey bars) serum, compared to no serum control, set as 100% 
recovery. PGK.GFP LVs were incubated for 1 h at 37° C with medium (no serum 
control) or serum o f 2 healthy human donors, 3 different dogs or a pool o f  canine 
serum. Results are presented as mean±range o f 2 independent experiments. (C) 
Representative images o f  primary human or canine hepatocytes cultures transduced 
with the indicated LVs (M OI100) or left untransduced (UNT) and analysed 3 days after 
transduction by live fluorescence microscopy. The reverse transcriptase inhibitor
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azidothymidine (AZT) was used as a control fo r  psudotransduction. (D) miRNA levels in 
DH82 cells were quantitated by RT-qPCR using primers and probe specific fo r  the 
indicated miRNAs. Results are presented as mean±standard error o f the mean (SEM) o f  
different RNA extractions (n=5). (E) Histogram and GFP mean fluorescence intensity 
(MFI) o f  flow cytometry analysis o f DH82 cells transduced with PGK. GFP (light grey 
line) or PGK.GFP. 142T (dark grey line) LV  at the indicated MOI, or left UNT (black 
line).
To verify promoter activity in canine hepatocytes and exclude canine-specific 
restriction to LV transduction, we transduced primary human and canine hepatocytes in 
vitro at multiplicity of infection (MOI) 100 with LVs expressing GFP under the control 
of the ubiquitously expressed phosphoglycerokinase (PGK) promoter or the ET 
promoter. We observed high levels of transduction and transgene expression in 
hepatocytes derived from both species (Figure 2C). Interestingly primary human 
hepatocytes were transduced better than canine hepatocytes.
The miR-142 sequence is conserved between human and dog. To ensure that miR- 
142-mediated regulation would be reproduced in dogs, we assessed the conservation of 
miR-142 expression and activity in canine hematopoietic-lineage cells. Expression 
levels of selected microRNAs were analyzed in DH82 cells, a cell line derived from 
canine macrophages, using a quantitative reverse-transcription PCR (Figure 2D). The 
expression patterns resembles that of U937 cells, a human monocytic cell line, 
demonstrating cross-species conservation of many microRNAs35. Importantly, miR-142 
was found to be expressed at high levels. To examine miR-142 activity on transgene 
suppression, DH82 cells were transduced with reporter LVs encoding GFP with or 
without regulation by miR-142, and GFP expression was analyzed by flow cytometry. 
As shown in figure 2E, canine miR-142 mediated down-regulation of GFP expression 
more than 100-fold and to levels comparable with the negative population when low 
vector concentration was used.
Taken together, these data indicate that cFIX transgene cloned in the vector is 
functional, the ET promoter and miR-142T activity are preserved in cells of canine 
origin and that the extent of LVs inactivation in canine serum is not incompatible with 
their in vivo administration. Based on these promising data we proceeded with large- 
scale manufacturing and testing of ET.cFIX.142T LV in the haemophilia B canine 
model.
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4.1.2 LV-mediated liver gene therapy is safe and feasible in a haemophilia B dog and
allows long-term transgene expression
Taking advantage of a manufacturing process previously validated for the production 
of clinical-grade LVs, we produced a large-scale batch (2009/D2) of LV qualified for in 
vivo administration. The process consists in quadritransfection of a producer 293T cells 
bank, collection of vector-containing supernatants, benzonase treatment to reduce 
plasmid DNA carryover, followed by 2 steps of column chromatography (an ion 
exchange and gel filtration) and sterilising filtration, with a overall yield of purified LV 
particles of approximately 25% of the initial output (Figure 3). A similar process has 
been recently reported252. More details can be found in 3.4. Quality assessment of 
vector preparation is summarised in Table 1. The process yielded a total of l.lx lO 10 
TU, corresponding to 864 pg p24 in 160 ml PBS for infusion. The LV had an infectivity 
of 1.3xl04 TU/ng p24. The preparation was tested for the absence of RCL. The 
preparation had a low endotoxin content, compatible with i.v. administration in dogs 
(maximal tolerated dose 5 endotoxin unit/kg/hour) and was sterile. We treated an 8- 
month old, 20-kg male haemophilia B dog (M57) by intraportal administration of the 
whole LV lot described above (Table 1), corresponding to a dose of 5.7x108 TU/kg and 
44 pg p24/kg.
The infusion was well tolerated and uneventful, except for a transient rise in body 
temperature, which returned to normal after 1 day. We determined aminotransferases 
(alanine aminotransferase, ALT and aspartate aminotransferase, AST) levels in serum 
collected from the treated dog in the first days after LV administration (Figure 4A,B). 
Both ALT and AST increased 6 and 11 fold respectively as compared to baseline, 
reaching values slightly above the normal range for 3 and 1 day, respectively (250 and 
200 U/l), indicating a minor and self-limiting hepatocellular toxicity. Platelet counts 
were slightly below the normal range for 6 days after LV administration (Figure 4C). 
These events were asymptomatic and did not require intervention. Since haematocrit 
was also low (32%, normal range 37-55%), the minor reduction in platelet counts is 
consistent with haemodilution, as the dog received >500 ml of liquids during the 
infusion procedure (200 ml of normal dog plasma transfusions both before and after 
surgery and the LV volume). All the other blood chemistry parameters were in the 
normal range. We also monitored serum levels of some canine cytokines (IL-2, IL-4,
80
IL-6, IL-7, IL-8, IL-10, IL-15, TNF-a, TGF-[3, IFN-y) for the first 50 days after LV 
administration and found a sharp induction of TNF-a, IL-6 and IL-8 levels since the 
first hours after LV administration, rapidly declining over the following hours, 
consistent with an acute inflammatory response to LV particles (Figure 4D-F). All the 
other cytokines were found at levels not significantly different from control untreated 
animals.
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Figure 3: Flow chart o f  large-scale L V  production. CF10: 10-tray cell factories. 
Further details can be found in 3.4
Table 1. Quality controls of the large-scale purified LV Batch 09/D2
Batch 2009/D2 Specification
Particles pg p24/ml 5.4 For information only
Titre TU/ml 7.0xl07 >1.0x10*
Infectivity TU/ng p24 1.3xl04 >1.0 xlO4
Transgene Activity Positive Positive
81
Total DNA [ig/ml 2.6 For information only
Producer cell protein ng/ml 82 For information only
Endotoxin EU/ml 0.3 <1
Sterility Negative Negative
RCL Negative Negative
Volume ml 160
Particles Total p,g p24 864
Titre Total TU l.lx lO 10
Endotoxin Total EU 48
The table shows the results of selected quality control assays performed on the large- 
scale purified LV Batch 2009/D2. The specifications for GMP-grade LV production are 
listed. Please note that this batch is a research-grade production. EU: endotoxin units. 
TU: transducing units.
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Figure 4: Acute toxicity and cytokines levels after portal vein infusion o f  
LV.ET.cFIX.142T in the haemophilia B  dog (wt transgene). ALT (A) and AST (B)
serum levels, blood platelets counts (C), TNF-a, (D), IL-6 (E) and IL-8 (F) serum levels 
measured in samples collected at the indicated times after LVadminisfration.
We measured the whole blood clotting time (WBCT), aPTT and cFIX antigen levels 
in blood or plasma samples collected from dog M57 at routine intervals after LV 
administration. At the current follow-up (>3 years after treatment) the dog is alive and 
well. Both WBCT and aPTT were stably shortened, albeit without reaching normal 
levels (Figure 5A,B) and anti-cFIX inhibitors tested negative in two independent
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determinations (at day 7 and 50 after LV administration). We found detectable cFIX 
antigen levels, ranging from 0.5 to 4.5 ng/ml, corresponding to 0.01 to 0.09% of normal 
levels (Figure 5C). We calculated cFIX activity based on a curve correlating cFIX 
levels and WBCT or aPTT256 and found that cFIX activity averaged 0.1% of normal and 
ranged from 0.01 to 0.7% of normal (Table 2). Although the reconstituted activity was 
low, the frequency of spontaneous bleeding events was significantly lower as compared 
to the expected, as the dog experienced only 3 out of 17 spontaneous bleedings 
expected for the time of observation after gene therapy. A liver biopsy was taken at 16 
months after LV administration and resulted negative for any pathological abnormality.
Figure 5
40-
20 -
■nonra]*raricje
0 50 100 150 200 250 300 350 400 600 1000 1200800
Days post LV
80- ■
norma! range
20 -
50 100 150 200 250 300 350 4000 600 800 1000
Days post LV
c 1.0
0 .8 -
0 .6 -otz
0.4-
0 .2 -
0.0
100 150 200 250 300 350 400 600 10000 50 800
Days post LV
83
Figure 5: Efficacy o f  liver gene therapy with LV.ET.cFIX.142T in the treated 
haemophilia B  dog (wt transgene). WBCT (A), aPTT (B) and cFIX antigen levels 
measured on blood or plasma samples collected at the indicated times after LV  
administration.
Table 2. Dose of LV and treatment efficacy in the haemophilia B dog treated with 
LV.ET.cFIX.142T (wt transgene)
DOG M57 (Hemil)
TU/kg 5.7xl08
pg p24/kg 44
FU (days) 1116
WBCT (min) 20 (14-32)
WBCT-based cFIX activity (% normal) 0.15(0.015-0.7)
aPTT (sec) 72.5 (63.6-85)
aPTT-based cFIX activity (% normal) 0.12(0.01-0.2)
cFIX antigen (% normal) 0.05 (0.01-0.09)
The table shows the infused dose of LV (titre and particles) per weight, the follow up 
(FU) time, the results of the coagulation assays performed to determine cFIX activity 
and the cFIX antigen levels (determined by ELISA). Results are presented as mean of 
values over time (range of determined values).
Overall these data indicate that liver gene therapy by LVs in a dog affected by 
haemophilia B was feasible and provided long-term expression of cFIX with some 
therapeutic benefit, without eliciting anti-FIX immune responses. However, cFIX 
activity could only reach approximately 0.1% of normal levels at the dose infused. 
Thus, it is clear that an increase in LV dose and/or potency is needed to improve 
therapeutic efficacy.
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4.2 Evaluating a codon-optimised FIX transgene in the haemophilia 
B mouse and dog model
Since increasing the LV dose to treat dogs represents a challenge for the current 
manufacturing capacity of large-scale purified vector batches, it becomes crucial to 
maximize vector potency. In order to increase vector potency we first evaluated whether 
increased transgene expression levels can be obtained in vivo by exploiting a codon- 
optimised cFIX transgene (co-cFIX). Codon-usage optimisation is aimed at maximizing 
the output of a transgene product by both stabilizing transgene mRNA and enhancing its 
translation. This process can be carried through bioinformatics tools and consists of 
substitutions of codons with synonymous ones that are the most frequently found in 
highly expressed genes in a species and are recognized by the most abundant tRNAs. 
Moreover, cis-acting elements that could impact on mRNA stability are eliminated or 
changed265' 266.
4.2.1 A codon-optimised transgene increases FIX expression 2- to 3-fold in 
haemophilia B mice
We set out to evaluate the transgene expression levels achieved upon liver gene 
therapy with LV expressing the co-cFIX transgene in haemophilia B mice. This 
transgene was generated by changing 156 out of the total 452 triplets composing its 
cDNA (by a subcontractor). Within the modified codons, 140 were changed by third- 
base substitution, while 16 codons (including the STOP codon) were hilly changed. We 
then generated a miR-142- regulated LV bearing this co-cFIX transgene under the 
transcriptional control of the ET promoter (ET.co-cFIX.142T, Figure 1).
We compared the potency of this improved expression cassette with that of the same 
cassette containing the wt cFIX transgene (ET.cFIX.142T), upon i.v. administration in 
haemophilia B mice. The titre and infectivity of these LVs were similar. We treated 
haemophilia B mice with two different matched doses (5 or 10xl08 TU/mouse) of 
ET.co-cFIX.142T or ET.cFIX.142T (n=4/group). We measured cFIX protein expression 
and clotting activity on plasma samples collected from treated mice at regular intervals 
after LV administration (Figure 6). We observed that cFIX activity was 3.4- and 2.2- 
fold higher for the co-cFIX than its wt counterpart in both dose cohorts, reaching up to 
38.4 ± 4.8% (mean ± standard error of the mean, SEM) of normal clotting activity in the
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high-dose group (Figure 6B,D). Vector copies per diploid genome (vector copy number, 
VCN) were similar in the liver of treated animals receiving matched doses of LVs 
bearing wt or co-cFIX, measured at the end of experiment. This result indicates that the 
observed increase in clotting activity was not due to increased transduction. FIX 
inhibitors were undetectable by Bethesda assay in all treated mice. These data show that 
a co-cFIX transgene can significantly increase expression, without any evident 
impairment of specific enzyme activity (as measurable by the ratio of activity to 
antigen) nor increased immunogenicity . Based on these data, we next evaluated the 
use of this co-cFIX transgene in the haemophilia B canine model.
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Figure 6: Codon-optimised cFIX  transgene in haemophilia B  mice. cFIX expression 
and clotting activity measured by ELISA (A,C) and aPTT (B,D) respectively on plasma 
samples collected from treated mice at the indicated times after LV administration. 
Mice were treated with 5x108 (A and B) or 10xl08 (C and D) TU/mouse o f  
ET.cFIX.142T (squares, n=4) or ET.co-cFIX.142T (triangles, n=4). VCN in genomic 
DNA from the liver o f  treated mice measured at the end o f  experiment is indicated. 
Results are presented as mean±SEM. *: pGLOBAL<0.05 (non parametric combination 
statistics).
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4.2.2 LV-mediated liver gene therapy with a higher dose and a co-cFIX transgene
reconstitutes higher FIX activity in a second haemophilia B dog
We produced a second large-scale batch (2011/D 13-15) of purified LV carrying the 
co-cFIX transgene. In an effort to increase also the LV dose to administer to the dog, we 
used improved transfection and collection conditions to increase the LV yield. We also 
optimised the formulation medium by adding 5% DMSO to increase vector stability and 
reduce adsorptive loss during manipulation and administration. Quality assessment of 
the new vector preparation is summarised in Table 3. This LV batch had a 3.4-fold 
increased infectivity as compared to the previous batch (most probably due by the 
combination of process optimisation and the use of codon-optimised transgene), thus 
resulting in a 4-fold higher TU dose and only slightly higher p24 dose to be 
administered (4.5xl010 total TU, 1030 total pg p24, infectivity 4.4xl04 TU/ng p24). The 
preparation had a low endotoxin content, compatible with i.v. administration in dogs 
and was sterile.
Table 3. Quality controls of the large-scale purified LV Batch 11/D13-15
Batch 2011/D13-15 Specification
Particles pg p24/ml 6.3 For information only
Titre TU/ml 2.7x10s >1.0x10*
Infectivity TU/ng p24 4.4x10“ >1.0x10“
Transgene Activity Positive Positive
Total DNA pg/ml 1.4 For information only
Producer cell protein ng/ml 221 For information only
Endotoxin EU/ml <0.8 <1
Sterility Negative Negative
RCL Negative Negative
Volume ml 164
Particles Total pg p24 1030
Titre Total TU 4.5x10'°
Endotoxin Total EU <137
The table shows the results of selected quality control assays performed on the large- 
scale purified LV Batch 2011/D13-15. The specifications for GMP-grade LV 
production are listed. Please note that this batch is a research-grade production. EU: 
endotoxin units. TU: transducing units.
We treated a second haemophilia B dog (021, male, 21-months old, 22 Kg of body 
weight) by intraportal administration of the whole LV preparation described in Table 3,
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corresponding to a dose of 2.3xl09 TU/Kg and 47 p,g p24/Kg. During infusion, the dog 
experienced an unexpected acute hypotension attributed to a type-I hypersensitivity 
reaction to an unknown component of the vector batch. This event was successfully 
managed by immediate administration of an antihistamine drug (Benadryl 1 mg/kg, i.v.) 
and a corticosteroid (Dexamethasone 25 mg/kg i.v.). LV infusion was subsequently 
completed upon blood pressure recovery. We observed a transient rise in body 
temperature. ALT and AST serum levels increased 2 and 4 fold respectively as 
compared to baseline, resulting in levels slightly above the normal range for 3 and 1 
day, respectively (160 and 120 U/l). This increase indicates a minor and self-limiting 
hepatocellular toxicity, similar or even lower to that observed in dog M57 (Figure 
7A,B). Platelet counts were slightly below the normal range for 2 days after LV 
administration (Figure 7C). Since haematocrit was also low (26%), the minor reduction 
in platelet counts is consistent with haemodilution, as described above (4.1.2). All the 
other blood chemistry parameters were in the normal range.
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Figure 7: Acute toxicity after portal vein infusion o f  LV.ET.co-cFIX.142T in the 
haemophilia B  dog (codon-optimised transgene). ALT (A) and AST (B) serum levels, 
blood platelets counts (C) measured in samples collected at the indicated times after LV  
administration.
The WBCT, aPTT and cFIX antigen levels were measured in blood or plasma 
samples collected from dog 021 at routine intervals after LV administration (Figure 8). 
At the current follow-up (>6 months after treatment) the dog is alive and well. We could 
measure cFIX antigen levels ranging from 20 to 40 ng/ml, corresponding to 0.4 to 0.8% 
of normal levels (Figure 8C). We determined cFIX activity based on the WBCT or 
aPTT256 and found that it ranged from 0.1 to 1.5% of normal (Table 4). 021 has not
88
experienced any spontaneous bleeding over the last 6 months, indicating a clinical 
benefit. Since this dog received a 4-fold higher LV dose (in TU) and showed 
approximately 10-fold higher cFIX antigen and activity with respect to the previously 
treated dog, transgene codon-usage optimisation may have increased FIX levels by 2.5- 
fold as compared with wt cFIX transgene, in line with the data obtained in the mouse 
model.
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Figure 8: Efficacy o f liver gene therapy with LV.ET.co-cFIX.142T in the treated 
haemophilia B dog (codon-optimised transgene). WBCT (A), aPTT (B) and cFIX
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antigen levels measured on blood or plasma samples collected at the indicated times 
after L V  administration.
Table 4. Dose of LV and treatment efficacy in the haemophilia B dog treated with 
LV.ET.co-cFIX.142T (codon-optimised transgene) in comparison with the 
previously treated dog (Table 2)
DOG M57 (Hemil) 021 (Valentine)
TU/kg 5.7xl08 2.3xl09
Hg p24/kg 44 47
FU (days) 1116 189
WBCT (min) 20 (14-32) 17.3 (15-22.5)
WBCT-based cFIX activity (% normal) 0.15(0.015-0.7) 0.4 (0.1-1.15)
aPTT (sec) 72.5 (63.6-85) 63.9 (58-68)
aPTT-based cFIX activity (% normal) 0.12(0.01-0.2) 0.2(0.18-1.5)
cFIX antigen (% normal) 0.05 (0.01-0.09) 0.6 (0.4-0.8)
The table shows the infused dose of LV (titre and particles) per weight, the follow up 
(FU) time, the results of the coagulation assays performed to determine cFIX activity 
and the cFIX antigen levels (determined by ELISA). Results are presented as mean of 
values over time (range of determined values).
4.3 A codon-optimised and hyper-active FIX transgene increases the 
potency of LVs after liver gene therapy in haemophilia B mice
In an effort to further increase vector potency, we evaluated the use of a hyper­
functional FIX carrying a R338L amino acid substitution, previously associated with 
clotting hyperactivity and thrombophilia268. FIX-R338L is a naturally occurring mutant 
found in a young man with a diagnosis of deep-venous thrombosis and termed FIX 
Padua, after the city of patient origin. It was reported that the patient had >700% of 
normal FIX activity with normal FIX antigen levels. This mutation affects a residue that 
is crucial for FX binding and causes a gain-of-function phenotype conferring high risk
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of thrombosis. Recombinant FIX-R338L was shown to have 5- to 10-fold higher 
specific activity with respect to wt FIX. While this mutant caused thrombophilia in a 
normal individual hemizygous for the mutation, its use in gene therapy for haemophilia 
B is attractive, as lower amounts of this hyper-functional FIX could potentially result in 
correction of the disease phenotype.
Therefore we generated wt or co-cFIX transgenes bearing a point mutation 
corresponding to the previously described FIX-R338L mutant. We cloned these 
transgenes in LVs bearing the hepatocyte-specific ET.142T expression cassette (Figure 
1). As shown in Figure 9A, haemophilia B mice treated with LV carrying the wt (n=4) 
or hyper-functional FIX-R338L (n=6; 7xl08 TU/mouse) expressed about 8% of normal 
cFIX antigen in the circulation, while mice treated with the hyper-functional co-cFIX- 
R338L transgene (n=7; 7xl08 TU/mouse) reached about 20% (consistent with the 
aforementioned 2- to 3-fold increased expression of co-cFIX). However, both the 
hyper-functional cFIX-R338L and co-cFIX-R338L transgenes exhibited >5-fold higher 
activity with respect to the antigen levels, resulting in up to 125% of normal clotting 
activity for the co-cFIX-R338L transgene (Figure 9B). These data show that the hyper­
functional co-cFIX-R338L transgene provides a > 15-fold gain in potency with respect 
to the wt sequence and is greater than what has been reported with other FIX mutants206, 
269. These data were confirmed in the group of our collaborator Thierry 
VandenDriessche for analogous codon-optimised and R338L human FIX transgenes, 
following LV-mediated liver gene therapy in haemophilia B mice.
To evaluate whether the co-cFIX-R338L transgene allows lowering LV doses to 
reach therapeutic activity, haemophilia B mice were injected with 1.25 or 2.5xl08 
TU/mouse. Treated mice expressed about 0.7 and 3.4% of normal cFIX protein, 
respectively. However, their clotting activity was about 6.4 and 19% of normal, with 6- 
to 9-fold hyperactivity with respect to protein level (Figure 9C,D). None of the mice 
treated with hyper-functional transgenes developed inhibitors. In a tail-clipping assay, 
haemophilia B mice treated with low dose co-cFIX-R338L LV lost significantly less 
blood than mice treated with a matched dose of co-cFIX LV and were indistinguishable 
from wt mice, indicating the superior performance of the R338L FIX in achieving 
haemostasis in vivo (Figure 9E). To exclude that the use of this mutant impaired 
tolerance induction towards cFIX protein, haemophilia B mice were treated with 5xl08
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TU/mouse of co-cFIX or co-cFIX-R338L and subsequently subjected to immunisation 
with cFIX protein 6 weeks after LV administration. Mice treated with LVs expressing 
either transgene did not develop anti-hFIX antibodies, even after antigen re-challenge 
with cFIX protein, indicating that gene therapy induced immune tolerance to the wt 
protein (Figure 9F). In contrast, untreated haemophilia B mice developed anti-cFIX 
antibodies after immunisation with cFIX protein.
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Figure 9: Codon-optimised cFIXR338L transgene in haemophilia B  mice. cFIX 
expression and clotting activity measured by ELISA (A,C) and aPTT (B,D,E,F) 
respectively on plasma samples collected from treated mice at the indicated times after 
LV  administration. VCN was measured at the end o f the experiments in liver genomic 
DNA. Mice were treated with 7xl08 TU/mouse (A and B) o f ET.cFIX.142T (squares, 
n—4; VCN 1.1±0.2) or ET.cFIXR338L.142T (diamonds, n -6; VCN 1.3±0.3) or ET.co-
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cFIXR338L.142T (triangles, n=7; VCN 2.2±0.2). Mice were treated with 2.5x108 
TU/mouse (black line, n=3; VCN 1.4±0.2) or 1.25xl08 TU/mouse (grey line, n—3; VCN 
0.6±0.1) o f  ET.co-cFIXR338L.142T. Results are presented as mean±SEM. ***: 
pGLOBAL<0.001 (non parametric combination statistics). (E) Tail-clipping assay on 
haemophilia B mice treated with 2.5x108 TU/mouse o f ET.co-cFIX.142T (n=3) or 
ET.co-cFIXR338L (n=3) as indicated. Blood loss (mean±SEM) was determined by 
measuring the absorbance at 575 nm o f haemoglobin content in the saline solution in 
which the tail was placed (black bars, left axis); cFIX activity (mean±SEM; white bars, 
right axis). Wt (n—5) and untreated haemophilia B (HaemoB) mice (n=5) were used as 
controls. ***: p<0.001, ns: not significant (ANOVA). (F) cFIX-specific antibodies 
(mean±SEM, black bars, right axis) and cFIX expression (mean±SEM, white bars, left 
axis) measured by ELISA in the plasma o f mice treated with 5x108 TU/mouse o f ET.co- 
cFIX. 142T (n=3), ET.co-cFIXR388L.142T (n=3), or PBS (n=3) before or after 
immunisation with cFIXprotein, as indicated.
To assess the possible risks associated with expression of hyper-functional FIX, we 
performed histopathological evaluation of liver, spleen, kidney, heart, lungs and brain 
of mice long-term reconstituted (10 months post LV) to supra-physiological FIX 
activity by co-cFIX-R338L LV (up to 125% of normal) and found no significant 
difference between the organs of mice treated with wt and hyper-functional transgene. 
Moreover, we determined D-dimer levels as a measure of fibrin degradation. D-dimers 
are not normally present in plasma, except when the coagulation system has been 
activated, as in the case of thrombosis270. We did not detect significant increase in D- 
dimer levels in mice treated with LV expressing hyper-functional R338L FIX 
transgenes, suggesting that thrombotic risk was not increased after gene therapy in 
haemophilic mice (not shown). However D-dimer levels are increased upon acute 
thrombotic events, thus repeating measures over time will be needed to more 
appropriately assess this risk. Moreover, thrombosis risk is expected to be low at the 
levels tested and further ad hoc studies in permissive thrombosis models are required to 
establish the long-term safety of delivering hyper-functional FIX transgenes271. Our 
data, together with the known impact of the R338L mutation on substrate interaction
9 C&rather than zymogen activation , suggest that expressing limited amounts of hyper­
functional FIX to reach a threshold therapeutic level represents a viable and promising 
strategy to improve the efficacy, feasibility and safety of haemophilia gene therapy.
These data prompted us to evaluate this hyper-functional co-cFIX-R338L transgene 
in the setting of LV-mediated liver gene therapy in the canine model. We thus produced 
a new large-scale batch of purified LV expressing the co-cFIX-R338L transgene
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(2012/DG). Quality assessment of the vector preparations are reported in Table 5. This 
batch contained a total of 2.3xl010 TU, 3151 total pg p24, infectivity 7.3xl03 TU/ng. 
While the infectivity of this LV preparation was slightly lower, total particles were 
approximately 3-fold higher and total TU approximately half as compared with the 
previous batch. Infusion of a haemophilia B dog with this preparation is expected at the 
time of this thesis being written.
Table 5. Quality controls of the large-scale purified LV Batch 2012/DG
Batch 2012/DG Specification
Particles pg p24/ml 13.7 For information only
Titre TU/ml l.OxlO8 >1.0 x io 8
Infectivity TU/ng p24 7.3xl03 >1.0 xlO4
Transgene Activity Positive Positive
Total DNA pg/ml 0.4 For information only
Producer cell protein ng/ml 210 For information only
Endotoxin EU/ml <0.5 <1
Sterility Negative Negative
RCL Negative Negative
Volume ml 230
Particles Total pg p24 3151
Titre Total TU 2.3x10'°
Endotoxin Total EU <115
The table shows the results of selected quality control assays performed on the large- 
scale purified LV Batch 2012/DG. The specifications for GMP-grade LV production are 
listed. Please note that this batch is a research-grade production. EU: endotoxin units. 
TU: transducing units.
4.4 LVs pseudotyped with the baculovirus gp64 envelope protein 
mediated efficient liver gene therapy in haemophilia B mice
The VSV-G is widely used to pseudotype lentiviral vectors (LV), because it makes 
the vector pantropic and stabilizes vector particles, enabling the production of high-titre 
vector stocks and their long-term storage (see 1.4). However the use of alternative 
vector pseudotypes may be advantageous, when a more restricted tropism is preferable, 
and to overcome the limitations associated with VSV-G, such as toxicity in vector- 
producer cells and complement-mediated inactivation of the vector in serum225,244,264.
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For these reasons we evaluated the use of the baculovirus Autographa californica 
nuclear polyhedrosis virus gp64 envelope protein to pseudotype LV for liver gene 
therapy. This envelope protein was previously reported to confer tropism restriction 
against haematopoietic-lineage cells to pseudotyped LVs and improved resistance to 
complement-mediated inactivation272. We first produced LVs pseudotyped with the 
gp64 envelope protein (gp64.LV) with a PGK.GFP cassette. We evaluated the extent of 
complement-mediated inactivation of gp64.LV in human and canine serum, as 
described in 4.1.1. The results show that gp64.LVs are more resistant to inactivation as 
compared to VSV-G-pseudotyped LVs (Figure 10A,B), with a maximum of 2-fold 
observed reduction in titre.
We next produced gp64.LV with a therapeutic cassette expressing hFIX driven by 
the ET promoter and including miR-142 target sequences (Figure 1). Haemophilia B 
mice were intravenously injected with 2.5 (n=2), 5 (n=4) or 10 (n=l) xlO8 TU/mouse 
and hFIX expression was measured on plasma collected at routine intervals after LV 
administration. The treatment resulted in all cases in stable levels of hFIX in the 
circulation and a vector dose-transgene expression direct correlation was observed 
(Figure 10C). None of these mice developed anti-hFIX antibodies (not shown). These 
data show that gp64.LV can be produced at high titres and mediate liver-directed hFIX 
expression at levels comparable to those obtained after matched doses of VSV-G- 
pseudotyped LVs in haemophilia B mice and may represent a valuable alternative to 
VSV-G for in vivo administration. However, VSV-G pseudotyped LV currently remain 
our preferred option due to the established experience with large-scale manufacturing 
and clinical usage.
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Figure 10: Gp64-pseudotyped LVs fo r  liver gene therapy. Percentage o f titre 
remaining after LV incubation with normal or heat-inactivated serum, as indicated, 
compared to no serum control, set as 100% recovery. PGK.GFP VSV-G-pseudotyped 
(A, grey bars) or gp64-pseudotyped (B, black bars) LVs were incubatedfor 1 h at 37° C 
with medium (no serum control) or serum o f 2 healthy human donors, or a pool o f  
canine serum. Results are presented as mean±range o f 2 independent experiments. (C) 
hFIX expression measured by ELISA on plasma samples collected from treated mice at 
the indicated times after LV administration. Mice were treated with 5x108 TU/mouse o f  
VSV-G-pseudotyped (n=3, grey squares) or 2.5xl08 TU/mouse (n=2, black diamonds), 
5x108 TU/mouse (n=3, black squares), lOxlO8 TU (n=l, black circles) o f  gp64- 
pseudotyped ET.hFIX.142T LVs. VCN in genomic DNA from the liver o f  treated mice 
measured at the end o f experiment is indicated. Resultes are presented as mean±SEM 
(for n=3), mean±range (for n=2), or single values (for n=l).
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4.5 LV biodistribution to KCs limits hepatocyte transduction to a 
different extent at different vector doses
We observed that there is no linear correlation between the injected LV doses and 
liver VCN, nor between transgene expression in hepatocytes and liver VCN (see for 
example Figure 6A,B, Figure 9C,D and Figure IOC). In order to clarify this aspect, we 
set out to examine the LV biodistribution among the liver cell subpopulations and to 
understand the relative contribution of these populations to the overall liver 
transduction. Specifically, we set out to determine VCN in different liver cell sub­
populations after liver gene transfer at different LV doses and to correlate these data 
with the percentage of transgene-expressing hepatocytes. To this end, we first set up a 
method to separate cellular fractions enriched in hepatocytes (parenchymal cells, PCs) 
or non-hepatocyte cells (non-parenchymal cells, nPCs) from freshly dissociated livers 
and to further purify LSECs and KCs from total nPCs by FACS-sorting. We then 
intravenously administered 2.5, 5 or 10x10s TU/mouse (n=10 per dose) of LVs bearing 
the hepatocyte-specific ET.GFP.142T cassette to wt adult mice. At 2 months after LV 
administration we determined both the percentage of GFP+ hepatocytes in liver sections 
and VCN in whole liver DNA from half of the mice of each dose cohort (n=5). In some 
of the mice we extracted DNA from different liver lobes and found no difference in 
VCN between different lobes and between those and the VCN measured in whole liver 
(not shown). We perfused the other half of the mice (n=5) through the inferior vena 
cava with a collagenase solution. We centrifuge at low speed the digested liver tissue to 
obtain hepatocytes-containing pellets. We subject the supernatant to density gradient to 
further fractionate PCs and nPCs and FACS-sort the nPC-containing interface to obtain 
CD45'CD3l+F4/80low LSECs and CD 45'CD llb+F4/80+ KCs (Figure 11), according to 
previously published protocols . We then determined the VCN in these populations: 
fractionated liver PCs or nPCs, FACS-sorted LSECs or KCs.
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Figure 11
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Figure 11: Schematic diagram o f  separation o f  PCs and nPCs from  total liver. The
liver is perfused through the inferior vena cava with an EDTA solution and collagenase 
IV. The digested tissue is centrifuged at low speed to obtain hepatocytes-containing 
pellets. The supernatant is subjected to density gradient and the nPC-containing 
interface is subsequently stained and FACS-sorted as indicated to obtain LSECs and 
KCs. Further details can be found in 3.15.
We first correlated the injected LV dose with the percentage of GFP+ hepatocytes or 
with the VCN measured in whole liver or in the cellular fractions enriched in PCs or 
nPCs (pre-sorting), or with the VCN measured in FACS-sorted LSECs or KCs (Figure 
12A-F). The results show that KCs have a very high VCN (up to 27 LV copies per cell), 
even if they represent a relatively small proportion of the liver cells and that the VCN is 
generally higher in nPCs than in PCs, suggesting that a minority of the total LV 
particles approaching the liver can transduce the hepatocytes. Moreover, we found a 
non-linear correlation between the injected LV dose and the percentage of GFP+ 
hepatocytes or between LV dose and the VCN measured in the whole liver. In 
particular, while GFP+ hepatocytes and whole-liver VCN nearly doubled from 2.5 to
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5xl08 TU, there was a disproportionately higher increase in GFP+ hepatocytes and 
lower increase in VCN when further doubling the dose (Figure 12A,B). VCN in PCs 
also increased more than 2-fold when increasing the LV dose from 5 to 10x10s TU 
(Figure 12C). Instead there was a more linear correlation between LV doses and VCN 
in LSECs (Figure 12E). Interestingly, there was a strong increase in VCN both in 
fractionated pre-sorting nPCs and FACS-sorted KCs when increasing the LV dose from 
2.5 to 5x108 TU and there was no further increase in VCN in both these cells population 
when doubling the LV dose from 5 to lOxlO8 TU (Figure 12D,F). These data suggest 
that increasing the LV dose between 2.5 and 5xl08 TU results in a relatively modest 
increase in VCN in PCs and consequently transgene expression, while a large fraction 
of the LV particles ends up in nPCs, in particular KCs. It appears that LSECs 
transduction is minor. Instead, as the LV dose reaches a threshold between 5 and lOxlO8 
TU, a “saturation” of LV transduction in KCs occurs and more LV particles are 
available to transduce hepatocytes and consequently the increase in VCN in PCs and 
transgene expression is more relevant. These effects are masked when the VCN is 
measured form the whole liver, because VCN changes in the opposite direction among 
PCs and nPCs and subtracts to each other.
According to published reports, we can consider the liver composed by 70% of PCs 
and 30% of nPCs, of which 50% are LSECs (15% of total liver cells), 20% are KCs 
(6% of total liver cells) and the remaining 30% are biliary ducts cells, hepatic stellate 
cells, infiltrating lymphocytes and other hematopoietic-lineage cells274. Thus, in order to 
gain a better understating of the LV biodistribution within the liver cell populations 
after i.v. injection of different doses, we calculated the relative contribution of the VCN 
for each sub-population, considered the theoretical relative abundance within the liver 
cells. In other words, we calculated VCN for each cell population “weighted” on their 
theoretical percentage of representation within the liver cells (e.g. VCN in PCs, VCNpc, 
is multiplied by 0.7 to obtain the relative contribution of VCNpc to total LV DNA in the 
liver, VCNnpc is multiplied by 0.3 and so on). Based on this calculation, we found that 
at doses of 2.5 or 5x108 TU, approximately 30% of the LV DNA is found in PCs (and 
consequently about 70% is in nPCs), while at the high dose of 109 TU 57% of the LV 
DNA is found in PCs and the remaining 43% in nPCs. Among nPCs the vast majority 
of LV DNA is found in KCs (approximately 70% at 2.5 or 5xl08 TU and 42% at 109
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TU), while only 2-4% of LV DNA is found in LSECs at the doses tested. These data 
further support our hypothesis that a skewing occurs in the LV biodistribution between
g
PCs and nPCs and better PCs transduction is achieved as the dose is raised above 5x10 
TU.
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Figure 12: Biodistribution o f  L V  within liver cell populations. Percentage o f GFP+ 
PCs (A) in liver sections (5-10 optical fields scored from 6-8 non-consecutive 
sections/mouse), or VCN measured in genomic DNA extracted from whole liver (B), 
fractionated liver PCs (C) or nPCs (D), FACS-sorted LSECs (E) or KCs (F), as
10 0
described (Figure 11), o f  mice treated with the indicated dose (X axis) o f ET.GFP.142T 
2 months after LV  administration (n—5). Correlations between VCN measured in whole 
liver (X axis) and liver VCN calculated based on the relative contributions o f (G) VCN 
in fractionated PCs and nPCs, or (H) based on the relative contributions o f VCN in 
fractionated PCs and FACS-sorted LSECs and KCs (Y axis). (I) Correlation o f liver 
VCN calculated based on the raltive contributions o f VCN in fractionated PCs and total 
nPCs (X axis) and liver VCN calculated based on the relative contributions o f  
fractionated PCs, FACS-sorted LSECs and KCs (Y axis). Correlations between the 
percentage o f GFP+ PCs (Y axis) and (J) VCN in whole liver (X axis) or (K) VCN in 
fractionated PCs (X axis). Results are presented as mean±SEM.
We also correlated the measured VCN in whole liver DNA with that calculated 
summing either the relative contributions of the VCN in fractionated PCs and nPCs pre­
sorting, or the relative contributions of the VCN in fractionated PCs and FACS-sorted 
LSECs and KCs (by the formula VCNtotai = (VCNpcx0.7)+(VCNnpcx0.3) or 
(VCNpcx0.7)+(VCNlsecx0.15)+(VCNkcx0.06) respectively). We found a strong 
correlation between the observed whole liver VCN and the calculated total VCN based 
on the relative contributions of each cell subpopulations, suggesting that our calculation 
based on the theoretical relative abundance of the subpopulations within the liver is 
appropriate (Figure 12G,H). Note that our separation method only results in an 
enrichment in hepatocytes in the PCs fraction and we estimated a contamination by KCs 
between 1 and 2%, thus, since KCs have a high VCN, the measurement of VCNpc 
results in a overestimation of the real VCN in hepatocytes. Therefore also the total VCN 
calculated as described before results in an overestimation with respect to the measured 
whole liver VCN, as it can be seen in Figure 12G,H. A very strong correlation and 
correspondence is found between the total VCN calculated summing the relative 
contributions of VCNpc and VCNnpc and that calculated summing the relative 
contributions of VCpc, VCNlsec and VCNkc (Figure 121). We also correlated the 
percentage of GFP+ hepatocytes with the whole liver VCN (Figure 12J). We observed 
an exponential correlation consistent with the correlation between GFP+ hepatocytes 
and LV dose, as a 3-fold increase in GFP+ hepatocytes only corresponds to a modest 
increase in the VCN in the whole liver. Instead, a perfectly linear correlation (r2 = 
1.0000) is found between the GFP+ hepatocytes and the VCNpc. This suggests that 
indeed the whole liver VCN does not correctly reflect the percentage of hepatocyte 
transduction, due to the different distribution of LV DNA observed within the liver cell 
subpopulations at different LV doses.
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4.6 Proteasome inhibition decreases transduction of KCs and 
improves the efficiency of hepatocyte gene transfer by LVs in vivo
We set out to improve LV transduction of hepatocytes in vivo through a clinically 
viable strategy which did not cause depletion or toxicity on KCs. Proteasome inhibitors 
have been shown to possess anti-inflammatory properties and to decrease activation of 
KCs in vivo ’ . Moreover proteasome inhibition was reported to improve LV
777  778transduction in some cell types ’ , thus we reasoned that it may increase hepatocyte
transduction as well. To this end, we assessed the impact of proteasome inhibition on 
LV biodistribution within the liver cell populations. We intravenously administered 
Bortezomib, a well-known and clinically used proteasome inhibitor, to mice prior to LV 
administration. Pharmakokinetic studies have shown that the peak of proteasome 
inhibition in the liver is achieved at 1 hour after i.v. administration of the drug279. We 
administered a single dose of Bortezomib (1 mg/kg) 1 hour before the administration of 
5xl08 TU/mouse of LVs bearing the hepatocyte-specific ET.GFP.142T cassette to 
normal adult mice (n=6). At 2 months after LV administration we determined both the 
percentage of GFP+ hepatocytes in liver sections and VCN in whole liver DNA from 
half of the mice (n=3). We determined the VCN in fractionated liver PCs or nPCs, 
FACS-sorted LSECs or KCs from the other half of the mice (n=3), as described in 4.5. 
We first compared the percentage of GFP+ hepatocytes observed in mice pre-treated 
with the drug with respect to that observed in mice treated with the same LV dose 
without Bortezomib pre-administration (Figure 13A). We found an almost 3-fold 
increase in transgene-expressing hepatocytes. We then compared the VCN in whole 
liver, VCNpc, VCNnpc, VCNlsec and VCNkc observed in Bortezomib pre-treated mice 
with those observed in non pre-treated mice injected with the same LV dose (Figure 
13B-F). We found no increase in whole liver VCN (Figure 13B). Interestingly we found 
an approximately 2-fold decrease in VCNnpc and VCNkc (Figure 13D,F). This finding 
may suggest that proteasome inhibition results in less KCs transduction at the time of 
injection or in death of the KCs with the highest VCN. Unexpectedly we found no 
increase in VCNpc (Figure 13C), however, if we consider that the population enriched 
in PCs contains 1-2% of contaminating KCs and that VCNkc is decreased by 2-fold, we
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can estimate an approximately 1.5-fold increase in VCNpc by subtracting 1-2% of 
VCNkc by the respective VCNpc.
Figure 13
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Figure 13: Biodistribution o f L V  within liver cell populations with or without pre­
treatment with a proteasome inhibitor. Percentage o f GFP+ PCs (A) in liver sections 
(5-10 optical fields scoredfrom 6-8 non-consecutive sections/mouse), or VCN measured 
in genomic DNA extracted from whole liver (B), fractionated liver PCs (C) or nPCs 
(D), FACS-sorted LSECs (E) or KCs (F), as described (Figure 11), o f  mice treated with 
5x108 TU/mouse o f LVET.GFP.142T 2 months after LV administration, with (+ Bort, 
n=3) or without (- Bort, n=5) pre-treatment with Bortezomib (lmg/kg) 1 h before LV  
administration. Results are presented as mean±SEM. *: p<0.05, **: p<0.01 (t-test).
When we calculated the distribution of the LV DNA in the liver cell subpopulations, 
as explained in 4.5, we observed that 40% of LV DNA is found in PCs (and 60% in 
nPCs) in mice receiving Bortezomib prior to LV administration, compared to the 30% 
of LV DNA found in PCs (and 70% in nPCs) in mice not receiving the drug prior to LV 
administration. This change is likely to be underestimated for the reason described 
above. These data suggest that proteasome inhibition skews the LV biodistribution 
within the liver favouring transduction of PCs at the expense of KCs transduction.
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4.6.1 Proteasome inhibition increases the potency of LV-mediated liver gene therapy
in haemophilia B mice
To evaluate whether proteasome inhibition improves the efficacy of liver gene 
therapy for haemophilia B, we administered a single dose of Bortezomib (1 mg/kg) to 
haemophilia B mice 1 hour before the injection of ET.hFIX.142T LVs. We measured 
hFIX levels in the plasma of treated mice at different time points after LV injection. As 
shown in figure 14A mice receiving the drug (n=4) consistently expressed 2- to 3-fold 
more hFIX as compared to mice which did not receive it (n=3). Mice were monitored 
for anti-hFIX antibodies and found to be negative, indicating that the treatment did not 
provoke a detectable immune response to the transgene. We determined VCN in gDNA 
extracted from the liver of treated mice 30 weeks after LV injection. There was no 
increase in the total vector content of the liver in bortezomib-pre treated mice, in line 
with data described before (Figure 13).
It is known that Bortezomib inhibits function and survival of pDC, which are major 
producers of type-I IFNs280. Since we have shown that type-I IFN signalling limits 
hepatocyte transduction241, it is possible that Bortezomib down-regulates this pathway 
and consequently improves hepatocyte transduction. To test this hypothesis we 
evaluated whether Bortezomib pre-treatment increases or not hepatocyte transduction, 
upon i.v. injection of ET-hFIX.142T LVs in mice defective for type-I IFN receptor 
(IfnaRl'/_; Figure 14B). We found that Bortezomib treatment strongly increases 
(approximately 5-fold) LV-mediated hFIX liver gene transfer in these mice, suggesting 
that the underlying mechanism cannot be ascribed to suppression of the IFN response.
To shed light on the mechanism by which proteasome inhibition increases LV 
hepatocyte transduction in vivo, we evaluated whether Bortezomib treatment increases 
LV transduction in primary hepatocytes in vitro as well. We transduced human primary 
hepatocytes with a low-dose PGK.GFP LV (MOI 2) in the presence or absence of 
Bortezomib (100 nM) given at the time of transduction. We calculated the percentage of 
GFP+ hepatocytes and measured VCN in transduced hepatocytes 1 week after 
transduction (Figure 14C-E). We observed a significant 2-fold increase in the 
percentage of GFP+ hepatocytes and an almost 2-fold increase in VCN when 
transduction was performed in combination with Bortezomib, as compared to those 
observed in hepatocytes transduced without Bortezomib. To exclude an effect of the
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proteasome inhibitor on the half-life of GFP, Bortezomib was given 2 days after LV 
transduction and no increase in the percentage of GFP+ hepatocytes nor in VCN was 
observed in this condition. These data indicate that proteasome inhibition increases LV 
transduction of hepatocytes in vitro through a cell-autonomous mechanism (directly 
involving hepatocytes themselves).
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Figure 14: Proteasome inhibition in LV-mediated liver gene therapy. hFIX expression 
measured by ELISA on plasma samples collected from treated haemophilia B (A) or 
IfnaRl-/- (B) mice at the indicated times after LV administration. Mice were treated 
with 5x108 TU/mouse o f ET.hFIX.142T LVs with (n=4, + Bort, black line) or without 
(n=3 HaemoB, n=4 IfnaRl-/-, - Bort, grey line) pre-treatment with Bortezomib 
(1 mg/kg) 1 h before LV administration. Resultes are presented as mean±SEM. (C) 
Representative images o f  human primary hepatocytes cultures transduced with
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PGK.GFP LVs (M OI2), with (n=4) or without (n=4) Bortezomib (100 nM) at the time 
o f transduction, or left UNT as indicated and analysed 7 days after transduction, by live 
fluorescence microscopy. Percentage o f GFP+ hepatocytes (D; 7 fields/sample) and 
VCN (E) from the above described experiment. Nuclei were stained with Hoechst. To 
control fo r  inhibition o f GFP degradation Bortezomib (100 nM) was added 2 days after 
LV administration (n=3, LV+Bort Ctrl). *: pGLOBAL<0.05 (non-parametric 
combination statistics); ***: p<0.001 (ANOVA).
Overall our data show that a single-dose of proteasome inhibitor before LV 
administration improves hepatocyte transduction by 2- to 3-fold and this may represent 
a clinically viable strategy to improve the potency of LV for liver gene therapy.
4.7 LV-mediated liver gene therapy reverts anti-FIX antibodies and 
reconstitutes FIX expression in haemophilia B mice with pre-existing 
anti-FIX immunity
In order to evaluate whether LV-mediated liver gene therapy can eradicate pre­
existing anti-FIX antibodies and establish FIX expression in haemophilia B mice, we 
performed gene therapy after inducing an anti-FIX immune response. We immunised 
adult haemophilia B mice with hFIX protein. All the immunised mice mounted a robust 
anti-hFIX humoral response and developed inhibitors at an average titre of 4 BU/ml 
with some mice having high-titre inhibitors (>10 BU/ml; Figure 15A-C). Four weeks 
later we divided the mice in 3 groups. One group received i.v. administration of 109 
TU/mouse of ET.FIX.142T LV (n=5), another group received i.v. administration of the 
same dose of LV expressing the unrelated antigen ovalbumin (ET.OVA.142T, n=3), 
while one group was vehicle-injected (PBS, n=4). We determined anti-FIX binding and 
neutralizing antibodies and FIX expression in the plasma of treated mice at routine 
intervals after immunisation (Figure 15A-D). In sharp contrast to PBS-treated mice, 
which maintained high-levels antibodies and even showed increased inhibitors titres (up 
to 6 BU/ml), all the mice receiving ET.FIX.142T LV showed a gradual decline in anti- 
FIX antibodies over the 8 weeks following gene therapy (12 weeks post immunisation) 
and inhibitors became undetectable (Figure 15A-C). Concomitantly with the decrease in 
anti-FIX antibodies, FIX expression gradually raised, reaching 25% of normal levels at 
8 weeks after gene therapy, which is the expected level for the administered LV dose 
(Figure 15D). In contrast, mice receiving control ET.OVA.142T LV did not show any
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decline in anti-FIX antibodies, which were found at levels undistinguishable from those 
found in saline-injected mice (Figure 15A,B).
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Figure 15: LV-mediated liver gene therapy in haemophilia B  mice with pre-existing 
anti-FIX immunity. Anti-FIX total Ig antibodies (A,B,E,F) tested at 2 plasma dilutions, 
as indicated (10~2 A and E, 10~3 B and F), FIX expression (D,G) and anti-FIX inhibitors
(C) measured in plasma samples collected from mice at the indicated times after 
immunisation. In A,B,C,D mice were immunised with hFIX protein in IF  A and 
subsequently injected with PBS (n=4, circles) or 109 TU/mouse ofET.hFX.142T (n=5, 
squares) or ET.OVA.142T (n=3, triangles) LVs 4 weeks after immunisation, as 
indicated. In E,F, G mice were immunised as above and subsequently injected with PBS
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(n=3, circles), 109 TU/mouse ofET.hFIX.142T (n=5, squares) LVs or with hFIX protein 
at 200-400 IU/kg i.v. every other day fo r 2 weeks (n=4, triangles) 10 weeks after 
immunisation, as indicated. Results are presented as mean±SEM.
We then repeated the experiment, this time performing gene therapy in haemophilia 
B mice at a later time after immunisation, when the anti-FIX humoral response was 
more mature. To this end we intravenously administered saline (PBS, n=3) or 109 
TU/mouse of ET.hFIX.142T LV (n=5) to haemophilia B mice 10 weeks after 
immunisation, when most of the antibodies-secreting B cells resided in bone marrow 
(A. Annoni, unpublished observation). We monitored anti-FIX antibodies and FIX 
expression in plasma of treated mice at routine intervals after immunisation (Figure 
15E-G). Similarly to what was observed when gene therapy was performed 4 weeks 
after immunisation, LV-treated mice showed a gradual decline in anti-FIX antibodies 
over the 8 weeks following gene therapy (18 weeks post immunisation) and FIX 
expression was established at an average of 30% of normal levels, corresponding to the 
expected outcome of the administered LV dose (Figure 15G). In an attempt to compare 
the efficacy of gene therapy with that of ITI in reverting the anti-FIX antibody response, 
we administered to 4 haemophilia B mice an ITI-like regimen (consisting of high-dose 
recombinant hFIX protein at 10 IU/mouse corresponding to 200-400 IU/kg i.v. every 
other day for 2 weeks) 10 weeks after immunisation. Two out of 4 mice died during the 
course of this treatment (one of which within minutes after the third injection). We 
could not ascertain the cause of death, but it is possible that injection of the hFIX 
protein in these mice caused anaphylactic or immune complex-mediated 
hypersensitivity reactions281. Follow-up of these mice was interrupted 5 weeks after the 
initiation of the ITI (15 weeks after immunisation) due the subsequent death of another 
of these 2 remaining mice. However, during this time ITI-treated mice did not show a 
reduction in anti-FIX antibodies (Figure 15E,F). These data indicate that liver gene 
therapy can revert established pre-existing anti-FIX binding antibodies and inhibitors 
and reconstitutes FIX expression to therapeutic levels in haemophilia B mice. These 
data also suggest that gene therapy may be more effective and safer than ITI in 
eradicating anti-FIX antibodies.
In order to shed light on the mechanism involved in the observed reduction of the 
anti-transgene antibody response after liver gene therapy, we studied the B-cell
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response in treated mice. Gene therapy-treated mice showed significantly fewer anti- 
FIX antibody secreting B  cells than saline-injected controls in the draining lymph node 
near the immunisation site at 10 weeks after LV administration (Figure 16A,B). Further 
analysis of other lymphoid organs such as the spleen and bone marrow will be required 
to better assess this response. We also found a strong reduction in the number of hFIX- 
specific memory B  lymphocytes (B m em ) in mice treated with gene therapy as compared 
to control saline-injected mice (Figure 16C,D). These data suggest that gene therapy 
resulted in a contraction of pre-existing transgene-specific Bmem that in turn resulted in 
a decrease in anti-FIX antibodies producing B  cells (and subsequent decrease in 
circulating antibodies) because of missing replacement at turnover. These data suggest 
that sustained endogenous production of hFIX upon liver gene therapy may cause 
anergy or apoptosis of Bm em  leading to a progressive inhibition of the antibody 
response, as reported for FVIII-specific Bm em  in a mouse model282.
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Figure 16: Analysis o f  B-lymphocyte responses after LV-mediated liver gene therapy 
in mice with pre-existing immunity. Anti-FIX total Ig (A) or IgG (B) antibody (Ab) 
producing B cells/106, measured by ELISPOT in draining lymph nodes near the 
immunisation site o f  mice immunised with hFIXprotein in IFA and subsequently treated 
with PBS (n—4, black bars) or 109 TU/mouse ofET.hFlX.142TLV (n—5, white bars) 4 
weeks after immunisation (see Figure 15 A,B,C,D). Percentage (C) or total number (D)
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o f FIX-specific memory B  lymphocytes (Bm em ) measured by flow cytometry in 
lymphnodes o f mice immunised as above and treated with PBS (n=3, white bars) or 109 
TU/mouse o f ET.hFlX.142T LV (n=4, black bars) 10 weeks after immunisation (see 
Figure 15 E,F,G). FIX-specific B m em  were identified as CD19+ B220+ IgD' IgM  FIX- 
Alexa647+ cells. Results are presented as mean±SEM. *: p<0.05 (t-test).
4.8 Evaluating IDLVs for liver gene therapy
In order to assess whether integration is dispensable for long-term efficient liver gene 
replacement therapy, we set out to compare the efficiency of gene transfer, the levels 
and stability of transgene expression mediated by IDLVs and integrase-competent LVs 
(ICLVs) in a hepatocyte cell line, primary human hepatocytes and in the mouse liver, 
upon i.v. administration. We also set out to determine the nature of any persistent IDLV 
genome in the transduced livers. Moreover, we sought to investigate the ability of 
IDLV-mediated liver gene transfer to induce transgene-specific immune tolerance.
Towards these goals, we first generated GFP-expressing LV with either integrase 
defective or integrase competent packaging constructs. To drive transgene expression 
we used the hepatocyte-specific ET promoter. The vectors carried target sequences for 
miR-142 in the transgene 3' UTR (ET.GFP.142T, Figure 1). Physical particle content 
was determined p24 quantification. To determine infectivity, defined as TU per 
physical particle, we designed an ad hoc qPCR that selectively amplifies the reverse 
transcribed vector genome and discriminates it from plasmid DNA, carried over from 
the transfection used to produce the vectors (Figure 17). IDLV and ICLV had similar 
infectivity on several human cell lines (Table 6 and data not shown).
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Figure 17: Quantification o f reverse-transcribed vector genome in transduced cells.
(A) Schematic representation o f linear/integrated provirus, 1-LTR, 2-LTR circles and 
the transfer vector plasmid (used to produce the vector). The approximate position o f  
the sense and antisense primers o f  the qPCR designed to quantify the reverse 
transcribed vector genomes is indicated (RT-LV). Note that PCR on transfer vector 
plasmid does not result in any amplification due to the missing DUS region in the 5 ’ 
LTR. (B) VCN measured in DNA extracted from standard cell clones with known vector 
content (previously determined by Southern blot) in which transfer vector plasmid is 
spiked in at different concentrations. VCN was determined using the qPCR designed to 
selectively amplify reverse transcribed genomes (RT-LV, diamonds, as shown in (A)), or 
using the standard qPCR assay used to amplify the lentiviral vector backbone (LV, 
squares), or using a qPCR assay designed to amplify the plasmid backbone (plasmid, 
triangles). Plasmid: plasmid sense 5 ’-gaatatcagagagtgagaggaacttgttt-3 ’, plasmid 
antisense 5 ’-tgtgaaatttgtgatgctattgctt-3 ’, plasmid probe FAM 5 ’-tgcagcttataatggttacaa- 
3 ’. Note that while LV quantification is affected by transfer vector plasmid 
contamination and results in overestimation o f VCN at increasingly higher spiked 
plasmid concentration, RT-LV quantification is not affected by transfer vector plasmid 
contamination and results in a reliable value, except at very high spiked plasmid 
concentrations.
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Table 6. Titre and infectivity of IDLV vs ICLV
Vector p24 (pg/ml) Titre (TU/ml) Infectivity (TU/ng p24)
IDLV n=3 211±9 3.7xlOy±1.2xlOy 1.8x 104± 3 .6x 103
ICLV n=3 162±28 5.0xl0y±5.8xl0* 3 .9x 104± 1. 1x 104
P ns (0.1270) ns (0.3606) ns (0.0907)
The table summarizes the p24, titre and infectivity of 3 different vector batches of 
ET.GFP.142T either packaged with an integrase-defective (IDLV) or integrase- 
competent (ICLV) configuration, as measured on 293T cells. Data are presented as 
mean±SEM. ns: not significant (t-test).
4.8.1 IDLV efficiently transfer episomal genomes into human hepatocytes in vitro 
but drive lower levels of transgene expression than their integration-competent 
counterparts
We compared IDLV and ICLV transduction efficiency and transgene expression 
levels in human cell lines and primary hepatocytes in vitro. We transduced the 
hepatocyte Huh7 cell line and measured VCN and GFP expression at 3 days and 2 
weeks post-transduction (Figure 18A). Initially comparable amounts of reverse 
transcribed vectors were present in IDLV and ICLV-transduced cells. However, the 
frequency of GFP+ cells and the mean fluorescence intensity of GFP were lower in 
IDLV-transduced cells, compared to ICLV-transduced cells (p<0.01; n=3), indicating 
less efficient expression from the former vector. Analysis of the same cultures 2 weeks 
after transduction showed near complete loss of vector genomes and GFP+ cells in the 
IDLV-transduced cells, as expected for an episomal form.
We then tested the same vectors on human primary hepatocytes, which do not 
proliferate in culture, and showed that IDLV attained similar levels of transduced vector 
genomes 1 week after transduction but expressed GFP at substantially lower levels than 
matched doses of ICLV (Figure 18B,C). Overall, these data indicate that IDLV 
efficiently transfer episomal vector genomes into hepatocytes. However, these forms 
provide a less proficient substrate for the transcriptional machinery than the integrated 
pro viral vectors.
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Figure 18: ID LV performance in hepatocytes cultures. (A) Percentage o f  GFP+ cells 
and MFI o f GFP (left axis) and VCN (right axis) in Huh7 cells transduced with ICLV or 
IDLV at the indicated MOI and analyzed 3 days or 2 weeks after transduction by flow  
cytometry. Black bars correspond to ICLV-transduced cells, grey bars to IDLV- 
transduced cells. Circles show VCN. Results are presented as mean±SEM (n=3). (B) 
Representative images o f human primary hepatocytes transduced as indicated or left 
UNT and analyzed by live fluorescence microscopy 1 week after transduction. Nuclei 
are stained with Hoechst. (C) Percentage o f GFP+ cells and MFI o f GFP (5 
fields/sample; left axis) and VCN (circles, right axis) in cultures from quiescent human 
primary hepatocytes. Results are presented as mean±range (n~2).
4.8.2 IDLV support FIX expression from hepatocytes in mice
To ascertain that IDLV could be used to transduce hepatocytes in vivo we injected 
increasing doses (5, 20 and 40 pg p24, n=8) of GFP-expressing IDLV (ET.GFP.142T) 
intravenously in adult mice and measured GFP expression in hepatocytes and vector 
DNA content in the liver at 5 weeks post-injection (Figure 19A). A vector dose- 
dependent increase in hepatic transduction was apparent, yielding up to 13% of GFP+ 
hepatocytes in the treated livers, analyzed by GFP-specific immunostaining. 
Subsequently, we administered matched doses (20 pg p24) of GFP-expressing IDLV 
and ICLV (ET.GFP.142T) intravenously to adult mice (IDLV n=20, ICLV n=4, in 3 
independent experiments) and measured GFP expression and vector DNA content in the 
liver at different times post injection (Figure 19B,C). At 1 week post injection, GFP- 
expressing hepatocytes were readily detectable in IDLV-treated mice, although to a 
substantially lower frequency and intensity as compared to those observed in mice 
treated with matched doses of ICLV. The content of reverse transcribed vector genomes 
was only slightly lower in mice treated with IDLV vs. ICLV and reached up to 1.5 
vector copies per diploid genome. However, while GFP expression and vector content 
remain stable in ICLV-treated mice, the frequency of GFP+ hepatocytes and the vector 
content progressively diminished with increasingly longer times post-injection for the 
IDLV-treated groups.
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Figure 19: ID LV performance in the mouse liver. (A) Percentage o f GFP+ 
hepatocytes and VCN in the liver o f  mice treated with the indicated p24 o f  
IDLV.ET.GFP.142T and analyzed at the indicated time post-injection. GFP+ cells were 
identified either by immunostaining or direct fluorescence. Results are presented as 
mean±SEM o f n=3 mice per time point, 5-10 optical fields scored from 5-10 non- 
consecutive GFP-immunostained (filled bars) or unstained (open bars) liver 
sections/mouse (left axis). Circles show VCN (mean±SEM, right axis). (B) Same 
analysis performed for IDLV- (grey bars) vs. ICLV- (black bars) treated mice, n=3-7 
mice per IDLV time point from 3 independent experiments. (C) Representative images 
o f unstained liver sections from mice reported in (B). Nuclei were stained with TOPRO- 
3.
We then administered matched high doses (260 |xg p24) of IDLV or ICLV 
expressing cFIX cDNA (ET.cFIX.142T) in adult haemophilia B mice (Figure 20, IDLV 
n=15, ICLV n=8). IDLV delivery resulted in prolonged production of FIX in mouse 
plasma at levels considered within the therapeutic range (up to 1.5% of normal levels). 
In agreement with the different efficiencies of expression observed for the GFP marker, 
the FIX levels supported by IDLV were up to 15-fold lower than those supported by the 
cognate ICLV. Twelve weeks post-injection, some of the IDLV-treated mice (n=7) and 
of the ICLV-treated ones (n=3) were subjected to 70% partial hepatectomy. In the
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recovering mice, FIX levels remained comparable to those measured before 
hepatectomy in the ICLV-treated group (Figure 20A). In contrast, while FIX levels in 
the IDLV-treated mice were relatively stable prior to partial hepatectomy, they declined 
significantly shortly afterwards in the interval between week 12 and week 20 (p<0.05; 
Figure 20B). Instead there was no statistically significant decline in FIX expression in 
the IDLV-treated cohort in the same time interval (week 12-20). Nevertheless, FIX 
expression had become sub-therapeutic after 1 year (Figure 20C).
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Figure 20: IDLV-mediated deliveiy o f  F IX  in haemophilia B  mice. FIX activity was 
measured on plasma samples collectedfrom treated mice at the indicated times after LV  
administration. Mice were treated with 260 pg p24 o f ICLVET.cFIX.142T (A) or 
IDLVET.cFIX.142T (B). Partial hepatectomy (PHX) was performed at week 12. In both 
panels, grey lines correspond to untreated (UNT) mice. (C) Mice injected with 
IDLV.ET.cFIX.142T monitored fo r 1 year after LV administration and not subjected to 
partial hepatectomy.
These data indicate that IDLV, although being less efficient than their ICLV 
counterparts at expressing transgenes from human and murine hepatocytes, can support
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therapeutically relevant levels of transgene expression in vivo. The post-hepatectomy 
drop in FIX observed in IDLV-treated mice suggests that FIX expression could be 
attributed mainly to non-integrated vector episomes. Thus, we investigated the residual 
IDLV integration frequency.
4.8.3 IDLV integrate only to background levels and with features incompatible with 
residual catalytic activity of the HIV integrase
As the D64V mutation reduces LV integration by 2 to 3 logs (see also Figure 18)245, 
low-level integration still occurs using this mutant. We therefore assessed residual 
IDLV integration in the treated livers. We retrieved vector sequences from the treated 
livers at 6 to 12 weeks after vector administration by highly-sensitive LAM-PCR258,259 
and deep sequencing. The number of unique IS found in the IDLV-treated liver samples 
was significantly lower as compared to the ICLV samples. In the IDLV liver samples 
(n=16) a total of 35 unique mappable integration sites (IS) could be recovered versus 
the 785 IS found in the ICLV samples (p<10'9), with an almost 100-fold lower 
frequency of retrieval (Table 7). Accordingly, we retrieved an excess 2-LTR junctions 
in IDLV-treated liver samples as compared to ICLV-treated ones, suggestive of the 
presence of episomal vector forms (2-LTR junctions: IDLV: 54.5%, ICLV: 2.8%; Table 
7 and Figure 21). The few retrieved integrations did not show an enrichment for genes 
and frequently showed deletion in the LTR ends (IDLV: 25,7%, ICLV: 0,6%; Table 7).
These studies indicate that the occurrence of background integration in treated livers 
exhibits molecular features reminiscent of those described for plasmids and other types 
of episomal DNA. This analysis further underscores the minimal risk of insertional 
mutagenesis by IDLV.
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Table 7. Deep sequencing of ICLV- and IDLV-transduced liver samples
Vector Raw
Sequence
Reads
1-LTR/
Internal
Control
2-LTR Reads
with
LTR+
s20nt
Genomic
Sequence
Unique
Mappable
Integration
Sites
LTR 
Deleted at 
Genome 
Junction by 
>3nt
ICLV
2787 211 51 1688 152 2(10,11 nt)
2179 13 0 244 244 1 (22 nt)
3169 896 53 101 101
2822 250 258 288 288 2 (8,23 nt)
IDLV
1451 284 760 340 0
971 530 237 186 2
1227 373 82 767 0
1365 466 154 26 2 1 (21 nt)
2264 371 838 841 2
2752 400 996 1322 1
1349 221 795 308 4
1173 193 587 277 3 1 ( l i n t )
2809 347 1538 502 1 1 (8 nt)
1722 215 801 421 4 2 (19,24 nt)
3494 350 2124 916 4 2 (14,21 nt)
3260 223 2397 500 2
3291 316 1799 621 4 1 (25 nt)
2771 330 1963 232 2
2882 275 2795 318 0
3251 241 1787 808 4 1 (8 nt)
The table shows 454 sequencing results of ICLV- and IDLV-transduced liver samples.
1-LTR and vector internal control fragments (resulting from the 3’LTR-U3 LAM-PCR 
primer annealing at the 5’LTR-U3) cannot be distinguished by sequencing. Of note, the
2-LTR LAM-PCR product (restriction enzyme Tsp509I, AATT) exhibits only a length 
of 18 bp without LTR and linker sequence, resulting in an overrepresentation of 
sequenced 2-LTR amplicons versus 1-LTR and Internal Control (see Figure 21). 1- 
LTR: 1-LTR amplicon. 2-LTR: 2-LTR amplicon. nt: nucleotides.
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Figure 21: Schematic overview o f  proviral and episomal IDLV-based 3 ’LTR LAM- 
PCR results. The 3 ’LTR LAM-PCR primer sets (arrows) are hybridizing to the unique 
5 ’ region present in both 5 ’ and 3 ’ LTR sequences. In case o f  integrated proviral DNA, 
LAM-PCR results confer either to the vector-genome junction or to internal vector 
sequences, termed “internal control” In case o f  episomal 1-LTR circles, only an 
internal control can be detected. In case o f episomal 2-LTR circles, an internal control 
and the LTR-LTR junction can be identified. O f note, the use o f  one restriction enzyme 
(RE) generates internal control and LTR-LTR junction LAM-PCR products o f  defined 
lengths, respectively (Table 7).
4.8.4 IDLY delivery tolerises the recipient to foreign antigens and induces antigen- 
specific Tregs
We then investigated whether hepatocyte-targeted expression by IDLV induces 
transgene-specific immunological tolerance. To investigate whether active tolerance 
was established, we challenged treated mice by i.m. vaccination with GFP-encoding 
plasmids and evaluated the frequency of GFP-specific CD8+ T cells in spleen and liver
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(Figure 22A,B). Whereas the low frequency of GFP-specific CD8+ T cells induced in 
the spleen and liver of IDLV.142T-treated mice did not increase upon re-challenge, 
there were many more antigen-specific effectors in the control unregulated IDLV- 
treated mice after the primary (IDLV) and the secondary challenge (plasmid i.m.). In 
addition, residual levels of vector genomes were still detectable in the liver of mice 
previously treated with IDLV.142T after re-challenge (Figure 22B).
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Figure 22: Transgene-specific tolerance after ID LV  liver gene transfer. (A) Number 
o f IFN-y-producing GFP-specific CD8+ T cells per 106 total CD8+ T cells in the spleen 
o f  mice subjected or not to antigen re-challenge (by i.m. vaccination with GFP- 
encoding plasmids) 6 weeks after IDLV treatment. Single values are plotted and the 
mean±standard deviation (SD) is shown (n=6/group). Representative wells are shown 
on top. (B) Number o f the CD8+ GFP2oo-2 0 8-pentamer-positive T cells infiltrating the 
liver o f  mice treated with the indicated IDLV (IDLV.PGK n=9; IDLV.PGK.142T n=6; 
IDLV.ET.142T n=3) after antigen re-challenge. Single values are plotted and mean±SD
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is shown. Mean±SD VCN in the liver is indicated. (C) Percentage o f GFP+ hepatocytes 
and VCN in the liver o f immune-deficient mice previously injected with ET.GFP.142T 
ICLV and adoptively transferred (AT) with cells derived from naive, IDLV.PGK- and 
IDLV.ET.142T-treated mice (n=3/group). Mean±SEMpercentage o f GFP+ hepatocytes 
(left axis). Circles show VCN (mean±SEM, right axis). A representative fie ld  is shown 
on top. Note that residual vector DNA in the liver o f mice in which GFP-expressing 
hepatocytes were completely cleared can be ascribed to the persistence o f vector 
genomes in transduced macrophages and endothelial cells that did not express GFP.
(D) Plasma samples from the various groups o f animals were screened fo r anti-FIX 
neutralizing antibodies using an aPTT mixing assay using a positive control o f  2.6 BU  
and a known negative control. Samples were assayed in a blinded fashion. Groups 
include haemophilia B mice treated with the indicated ET.cFIX.142T vector or 
untreated (UNT) 12 weeks after vector administration, with or without challenge with 
cFIX and IF  A.
To further confirm that IDLV.142T is able to direct the immune system towards 
immune tolerance induction to transgene antigens, we reconstituted immune-deficient 
recipients by adoptive transfer of immune cells derived from either immunized (IDLV- 
treated) or tolerised (IDLV.142T-treated) mice (Figure 22C). Rag2‘/'y-chain'A mice were 
therefore first transduced with hepatocyte-targeted ICLV (ET.GFP.142T) to obtain 
robust GFP expression in hepatocytes. A pool of splenocytes and liver lymphocytes 
derived from naive, control IDLV-treated or IDLV.142T-treated animals were 
transferred 1 month later. While comparable amounts of GFP-expressing hepatocytes 
were detected in the mice reconstituted with naive cells or cells derived from tolerant 
(IDLV.142T-treated) mice, a complete clearance of GFP+ hepatocytes was observed in 
recipient mice reconstituted with cells derived from control unregulated IDLV-treated 
mice, accompanied by loss of vector DNA. These results indicate that only those cells 
derived from control mice exhibited full effector potential upon adoptive transfer, while 
the effector cells derived from tolerised mice (IDLV.142T-treated) are kept in check by 
the induced regulatory compartment. Taken together, these data indicate that GFP- 
specific immunological tolerance was established.
To assess if immune tolerance could be induced by IDLV towards a therapeutically 
relevant secreted antigen, we evaluated the anti-FIX immune response in haemophilic 
mice treated with FIX-encoding IDLV.142T. Bethesda assays showed no anti-FIX 
inhibitory activity (Figure 22D). Importantly, when these IDLV.142T-treated mice were 
challenged with FIX protein in IFA they remained negative for anti-FIX neutralizing 
antibodies. In contrast, haemophilic mice that were not injected with any vector but
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immunized with FIX and IFA showed induction of neutralizing antibodies (Bethesda 
titer >2.6 BU vs. below the level of detection in all recipient mice in the other cohorts). 
These results indicate that FIX-specific immunological tolerance was established.
To define whether antigen specificity of liver infiltrating Tregs is affected by 
IDLV.142T administration, antigen-driven conversion of naive CD4+FOXP3' T cells 
into FOXP3+ Tregs was evaluated. To this end, we adoptively transferred naive CD4+ T 
cells obtained from double transgenic mice for an OVA-specific TCR (MHC II 
restricted, OT-II) and a GFP reporter knock-in downstream to the Foxp3 promoter. OT- 
II CD4+ F0XP3 GFP Ly5.2 T cells were isolated, FACS-sorted to deplete FOXP3+ cells, 
and adoptively transferred into naive Ly5.1 recipient mice before the injection of OVA- 
encoding IDLV or IDLV.142T (Figure 23A). Three weeks later recipient mice were 
euthanized and GFP expression, used as surrogate marker for FOXP3, was determined 
in OT-II Ly5.2 CD4+ T cells. A significantly higher frequency of OVA-specific Tregs 
was detected specifically in the IDLV.142T-treated mice as compared to the untreated 
or control unregulated IDLV-treated mice (Figure 23B). These results indicate that the 
pattern of OVA expression driven by miR142-regulated IDLV in the liver favoured the 
conversion of transgene-specific naive CD4+ T cells into transgene specific FOXP3+ 
induced Tregs (Figure 23B,C).
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Figure 23: Induction o f  transgene-specific Tregs by ID LV treatment. CD4+ cells 
isolated from OTIl Ly5.2 (CD45.2) Foxp3-GFP transgenic mice were FACS-sorted to 
remove GFP+ cells obtaining a homogeneous population o f CD4+ non-regulatory T  
cells with a unique antigen specificity (OVA3 2 3 .3 3 9  presented in IAb molecule). (A) 
Tregs-depleted OTIl CD4+GFP~ cells (2.5x106/mouse) were adoptively transferred 
intravenously into naive C57BL/6 Ly5.1 (CD45.1) recipient mice one day before the 
injection o f  IDLV.PGK.OVA (n=3) or IDLV.ET.OVA.142T (n=3). Three weeks after 
IDLV administration livers were harvested and infiltrating lymphocytes isolated. OVA- 
specific induced Tregs were measured as GFP+ cells gated on CD4+Ly5.2+. (B) A 
representative histogram and (C) mean±SEMpercentage o f  induced Tregs are shown.
Overall, these data indicate that hepatocyte-targeted expression of foreign antigens 
including intracellular or secreted, therapeutically relevant (FIX) and model antigens 
(GFP, OVA) by IDLV can result in a state of transgene-specific immunological 
tolerance, due to induction of transgene-specific regulatory compartment. The 
mechanisms underlying the observed outcome are likely to be different between 
intracellular and secreted antigens and will deserve further studies.
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5.DISCUSSION
5.1 LV-mediated liver gene therapy in haemophilia B dogs
The progression from small to large animal models has established a paradigm that is 
often used before the initiation of human trials, as it allows investigators to address 
issues of scaling up vector production to access larger amount of target tissue, to 
determine the toxicity and immune response to the procedure, the duration of transgene 
expression and the degree of correction of the disease phenotype in a mixed genetic or 
outbred animal283. The dog has been widely announced for its utility as a model for 
human hereditary diseases such as the haemophilias, lysosomal storage disorders and 
myopathies284. NHPs have also been largely adopted to perform pre-clinical studies and 
predict the toxicity of viral vectors administrations as well as the efficiency of
1 TO 17f OflTexpression cassettes with human transgenes ’ ’ . However only few disease
phenotypes are conveniently available in these animals and the restrictions to lentivirus 
infections in most of them may limit their usefulness in evaluating LV-mediated gene 
therapies285.
We have also shown that canine hepatocytes can be efficiently transduce in vitro, 
indicating that there are no major obstacle in translating LV-mediated liver gene 
therapies in these animals. Since little is known about microRNAs in dogs286, we also 
assessed the expression levels of some microRNAs and activity of miR-142 in a canine 
hematopoietic-lineage cell line and verified the applicability of miR-142-regulated LVs 
for liver gene therapy or potentially other therapeutic strategies36.
Taking advantage of a manufacturing process previously validated for the production 
of clinical-grade LVs for ex vivo gene therapy, we were able to produce large-scale 
batches of purified LVs qualified for in vivo administration and have performed the 
"first-in-dog" liver-directed LV gene therapy to our knowledge. Our results obtained in 
haemophilia B mice indicate that the “effective” LV dose to achieve 5-10% of normal 
FIX levels (and convert a severe to a mild haemophilic phenotype) corresponds to 
5x108 TU/mouse (2-2.5xl010 TU/kg), equivalent to 10-20 pg p24/mouse (0.5-1 mg 
p24/kg) considering a standard particle infectivity of 2.5-5 TU/ng p24. According to 
manufacturing capability and precautions dictated by first testing in large animals, we
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administered to dog M57 a LV dose of 5.7x108 TU/kg, 44 |ig p24/kg, approximately 
40-fold lower in TU (and 12- to 24-fold lower in p24) than the above mentioned dose 
on a per weight basis. Since cFIX activity settled at approximately 0.1% of normal in 
this dog (about 50-fold lower than the above mentioned levels), this outcome suggests 
that our predictions based on the dose-response observed in the mouse model are 
reliable in the canine model as well. This also suggests that the TU dose is a better 
predictive factor than the particle dose, at least in this low-dose range. By process 
optimisation and transgene codon-optimisation we could administer to a second dog 
(021) a LV dose 4-fold higher in TU/kg and only slightly higher in p24/kg. This dog 
achieved about 0.5-1% of normal FIX activity, approximately 10-fold higher than that 
achieved in the first dog, which can be explained by the higher dose and the co-cFIX 
transgene, which probably provided a 2.5-fold improvement in transgene expression. 
This also suggests that the 2- to 3-fold gain in potency observed in haemophilia B mice 
with the co-cFIX transgene has been recapitulated in the canine model. It has been 
recently reported that a short course of Dexamethasone administered around LV 
administration increases LV transduction of hepatocytes in mice287. We cannot exclude 
that the single-dose of Dexamethasone administered to this dog during LV infusion also 
helped hepatocyte transduction. By exploiting the Padua mutation which confers 5- to 
10-fold hyperactivity to FIXa, we may now be able to achieve >5% of normal FIX 
activity in the canine model, following liver gene therapy with the co-cFIX-R338L 
transgene. By this additional 5- to 10-fold gain in potency we could reasonably decrease 
the effective LV dose to about lx l09 TU/kg, a target that we can comfortably reach 
with the current manufacturing technology for the treatment of haemophilia B dogs. 
During the cumulative 3.6-years period of observation of the two treated dogs only 3 
out of 19 expected spontaneous bleedings occurred, indicating that the therapy provided 
a clinical benefit.
We observed transient fever and a mild self-limiting hepatic toxicity in both dogs 
receiving portal-vein administration of LV. This toxicity may be due to VSV-G- 
mediated fusion of transduced hepatocytes and subsequent death and may be decreased 
by using alternative envelope proteins such as gp64. Alternatively it may be due to an 
inflammatory response or mast-cell derived histamine release secondary to innate 
immune recognition and complement binding of LV particles. This toxicity did not
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increase with a higher LV TU dose and may be mainly due to particles themselves. 
Rather, it was slightly decreased in the dog receiving anti-inflammatory and anti­
histamine drugs, suggesting that there may be an important contribution of acute 
inflammation. The slight reduction in platelet counts is consistent with haemodilution 
due to the large amounts of liquid infused during the administration procedure. 
Haematocrit was also decreased for few days after the procedure, further confirming 
this hypothesis.
In one out of two dogs we observed an unexpected severe hypotensive reaction 
during LV infusion, probably due to a type-I anaphylactoid reaction to an unknown 
component of the LV batch. There were no major differences in the levels of protein or 
DNA contaminants or endotoxin between the infused batches. However, it is possible 
that the LV batch contained trace amounts of bovine serum albumin or penicillin 
derived from the supernatant of producer cells. Since haemophilia B dogs receive 
frequent plasma transfusions in response to spontaneous bleedings it is also possible 
that they are particularly sensitive to allergic reactions. This reaction was managed by a 
single-dose of an anti-inflammatory and a anti-histamine drug administered during the 
course of infusion. Pre-administration of analogous treatments before LV infusion may 
be proposed in the case of future LV administration to dogs or humans.
We observed a transient, rapidly declining rise in serum levels of TNF-a, IL-6 and 
IL-8. This is consistent with an inflammatory response secondary to a type-I IFN 
response due to the recognition of the viral RNA by pDCs, as observed in previous 
studies conducted in mice (see also 1.4.1)241. The administration of anti-inflammatory 
drugs as proposed may also contain this increase in serum cytokine levels.
Overall our results show that LV-mediated liver gene therapy is feasible in dogs and 
can provide long-term cFIX expression and activity up to 0.5-1% of normal and 
therapeutic benefit with a manageable self-limiting acute toxicity in the absence of 
long-term toxicities and without eliciting anti-transgene immune responses.
5.2 Codon-optimised hyper-active FIX transgene
Increasing the potency of gene transfer vectors is crucial for gene therapy, as much 
as for any “conventional” drug, as it results in an improved therapeutic index. Indeed 
lowering the dose necessary to achieve a therapeutic response decreases dose-dependent
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toxicities and immunogenicity. At the same time it reduces the costs and hurdles 
associated with manufacturing, ultimately resulting in a more comfortable therapeutic 
window of the proposed gene therapy. Towards this goal, we have undertaken efforts to 
improve expression and activity of the FIX transgene per vector copy.
Nature has evolved codon usage in genes to fine tune translation rate and adapt
988 980protein quantities in cells ’ . We have exploited a straightforward strategy aimed at
increasing vector potency: the modification of transgene sequences in order to 
maximise the output of the transgene product from a single expression unit. There is 
growing evidence that codon-usage and cw-acting sequences optimisation can increase
9Qfl  9Q1the potency of gene transfer vectors ’ ’ . A 3- to 4-fold increase in hFIX expression
levels has been obtained by codon-usage optimisation of the hFIX transgene upon liver 
gene therapy with sc AAV vectors in wt and haemophilia B mice292. We exploited a co- 
cFIX transgene to increase the potency of LV for liver-directed haemophilia B gene 
therapy and showed a robust 2- to 3-fold increase in cFIX expression over the wt 
transgene in 3 different experiments in haemophilia B mice and in one haemophilia B 
dog.
Increasing the transgene product output from a single expression cassette risks 
circumventing miR-142 regulation and may lead to transgene expression in APCs and 
anti-transgene immune responses. Directing hepatocytes to produce high quantities of 
the transgenic protein may saturate the translation or post-translational modification 
machinery and eventually expose cells to toxicity. Moreover, it appears that changing 
codons in genes can alter the translation velocity thus impairing proper folding and/or 
post-translational modifications267. Therefore, it is necessary to be cautious when 
generating codon-optimised transgenes and it is essential to carefully evaluate them in 
pre-clinical models. We showed long-lasting FIX activity in treated mice without any 
evident decrease of specific activity nor increased immunogenicity nor counterselection 
of transduced hepatocytes and decrease of FIX over time. This suggests that none of the 
previous concerns has occurred.
To further increase vector potency we exploited the naturally occurring single-amino 
acid R338L (Padua) mutation in FIX, associated with clotting hyperactivity and 
thrombophilia268. Engineered FIX variants with higher catalytic activity or augmented 
bioavalability have been previously reported and adopted in gene therapies studies
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involving Ads and AAV vectors269,293,294. These variants carry the same amino acidic 
substitution at residue 338, which is critical for substrate binding, mutations in other 
domains of the protein or combinations of multiple mutations. None of the previously 
described single mutations in the FIX reaches the same gain in catalytic activity 
conferred by the Padua mutation, to our knowledge. We showed that the corresponding 
mutation in the cFIX results in increased enzyme specific activity 5- to 10-fold and 
allows the use of lower LV doses to achieve sustained therapeutic efficacy in 
haemophilia B mice. We show for the first time the superior performance of FIX- 
1133 8L in achieving haemostasis in vivo in haemophilia B mice by a quantitative tail- 
bleeding assay. We also show that this mutation does not impair the tolerogenic 
outcome of LV-mediated liver gene therapy, as treated mice were unresponsive to 
immune challenge with the wt protein.
While FIX-R338L causes thrombophilia in an individual with normal FIX levels, it 
is highly unlikely that this would also occur in a haemophilic background. Clinical 
evidence indicate that FIX activity up to 300-400% of normal are tolerated and do not 
result in an increased risk of thrombosis. Indeed the mother of the patient in which the 
R338L mutation was found, who is heterozygous for the mutation, has not undergone 
thrombotic events268. Moreover this mutation causes an increased catalytic activity of 
FIXa and not non-specific zymogen activation268. Our extensive post-mortem 
pathological analysis of the organs of treated mice and the absence of D-Dimers 
elevation in the circulation suggest that thrombotic risk was not increased upon delivery 
of FIX-R338L transgene. However, a more extensive evaluation of the safety of 
delivering such hyper-functional FIX transgene will be appropriate before considering 
clinical translation. Several mouse models sensitive to vascular thrombosis have been 
described and may serve this purpose. These models include the feme chloride injury
071 oqcmodel and the FV Leiden mutation mouse model ’ .
By the novel combination of codon optimisation with the hyper-activating FIX- 
R338L mutation we achieved an unprecedented robust >15-fold gain in potency and 
therefore provide a promising strategy to improve the efficacy, feasibility and safety of 
haemophilia gene therapy with LVs as well as other vector platforms.
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5.3 Baculovirus gp64-pseudotyped LV for liver gene therapy
When directly injected into the circulation, LV particles can be inactivated by 
complement-mediated lysis due to the binding of high-affmity specific or non-specific 
low affinity pre-existing antibodies to the envelope protein or other membrane proteins 
carried over on the viral particles from producer cells ’ ’ . In addition, antibody
binding opsonises viral particles and favours both their elimination through
(
phagocytosis and inflammatory responses. It has been reported that RVs produced in 
cells of non-human origin carry on the surface galactosyl (al-3)galactosyl terminal 
glycosidic epitopes that are efficiently recognized by specific human and primate 
antibodies and there are inactivated by serum more than 100-fold in vitro. Moreover 
their systemic stability is drastically reduced upon i.v. injection in chimpanzees296. 
Other factors, particularly the envelope glycoprotein, also contribute in determining 
complement sensitivity. It has been shown that VSV-G-pseudotyped LV are sensitive to 
inactivation in serum from humans and primates263.
By using an in vitro assay of LV infectivity reduction by the heat-labile serum 
complement system, we showed that canine serum can inactivate VSV-G-pseudotyped 
reporter LVs 3- to 5-fold and inter-individual variability was present. We reasoned that 
this low-level inactivation would not compromise direct in vivo administration to dogs. 
Although all treated dogs were chosen among 3 candidates, on the basis of the results of 
the in vitro inactivation assay, serum of these dogs was still able to inactivate LVs 2- to 
4-fold. Since the transgene levels obtained in these dogs were in line with predictions 
based the dose infused and the dose-response observed in mice, this indicates that the 
level of inactivation observed in the in vitro assay did not impair liver transduction. The 
inactivation observed in serum derived from two human donors was higher 
(approximately 10-fold). The predictive value of this in vitro assay is questionable and 
in vivo studies may be more appropriate to assess the impact of pre-existing natural 
immunity on vector biodistribution and transduction. The incorporation of complement 
regulatory proteins on the surface of vector particles has been shown to improve 
complement-resistance and stability and it may also decrease innate immunity 
activation264,297, 298, thus it may be considered for clinical translation of LV-mediated 
liver gene therapy.
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In agreement with previous publications ’ , we showed that LVs psudotyped with
the baculovirus gp64 envelope protein are more resistant to inactivation by human and 
canine serum. The use of gp64 would also improve LV tropism for hepatocytes, by 
limiting transduction of hematopoietic-lineage cells and it has been shown to further 
reduce anti-transgene immune responses244. This may also reduce toxicity due to 
interactions with the complement system and hematopoietic-lineage cells. Restricting 
the spectrum of transduced cell types may also reduce safety concerns and the risk of 
germline transmission. Large-scale manufacturing, however, still needs to be adapted 
for this new envelope. On the other hand, since VSV-G expression is cytotoxic for 
producer cells, the use of gp64 may facilitate the development of stable packaging cell 
lines for an efficient scale-up of vector production. We showed that gp64.LVs can be 
produced to high titre and that they mediate efficient liver-directed gene therapy and 
expression of hFIX in haemophilia B mice to levels comparable to those obtained with 
matched doses of VSV-G pseudotyped LVs. For these reasons gp64 may provide a 
better alternative to VSV-G as a LV pseudotype for clinical translation of liver gene 
therapy. However, VSV-G pseudotyped LVs currently remain the preferred option, 
unless a robust process will be put in place for gp64-pseudotyped LV and complement 
sensitivity will represent a serious concern during future clinical development.
5.4 Proteasome inhibition in LV-mediated liver gene therapy
LVs efficiently transduce hepatocytes in vitro. However the tight KC network lining 
liver sinusoids and LSECs represent barriers for LVs approaching hepatocytes in vivo. 
In addition to these physical barriers, there are biological defences interfering with LV 
transduction of hepatocytes. Thus finding ways to circumvent these blocks can improve 
hepatocyte transduction.
It has been previously reported that KCs restrain hepatocyte transduction by LV299. 
Here we present the first comprehensive quantitative analysis of the biodistribution of 
LV within the liver cell subpopulations at steady state, without confounding factors 
deriving from anti-transgene immune responses. Our data provide evidence that KCs 
represent the major site of LV accumulation in vivo and likely an important impediment 
to efficient LV transduction of hepatocytes. KCs show very high LV copies per cell, 
although accounting for only about 6% of the total liver cells. Indeed up to 70% of LV
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DNA is found in these cells at steady state. However this percentage varies with 
different LV doses and decreases at increasing vector doses. This suggests that 
hepatocyte transduction becomes more efficient above a “threshold” LV dose at the 
expense of KCs transduction, when it is reasonable to speculate that “saturation” of 
transduction occurs or the cells with highest VCN undergo cell death. It is currently 
unknown whether this “saturation” is due to decreased KC phagocytic activity or simply 
to an increased likelihood for the LV particles to get access to hepatocytes. In any case, 
this phenomenon is consistent with the observed non-linear correlation between the LV 
doses and both transgene expression in hepatocytes and the VCN measured on whole 
liver. Furthermore it indicates that the whole liver VCN is not the best readout of the 
extent of hepatocyte transduction as it can mask a different contribution by PCs and 
nPCs. Instead, transgene expression in hepatocytes show a perfectly linear correlation 
with the VCN measured on the population enriched in PCs. Similar findings have been 
observed in the case of liver transduction with Ads, as KCs depletion improves their 
ability to transduce hepatocytes, which also show a non-linear correlation with the 
administered vector dose " . Our analysis can be applied to understand how different
treatments (such as KCs depletions or agents interfering with their function) as well as 
different LV pseudotypes affect the distribution of LV DNA within the liver cell 
subpopulations, in order to find ways to improve hepatocyte transduction. Of note, the 
LV doses used in our dog studies would probably fall below the threshold for more 
efficient hepatocyte transduction, which would likely strongly benefit from pre­
treatments such as bortezomib administration.
Some cell types and host species can restrict LV transduction to a different extent. It 
has been previously shown that proteasome inhibition improves LV transduction in 
several types of stem cells278, possibly by impairing cytosolic degradation of the 
uptaken vector particles that undergo uncoating, and thus enhancing their nuclear 
translocation. Here we show that proteasome inhibition with Bortezomib increases LV 
transduction of hepatocytes both in vitro and in vivo by a poorly understood mechanism. 
The increase in hepatocyte transduction observed in vitro indicates a cell-autonomous 
(hepatocyte-dependent) mechanism, which may conceivably contribute to the observed 
increase in hepatocyte-derived hFIX expression after liver transduction in vivo. 
However, since the whole liver VCN was not increased, this prompted us to investigate
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whether there was an increase of the VCN in hepatocytes at the expenses of the VCN in 
nPCs. We found a substantial decrease in VCN in nPCs and KCs in mice pre-treated 
with Bortezomib as compared to controls. However this was not accompanied by a 
detectable increase in VCN in PCs. Unfortunately our separation method does not yield 
purification of hepatocytes, but rather enrichment for these cells. Given the high VCN 
in KCs, as little as 1-2% of these cells contaminating PC preparations can affect the 
measured VCN in PCs and since pre-treatment with Bortezomib resulted in a 2-fold 
decrease in the VCN in KCs we speculate that this masked the complementary increase 
in VCN in PCs. As an alternative explanation, we cannot exclude that proteasome 
inhibition has altered the integration profile of LV in hepatocytes leading to an 
improved transgene expression without increased VCN in hepatocytes in mice303.
The decrease in VCN in KCs observed after Bortezomib pre-treatment can be 
explained by an impaired phagocytic activity at the time of LV transduction or by an 
enhancement of toxicity in highly transduced KCs and subsequent replacement from 
non-transduced progenitors, or both. Bortezomib has anti-inflammatory properties, due
'ync 'ifM
to inhibition of the NF-kB pathway ’ and has been reported to inhibit osteoclast 
activity and KCs activation276’ 305. Thus these data may play in favour of the first 
hypothesis. While acute toxicity on macrophages has not been reported, it is possible 
that temporary inhibition of proteasome activity resulted in protein toxicity in these 
cells that have high phagocytic activity.
It has been shown that type-I IFNs disfavour hepatocyte transduction, by inducing an
941 987anti-viral state and potentially up-regulating restriction factors ’ . In an attempt to
dampen these effects Agudo et al. have shown that treatment with the anti-inflammatory 
dexamethasone increases hepatocyte transduction by LVs and decreases KCs 
transduction in mice287. Our data show that Bortezomib increases hepatocyte 
transduction also in mice defective for type-I IFNs signalling (IfnaRl_/"), thus suggesting 
that Bortezomib-mediated increase in hepatocyte transduction is not exclusively due to 
inhibition of this pathway. However, since the increase in hepatocyte transduction was 
more pronounced in I f n a R l than haemophilia B mice, it is possible that there are 
additive or synergistic effects and it would be interesting to evaluate whether 
Bortezomib and dexamethasone in combination have a stronger effect on LV 
transduction of hepatocytes.
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Overall our data indicate that a single administration of the proteasome inhibitor 
Bortezomib prior to LV administration increases hepatocyte transduction by 2- to 3- 
fold. This is most probably obtained through a combination of both a cell-autonomous 
mechanism directly inhibiting restrictions and proteasome-mediated degradation of LV 
capsids, and a non-cell autonomous (hepatocyte-independent) mechanism interfering 
with KCs transduction. Since clinical experience indicates that Bortezomib toxicities 
are mostly due to long-term exposure to the drug, this represents a viable strategy to 
improve the potency of LV-mediated liver gene therapy.
5.5 LV-mediated liver gene therapy in mice with pre-existing FIX 
inhibitors
The major side-effect of FIX replacement therapy, development of inhibitors to the 
infused concentrate, is the main threat to the health of haemophilic patients and 
consequently the goal of intense research. Here we show that LV-mediated liver gene 
therapy has the potential to revert pre-existing anti-FIX humoral immunity and 
eradicate inhibitors in mice both following a relatively early and a relatively late 
intervention after the development of anti-FIX antibodies in haemophilia B mice. Once 
the anti-FIX antibody response has declined, liver gene therapy can provide sustained 
endogenous FIX expression to therapeutic levels. These effects are accompanied by a 
significant decrease in anti-FIX antibodies secreting cells in the lymphnodes of mice 
treated with gene therapy as compared to controls, although a complete evaluation of 
the B-cell response in other lymphoid organs will need to be performed. We also report 
almost complete disappearance of FIX-specific B m e m  in mice treated with gene therapy 
10 weeks after FIX immunisation, once the anti-FIX antibody response is fully mature.
We postulate that the mechanism by which this occurs is not dissimilar to that 
invoked to explain eradication of inhibitors by ITI. It has been reported that sustained 
exposure to high levels of antigen induces anergy or apoptosis of Bm em  in haemophilia 
A mice in which an anti-FVIH antibody response was induced282. Liver gene therapy 
can also exert this effect, with the accompanying benefit of inducing transgene-specific 
Tregs which keep under control CTL responses and T-helper mediated stimulation and 
maturation of antigen-specific B  lymphocytes. Once the Bmem have been shut down, the
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antibody response gradually declines, as plasma cells turnover. This may be further 
accelerated by additional treatments depleting the remaining plasma cells.
Gene therapy has been proposed as an attractive therapeutic strategy also for 
inhibitors-positive haemophilic patients, for which the current treatment is 
unsatisfactory and may thus provide a more favourable alternative306. Gene therapy may 
be an alternative treatment to ITI to eradicate inhibitors and at the same time provide 
sustained endogenous expression of the clotting factor. It has been recently reported that 
liver gene therapy with AAV vectors can establish cFVIII expression (by the “dual
^07vector” approach) in haemophilia A dogs with pre-existing anti-FVIII antibodies . 
This therapy also resulted in a gradual decline of anti-FVIII antibodies titre in treated 
dogs over the course of 1 year. We show eradication of FIX inhibitors by liver gene 
therapy in haemophilia B mice. Although the frequency of inhibitor development is 
lower in haemophilia B patients, clinical experience with ITI is limited and there is a 
higher risk of anaphylactic reactions in these patients undergoing ITI98," .  It is possible 
that haemophilia B mice with anti-FIX antibodies have experienced anaphylaxis or 
immune complex-mediated hypersensitivity upon high-dose i.v. injections of the 
recombinant FIX protein. This has been previously reported for FIX injections as well 
as other therapeutic proteins in mice with pre-existing antibodies281, 308. Further 
investigations will be necessary to elucidate this aspect. Although most of the FIX 
immunised haemophilia B mice did not develop high-titre inhibitors, our data suggest 
that liver gene therapy may be more effective and safer than ITI in eradicating FIX 
inhibitors and can provide therapeutic FIX levels in haemophilia B mice with pre­
existing anti-FIX immunity.
Our results demonstrate that liver gene therapy can establish tolerance not only in a 
naive immune system, but also in an already antigen-primed immune system and may 
candidate liver gene therapy as a therapeutic option also to revert autoimmune diseases.
5.6 IDLVs for liver gene therapy
IDLVs are emerging as an attractive platform for transgene expression for several 
purposes309. This platform harnesses the pantropism and proficiency of LV transduction 
without relying on integration and permanent modification of the cellular genome. Here 
we show that IDLVs can be used to express transgenes for a window of time in the
134
liver, provided that expression is stringently targeted to hepatocytes using 
transcriptional and miR-142-mediated regulation. Whereas the IDLV expression 
efficiency is lower than that observed for ICLV, expression levels suffice to induce 
immune tolerance. Moreover, the non-integrating feature of the platform provides for 
important safety advantages due to the low risk of genotoxicity and the reversibility of 
transgene expression.
The declining transgene expression of IDLV in proliferating cells has been mostly 
ascribed to the progressive loss of episomal DNA from the cell nucleus at mitosis, as 
compared to the stably integrated provirus of ICLV. Here, we reliably quantified the 
content of reverse transcribed vector genomes and the transgene expression level in 
transduced dividing or quiescent cells, and show that the expression efficiency per 
genome copy is significantly lower for IDLV than for ICLV in hepatocytes. This may 
be due to diffusion of the episomes to nuclear areas that are not involved in active 
transcription, inefficient chromatin deposition, or enrichment with histone modifications 
typical of transcriptionally silenced chromatin310. This is in contrast to what has been 
reported in other quiescent tissues, such as the retina and the brain, and may indicate 
tissue-specific factors affecting the expression and stability of episomal IDLV. It is 
conceivable that incorporation of additional genomic elements into the IDLV backbone 
may improve their expression proficiency and nuclear stability.
We show that background integration of IDLV occurs in vivo by mechanisms 
incompatible with residual activity of the mutant integrase, as they often present 
deletions in the LTR ends and lack the typical flanking genomic repeats at the insertion 
site. These events may be mediated by non-homologous end joining of linear episomes
*5 I  1
to sites of chromosomal breakage . Though we cannot rule out a contribution to the 
observed sustained FIX expression by this integrated IDLV, the significant decline of 
FIX expression by inducing hepatocyte proliferation after partial hepatectomy strongly 
suggests that in vivo expression is mostly mediated by the episomal forms.
The significantly lower and temporary hepatocyte expression of IDLV as compared 
to ICLV represents a limiting factor for their application to stable therapeutic gene 
replacement in the liver, at least in the current design. However, IDLV may be 
considered whenever reversible gene transfer is preferable, such as when testing a new 
gene therapy approach, especially if the clinical setting imposes high safety bars in the
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face of existing treatment options, as in haemophilia, or when the biological effects of 
gene-based delivery are difficult to predict or may entail substantial toxicity. Here we 
demonstrate the therapeutic potential of inducing a prolonged window of FIX 
expression in the plasma of haemophilic mice. Apparently, FIX expression was more 
prolonged than GFP expression following hepatic transduction with IDLV. This 
possibly reflects the higher vector doses used and/or differences in detection limits of 
the assays used to quantify expression of the respective transgene products. IDLV may 
be used for hepatic expression of therapeutic proteins, such as IFN or other cytokines, in 
chronic viral hepatitis or hepatic tumours, in which gene-based delivery may provide 
therapeutic concentrations of the factor at the disease site with limited systemic 
exposure and only for a defined window of time312,313. Alternatively IDLV may be 
exploited for the temporary expression of site-specific nucleases to perform gene 
targeting in hepatocytes.
Hepatic gene transfer has been associated with the induction of immunological 
tolerance to the transgene product using several vector platforms (see 1.1.8.1)54’ 274. In 
contrast to other viral vectors used in gene therapy, most subjects are immunologically 
naive to the IDLV vector components thus it is unlikely that IDLV-transduced 
hepatocytes would be recognized by vector-specific CTLs. Here we demonstrate a 
major accompanying benefit of IDLV-mediated hepatocyte-targeted transgene 
expression, i.e. the induction of transgene-specific Tregs and active tolerance to the 
transgene product. Most importantly, this response may extend beyond the duration of 
vector-mediated transgene expression. It has been shown that transgene persistence is 
not a strict requirement for the maintenance of immune tolerance314. The in vivo 
induction of antigen-specific Tregs by hepatocyte-targeted IDLV-mediated expression 
may well represent their most attractive feature to date and provides an intriguing 
contrast to the immunogenic nature of non-regulated antigen expression by IDLV 
delivery, which is currently being explored for the design of improved viral-based 
vaccines315, 316. Although IDLV are less efficient at expressing the transgene in 
hepatocytes as compared to their integrating counterparts, they are equally efficient at 
inducing transgene-specific tolerance, suggesting that the pattern and not the levels of 
transgene expression plays a crucial role in directing the immune system response in 
this setting. It is likely that different mechanisms are involved in tolerance induction
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towards intracellular or secreted antigens and further studies will be required to better 
elucidate this aspect.
A broad application of hepatocyte-targeted expression by ICLVs for immune 
modulation is currently limited by the concerns associated with integration in the target 
cell genome. IDLVs are advantageous for this purpose and could be exploited in 
“inverse vaccination” strategies to tolerise individuals to protein replacement therapies 
by preventing induction of neutralizing antibodies, which represent one of the major 
hurdles of this treatment317. Moreover these strategies may be adopted to prevent or 
revert the development of autoimmune diseases as well318.
5.7 Oncogenic risk in LV-mediated liver gene therapy
As we found that integrations is preferable for stable efficient liver gene transfer, we 
set out to assess the oncogenic risk associated with LV integration in hepatocytes. 
Whereas liver gene therapy by miR-142 regulated LVs did not cause detectably adverse 
events in any of the treated haemophilic mice, concerns remain regarding the long-term 
risk of vector insertional mutagenesis and studies in more stringent models are 
desirable. Most studies of vector genotoxicity have been performed in the 
hematopoietic system, thus very little is known about this risk in other tissues, such as 
the liver. Sensitive ad hoc murine models that are prone to develop HCC have been 
established (Ranzani et al., Nature Methods, in press). One model is characterized by 
the genetic deficiency of a tumour suppressor pathway (Cdkn2a'/'), the other is based on 
wt mice in which HCC induction is promoted (but not initiated) by repeated injections 
of carbon tetrachloride (CCI4). We have administered ET.FIX.142T LVs in the 
therapeutic configuration in parallel with a specifically tailored genotoxic LV design 
(used as a positive control for insertional mutagenesis) into these mice at neonatal age. 
While the latter vector reproducibly induced HCC, we have not detected any liver 
tumour by our therapeutic LV. We then retrieved 9,215 unique insertion sites from the 
treated mice. Whereas integrations of the genotoxic LV were enriched at previously 
validated HCC oncogenes, indicating positive selection of cancer-causing events, the 
therapeutic LV did not show an integration bias for these genes. Moreover, we did not 
detect any evidence of selection for the therapeutic LV insertions. These data indicate a 
low risk of insertional oncogenesis by LV-mediated liver gene therapy.
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5.8 Conclusions
LVs are attractive tools for liver gene therapy, by virtue of their ability to stably 
integrate their genome into host cells, which renders them applicable in young patients 
in which hepatocyte turnover is high. Moreover, in contrast to other vector platforms 
such as Ads and AAV vectors, there is no pre-existing humoral or cellular immunity 
against vector components in most humans.
We have undertaken a comprehensive study aimed at developing LV-mediated liver 
gene therapy, by improving its potency, strengthening and broadening its possible 
applications, utilising both small and large animal models. We performed the first LV- 
mediated liver gene therapy in haemophilia B dogs and show long-term transgene 
expression and some therapeutic benefit in two dogs with only mild acute hepatic 
toxicity and without long-term toxicities nor induction of anti-transgene immune 
responses. Our study reveals that one major issue limiting therapeutic efficacy is that in 
vivo biodistribution among liver cell populations limits hepatocyte transduction 
especially at low administered doses. We show that the use of optimised expression 
cassettes and hyperactive transgenes can increase the potency of LVs and that 
pharmacological pre-treatments help getting access to hepatocytes, thus bringing 
therapeutic doses to levels comfortably attainable by the current manufacturing 
technology and overall improving the therapeutic index of this therapy. Improvements 
in the production and purification of large-scale LV preparations as well as the current 
development of stable packaging cell lines will further facilitate large-animal testing 
and clinical translation. More extensive pre-clinical studies aimed at evaluating 
biodistribution and the risk of germline transmission will be required before clinical 
translation. We provide evidence that liver gene therapy can establish long-term 
transgene expression and tolerance in mice with pre-existing anti-transgene immunity. 
We report a comprehensive evaluation of IDLVs for liver gene therapy and show that, 
while not optimal for stable gene replacement therapy in their current design, they may 
represent a valuable strategy to induce stable antigen-specific tolerance by transient 
gene transfer and offer a treatment for immune-mediated diseases. On the other hand, 
since LV integration is preferable for efficient stable liver gene transfer, we stringently 
assessed the risk of oncogenesis associated to LV integration in ad hoc mouse models
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that are sensitised to develop HCC and found no detectable increase in carcinogenesis 
upon liver gene therapy with LVs.
Gene therapy has now restored vision in blind patients, immune defences in immune- 
deficient patients, blood in anaemic patients and coagulation in haemophilic patients 
and more has yet to come19, 20,22,23’25. Ex vivo gene therapy with HSPCs has entered 
clinical experimentation since more than a decade and there is great promise for future 
therapies. Liver gene therapy faced other challenges in clinical translation, mainly due 
to the hurdles associated with the immune consequences of direct in vivo 
administration. However it has steadily progressed to human testing. AAV vectors have 
now shown remarkable clinical benefits in haemophilia B patients upon liver gene 
therapy. LVs may well complement other available vectors to address the different 
challenges posed by the presentation of haemophilia and its complications in different 
patients and clinical conditions and may conceivably offer a therapeutic option for 
lysosomal and metabolic diseases.
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